

Prediction of Findings from the Ongoing COBRRA Trial Using Healthcare Database
Analyses

DUPLICATE – COBRRA VTE

March 11th, 2022

1. RCT Details

This section provides a high-level overview of an **ongoing** RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases.

1.1 Title

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRRA)

1.2 Intended aim(s)

To compare the incidence of major and clinically relevant non-major bleeding events among subjects recently hospitalized with VTE initiating apixaban or rivaroxaban.

1.3 Primary endpoint for replication

Time from randomization to the first confirmed, adjudicated occurrence of a major bleeding or clinically relevant non-major bleeding event through 90 days of anticoagulation treatment.

1.4 Required power for primary endpoint and noninferiority margin (if applicable)

The hazard ratio for the clinical trial is unknown because the trial is still ongoing. Based upon a recent meta-analysis comparing the safety of apixaban and rivaroxaban in a real-world evidence context, power was calculated using an array of effect sizes (Aryal et al. 2019).

1.5 Secondary endpoint for replication (assay sensitivity) and RCT finding

- Adjudicated major bleeding events
- Adjudicated clinically relevant non-major bleeding events
- Recurrent VTE
- All-cause mortality

1.6 Trial estimate

The trial is ongoing and scheduled to complete in June of 2023.

2. Person responsible for implementation of replication in Action

Luke Zobotka, BA and Mufaddal Mahesri, MD, MPH, implemented the study design in the Aetion Evidence Platform. They are not responsible for the validity of the design and analytic choices. All implementation steps are recorded, and the implementation history is archived in the platform.

3. Data Source(s)


Optum CDM, IBM® MarketScan®, CMS NOAC

4. Study Design Diagram

The study design diagram visualizes key aspects of the longitudinal study design for expedited review.

Figure 1.

Design Diagram – COBRRA TRIAL REPLICATION



5. Cohort Identification

5.1 Cohort Summary

An active-comparator, new-user design, propensity score matched, retrospective cohort study will be applied to compare patients that received apixaban or rivaroxaban. Subjects will be selected on the basis of having one or more diagnoses codes indicating hospitalization for PE or DVT and being of age 18 or older. Subjects will be excluded if they were not treatment-naïve with respect to the use of another DOAC or warfarin in the prior 180 days or have had any indication of stage IV or V CKD, ESRD, an active bleeding episode, cancer, obesity, liver disease, or another indication for long-term anticoagulation, such as atrial fibrillation (AF), in the prior 180 days. Patients were also excluded if they have used any contraindicated medications in the prior 180 days. All patients were required to have continuous enrollment for 180 days prior to cohort entry to ensure incident use of the study drugs.

5.2 Important steps for cohort formation

New use of the exposure (apixaban or rivaroxaban) is defined as no use of either drug in 180 days prior to meeting all eligibility criteria and initiation of exposure.

5.2.1 Eligible cohort entry dates

The apixaban indication for treatment of DVT and PE was approved by the FDA on Aug 21, 2014. Rivaroxaban was initially approved for the same indication on Nov. 2, 2012.

- IBM® MarketScan®: Aug 21, 2014 – December 31, 2019 (end of available data)
- Optum CDM: Aug 21, 2014 – June 30, 2020 (end of available data)
- CMS NOAC: Aug 21, 2014 – Dec 31, 2017 (end of available data)

5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date

Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in the **Appendix** and are summarized in the flowcharts below.

5.3 Flowchart of the study cohort assembly

For Apixaban vs. Rivaroxaban

	Optum CDM		IBM® MarketScan®		CMS - NOAC	
	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients
All patients in our database		81,796,156		205,537,714		6,886,908
Patients with Apixaban/Rivaroxaban [measured between Aug 21, 2014 and June 30, 2020.]		815,310		592,812		1,877,831
Excluded due to insufficient enrollment [-180, 0]	-114,272 (14%)	701,038	-44,015 (7%)	548,797	-211,569 (11%)	1,666,262
After wash-out for prior use of reference (Rivaroxaban) [-180, -1]	-216,874 (31%)	484,164	-203,091 (37%)	345,706	-622,705 (37%)	1,043,557
After wash-out for prior use of exposure (Apixaban) [-180, -1]	-333,847 (69%)	150,317	-205,703 (60%)	140,003	-682,837 (65%)	360,720
Excluded because patient qualified in >1 exposure category	-14 (<1%)	150,303	-23 (<1%)	139,980	-48 (<1%)	360,672
Exclusion of Missing Age [-180, 0]	-5 (<1%)	150,298	-0 (<1%)	139,980	-120 (<1%)	360,552
Exclusion of Gender (Exclude Missing Values) [start of all available data, 0]	-15 (<1%)	150,283	-0 (<1%)	139,980	-	-
Inclusion of Age >= 18 [0,0]	-141 (<1%)	150,142	-332 (<1%)	139,648	-	-
Inclusion of Proximal DVT or PE Hospitalization [Day -14, Day 0]	-135,497 (90%)	14,645	-124,142 (89%)	15,506	-323,753 (90%)	36,798
Exclusion of Anticoagulant Use [-180, 0]	-311 (2%)	14,334	-308 (2%)	15,198	-1,602 (4%)	35,196
Exclusion of CKD Stage 4/5 or ESRD [-180, Day 0]	-345 (2%)	13,989	-171 (1%)	15,027	-1,265 (4%)	33,931
Exclusion of Dialysis or Renal Transplant) [-180, 0]	-30 (<1%)	13,959	-43 (<1%)	14,984	-141 (<1%)	33,790
Exclusion of Bleeding [-180, 0]	-805 (6%)	13,154	-1,750 (12%)	13,234	-5,812 (17%)	27,978
Exclusion of Cancer [-180, 0]	-1,592 (12%)	11,562	-796 (6%)	12,438	-2,795 (10%)	25,183
Exclusion of Weight > 120 kg [-180, 0]	-868 (8%)	10,694	-549 (4%)	11,889	-	-

Exclusion of Significant Liver Disease [-180, 0]	-356 (3%)	10,338	-199 (2%)	11,690	-	-
Exclusion of Use of Contraindicated Medications [-180, 0]	-80 (<1%)	10,258	-85 (<1%)	11,605	-281 (1%)	22,790
Exclusion of Prosthetic Heart Valve [-180, 0]	-24 (<1%)	10,234	-8 (<1%)	11,597	-	-
Exclusion of Pregnancy [-180, 0]	-8 (<1%)	10,226	-17 (<1%)	11,580	-	-
Exclusion of Dual Antiplatelet Therapy [-180, Day 0]	-176 (2%)	10,050	-164 (1%)	11,416	-624 (3%)	22,115
Exclusion of Coagulopathy [-180, Day 0]	-196 (2%)	9,854	-132 (1%)	11,284	-338 (2%)	21,777
Exclusion of Atrial Fibrillation [-180, Day 0]	-261 (3%)	9,593	-142 (1%)	11,142	-637 (3%)	21,140
Final cohort		9,593		11,142		21,140

*Data may be omitted to comply with the CMS cell suppression policy

6. Variables

6.1 Exposure-related variables:

Study drug:

The study exposure of interest is defined by a prescription drug claim indicating apixaban dispensation. New initiation will be defined by no such records of apixaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study eligibility criteria.

Comparator agent:

The comparator is defined by a prescription drug claim indicating rivaroxaban dispensation. New initiation will be defined by no such records of rivaroxaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study eligibility criteria.

6.2 Preliminary Covariates:

- Age
- Gender
- CCI score

The covariate listed above represents only a small subset of the covariate vector that will ultimately be controlled for in the design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (**Appendix B**).

6.3 Outcome variables and study follow-up:

6.3.1 Outcome variables

Effectiveness outcome variables of interest (definitions provided in **Appendix**):

- **Primary outcome:** Major bleeding and clinically relevant non-major bleeding through 3 months of treatment with apixaban or rivaroxaban.
- Secondary outcomes:
 - To assess the frequency of major bleeding events and clinically relevant non-major bleeding individually
 - To assess extracranial and intracranial major bleeding events separately
 - To assess recurrent VTE
 - All-cause mortality

6.3.2 Study follow-up

Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on day of cohort entry. The **as-treated** will be the primary analysis. An allowable gap of 10 days between records indicating each treatment will qualify as “continuous therapy” with respect to follow-up in the as-treated analysis.

The follow-up will start the day after drug initiation (i.e., cohort entry date), and will continue until the earliest date of the following events:

- The first occurrence of the outcome of interest
- The date of end of continuous registration in the database
- End of the study period at 90 days

Effectiveness research with Real World Data to support FDA’s regulatory decision making

- Measured death event occurs
- Switch
- Discontinuation (10-day allowable grace period and risk window)
- Nursing home admission
- Initiation of another DOAC (dabigatran or edoxaban) or warfarin

In the secondary ITT analysis, we will not censor for discontinuation or switching among study drugs

7. Initial Feasibility Analysis

Action report name:

For apixaban vs. rivaroxaban

Optum CDM - <https://bwh-dope.aetion.com/projects/details/1775/rwrs/78117>

IBM® MarketScan® - <https://bwh-dope.aetion.com/projects/details/1776/rwrs/78118>

CMS NOAC - <https://bwh-dope.aetion.com/projects/details/1777/rwrs/78119>

Date conducted: Updated 01/13/2022

Complete Aetion feasibility analysis using age, gender, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the outcome. No measures of association will be computed, nor will incidence rates be stratified by treatment group.

- Report patient characteristics by treatment group
 - Apixaban vs Rivaroxaban

	Optum CDM			IBM® MarketScan®			CMS - NOAC		
Variable	Rivaroxaban - Comparator	Apixaban - Exposure	Difference	Rivaroxaban - Comparator	Apixaban - Exposure	Difference	Rivaroxaban - Comparator	Apixaban - Exposure	Difference
Number of patients	4,502	5,091		6,339	4,781		12,786	8,329	

Effectiveness research with Real World Data to support FDA’s regulatory decision making

Age									
...mean (sd)	61.82 (16.97)	69.00 (15.57)	-7.18 (-7.83, -6.52)	53.93 (15.65)	57.11 (15.97)	-3.18 (-3.78, -2.59)	70.91 (13.02)	74.18 (12.37)	-3.28 (-3.63, -2.93)
...median [IQR]	64.00 [51.00, 75.00]	72.00 [60.00, 81.00]		55.00 [44.00, 63.00]	57.00 [47.00, 66.00]		72.00 [66.00, 80.00]	75.00 [68.00, 83.00]	
Gender									
M	2,248 (49.9%)	2,172 (42.7%)	7.3% (5.3%, 9.3%)	3,418 (53.9%)	2,483 (51.9%)	2.0% (0.1%, 3.9%)	5,549 (43.4%)	3,206 (38.5%)	4.9% (3.5%, 6.3%)
F	2,254 (50.1%)	2,919 (57.3%)	-7.3% (-9.3%, -5.3%)	2,921 (46.1%)	2,298 (48.1%)	-2.0% (-3.9%, -0.1%)	7,237 (56.6%)	5,123 (61.5%)	-4.9% (-6.3%, -3.5%)
U									
CCI (180 Days)									
... mean (sd)	2.62 (2.35)	3.65 (2.64)	-1.04 (-1.14, -0.94)	1.61 (1.72)	2.19 (1.89)	-0.58 (-0.65, -0.51)	2.17 (2.08)	2.74 (2.27)	-0.58 (-0.64, -0.52)
...median [IQR]	2.00 [1.00, 4.00]	3.00 [2.00, 5.00]		1.00 [0.00, 3.00]	2.00 [1.00, 3.00]		2.00 [1.00, 3.00]	2.00 [1.00, 4.00]	

- Report summary parameters of study population **FEASIBILITY- FOR STUDY OUTCOME**
 - **For Apixaban vs Rivaroxaban**

FEASIBILITY FOR STUDY OUTCOME			
	Optum CDM	IBM® MarketScan®	CMS - NOAC
Number of patients in full cohort	9,593	11,142	21,140

Number of patients dropped as incomplete cases	0	0	0
Number of patients that did not begin follow-up	7	22	25
Number of patients in analytic cohort	9,586	11,120	21,115
Number of events	172	213	1,049
Number of person-years	1,433.02	1,933.00	3,484.88
Number of patients in group: Rivaroxaban - Comparator	4,499	6,339	12,786
Number of patients in group: Apixaban - Exposure	5,087	4,781	8,329
Risk per 1,000 patients	17.94	19.15	49.68
Rate per 1,000 person-years	120.03	110.19	301.01

- Report median follow-up time by treatment group
 - For Apixaban vs Rivaroxaban

FOLLOW-UP TIME FOR STUDY OUTCOME			
Median Follow-Up Time (Days) [IQR] – At 10 days gap			
Patient Group	Optum CDM	IBM® MarketScan®	CMS - NOAC
Overall Patient Population	57 [27, 90]	79 [38, 90]	67 [38, 90]
Referent - Rivaroxaban	54 [29, 90]	68 [38, 90]	62 [38, 90]
Exposure - Apixaban	61 [18, 90]	90 [38, 90]	75 [38, 90]

- Report reasons for censoring in the overall study population
 - For Apixaban vs Rivaroxaban

CENSORING REASONS FOR STUDY OUTCOME			
Reasons	Optum CDM	IBM® MarketScan®	CMS - NOAC
Outcome	123 (0.8%)	187 (0.8%)	601 (1.4%)
Death	79 (0.5%)	1 (0.0%)	459 (1.1%)

Start of an additional exposure	219 (1.5%)	369 (1.5%)	682 (1.6%)
End of index exposure	5,485 (36.6%)	10,122 (40.6%)	16,677 (38.5%)
Maximum follow-up time reached	6,595 (44.0%)	10,590 (42.5%)	18,372 (42.4%)
End of patient data	0 (0.0%)	1,218 (4.9%)	2,779 (6.4%)
End of patient enrollment	427 (2.8%)	1,455 (5.8%)	402 (0.9%)
DOAC or Warfarin Initiation + Nursing Home Admission	2,073 (13.8%)	961 (3.9%)	3,393 (7.8%)

- Report overall risk of the primary outcome.

	Optum CDM	IBM® MarketScan®	CMS - NOAC	Pooled
Risk per 1,000 patients	17.92974044	19.11685514	49.62157048	34.24477612

8. Initial Power Assessment

Action report name:

- **For Apixaban vs Rivaroxaban**
 - Optum CDM - <https://bwh-dope.aetion.com/projects/details/1775/rwrs/78120>
 - IBM® MarketScan®- <https://bwh-dope.aetion.com/projects/details/1776/rwrs/78121>
 - CMS NOAC - <https://bwh-dope.aetion.com/projects/details/1777/rwrs/78122>

Date conducted: Updated 01/13/2022

In order to complete the initial power analysis, a dummy outcome indicating a 90-day gap in database enrollment will be used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. A 1:1 PS-matched comparative analysis was performed, including age, gender, and CCI score as the only covariates. Power calculations are based on the formulas from Chow et al. (2008).

This emulation is of a trial that is not yet completed. The trial investigators have not published their power calculations. Therefore, we present a range of power calculations for different effect sizes given the feasibility counts and alpha of 0.05. The range in

potential hazard ratios come from prior studies in Aryal et al. (2019) comparing bleeding outcomes for apixaban versus rivaroxaban. The target enrollment for the trial is 2,760 patients. We anticipate having around 41,875 patients in our cohort.

1. Pooled

Superiority Analysis - Pooled					
Number of patients matched	32,390	32,390	32,390	32,390	32,390
Reference	16,195	16,195	16,195	16,195	16,195
Exposure	16,195	16,195	16,195	16,195	16,195
Risk per 1,000 patients	34.24477612	34.24477612	34.24477612	34.24477612	34.24477612
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	1109.188299	1109.188299	1109.188299	1109.188299	1109.188299
Power	0.960445201	0.999965466	1	1	1

2. Optum CDM

Superiority Analysis - Optum					
Number of patients matched	12,138	12,138	12,138	12,138	12,138
Reference	6,069	6,069	6,069	6,069	6,069
Exposure	6,069	6,069	6,069	6,069	6,069
Risk per 1,000 patients	8.19945337	8.19945337	8.19945337	8.19945337	8.19945337
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	99.524965	99.524965	99.524965	99.524965	99.524965
Power	0.19958509	0.4283428	0.72176747	0.93287238	0.99548076

3. IBM® MarketScan®

Superiority Analysis - MarketScan					
Number of patients matched	9,016	9,016	9,016	9,016	9,016
Reference	4,508	4,508	4,508	4,508	4,508
Exposure	4,508	4,508	4,508	4,508	4,508
Risk per 1,000 patients	19.11685514	19.11685514	19.11685514	19.11685514	19.11685514
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	172.357566	172.357566	172.357566	172.357566	172.357566
Power	0.310539399	0.648532959	0.918223967	0.995201595	0.999974911

4. CMS – NOAC

Superiority Analysis – CMS NOAC					
Number of patients matched	16,030	16,030	16,030	16,030	16,030
Reference	8,015	8,015	8,015	8,015	8,015
Exposure	8,015	8,015	8,015	8,015	8,015
Risk per 1,000 patients	49.62157048	49.62157048	49.62157048	49.62157048	49.62157048
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	795.4337748	795.4337748	795.4337748	795.4337748	795.4337748
Power	0.882335738	0.998928865	0.999999921	1	1

- Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and reported in the subsequent sections, after incorporating feedback and refining the protocol.

Reviewed by PI:	Shirley Wang	Initial Date reviewed:	08/03/2021
Reviewed by FDA:	Ken Quinto	Initial Date reviewed:	08/18/2021
Reasons for stopping analysis (if required):			

9. Balance Assessment

Action report name:

- **For Apixaban vs Rivaroxaban**
 - Optum CDM - <https://bwh-dope.aetion.com/projects/details/1775/rwrs/79764>
 - IBM® MarketScan®- <https://bwh-dope.aetion.com/projects/details/1776/rwrs/79768>
 - CMS NOAC - <https://bwh-dope.aetion.com/projects/details/1777/rwrs/80116>

Date conducted: 02/25/2022 and 03/08/2022

After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete list of covariates.

1. Provide plot of PS distributions stratified by treatment group.
 - a. **See Appendix B**
2. Report covariate balance after matching.
 - a. **See Appendix B**

*Data may be omitted to comply with the CMS cell suppression policy

3. Report reasons for censoring by treatment group.

Censoring Reasons for Study Outcome			
Reasons	Overall	Referent	Exposure
Death	439 (1.0%)	197 (0.8%)	242 (1.3%)
Start of an additional exposure	609 (1.5%)	354 (1.5%)	255 (1.4%)
End of index exposure	15,737 (37.6%)	9,948 (42.1%)	5,789 (31.8%)
Maximum follow-up time	18,479 (44.2%)	9,898 (41.9%)	8,581 (47.2%)
End of patient data	1,676 (4.0%)	761 (3.2%)	915 (5.0%)
End of patient enrollment	1,169 (2.8%)	660 (2.8%)	509 (2.8%)
DOAC or warfarin initiation + nursing home admission	3,712 (8.9%)	1,806 (7.6%)	1,906 (10.5%)

4. Report follow-up time by treatment group.

FOLLOW-UP TIME FOR STUDY OUTCOME			
Median Follow-Up Time (Days) [IQR] – At 10 days gap			
Patient Group	Optum CDM	IBM® MarketScan®	CMS - NOAC
Overall Patient Population	65 [31, 90]	74 [38, 90]	67 [38, 90]
Referent - Rivaroxaban	61 [35, 90]	67 [38, 90]	62 [34, 90]
Exposure - Apixaban	68 [28, 90]	88 [38, 90]	76 [38, 90]

10. Final Power Assessment

Date conducted: 03/08/2022

Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All other parameters in the table should be the same as in Section 8.

1. Pooled

Superiority Analysis - Pooled					
Number of patients matched	28,404	28,404	28,404	28,404	28,404
Reference	14,202	14,202	14,202	14,202	14,202
Exposure	14,202	14,202	14,202	14,202	14,202
Risk per 1,000 patients	17.898823	17.898823	17.898823	17.898823	17.898823
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	508.398168	508.398168	508.398168	508.398168	508.398168
Power	0.71080316	0.98035484	0.99992736	1	1

2. Optum CDM

Superiority Analysis - Optum					
Number of patients matched	6,064	6,064	6,064	6,064	6,064
Reference	3,032	3,032	3,032	3,032	3,032
Exposure	3,032	3,032	3,032	3,032	3,032
Risk per 1,000 patients	11.5111765	11.5111765	11.5111765	11.5111765	11.5111765
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	69.8037746	69.8037746	69.8037746	69.8037746	69.8037746
Power	0.1539359	0.31946556	0.56907891	0.82526402	0.96910355

3. IBM® MarketScan®

Superiority Analysis - MarketScan					
Number of patients matched	7,388	7,388	7,388	7,388	7,388
Reference	3,694	3,694	3,694	3,694	3,694
Exposure	3,694	3,694	3,694	3,694	3,694

Risk per 1,000 patients	8.02773904	8.02773904	8.02773904	8.02773904	8.02773904
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	59.308936	59.308936	59.308936	59.308936	59.308936
Power	0.13791552	0.27918325	0.50284704	0.76086404	0.94159663

4. CMS – NOAC

Superiority Analysis – CMS NOAC					
Number of patients matched	14,952	14,952	14,952	14,952	14,952
Reference	7,476	7,476	7,476	7,476	7,476
Exposure	7,476	7,476	7,476	7,476	7,476
Risk per 1,000 patients	27.146628	27.146628	27.146628	27.146628	27.146628
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	405.896382	405.896382	405.896382	405.896382	405.896382
Power	0.61328522	0.94876319	0.99927824	0.99999974	1

- Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:		Date reviewed:	
Reviewed by FDA:		Date reviewed:	
Reasons for stopping analysis (if required):			

11. Study Confidence and Concerns

Deadline for voting on study confidence and listing concerns:

Date votes and concerns are summarized:

- If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps.
- All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the success of the RWD study in the [Google Form](#). This form also provides space for reviewers to list any concerns that they feel may contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the individual respondent.
- After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here.

12. Register study protocol on clinicalTrials.gov

Date conducted:

- Register the study on [clinicalTrials.gov](#) and upload this document.

13. Comparative Analyses

Action report name:

Date conducted:

13.1 For primary analysis:

13.2 For sensitivity analyses:

14. Requested Results

14.1 Table 1: Baseline characteristics before and after adjustment

Effectiveness research with Real World Data to support FDA’s regulatory decision making

Variable	Before adjustment			After adjustment		
	Referent	Exposure	Std. diff.	Referent	Exposure	Std. diff.
Number of patients			-			-
Age categories						
...						

14.2 Table 2: Follow-up time

Patient Group	Median Follow-Up Time (Days) [IQR]
Overall Patient Population	
Referent	
Exposure	

14.3 Table 3: Censoring events

	Overall	Referent	Exposure
Outcome			
Death			
Start of an additional exposure			
End of index exposure			
Specified date reached			
End of patient data			
End of patient enrollment			
...			

14.4 Table 4: Results from primary analyses;

Analysis	No. exposed events	No. referent events	Exposed rate	Referent rate	HR (95% CI)
Crude					

Analysis 1					
Analysis 2					
...					

HR, Hazard Ratio; CI, Confidence Interval.

14.5 Table 5: Results from secondary analyses;

15. References

Chow S, Shao J, Wang H. 2008. *Sample Size Calculations in Clinical Research*. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 177

Madan Raj Aryal, Rohit Gosain, Anthony Donato, Han Yu, Anjan Katel, Yashoda Bhandari, Rashmi Dhital, Peter A. Kouides; Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. *Blood Adv* 2019; 3 (15) 2381 – 2387, doi: <https://doi.org/10.1182/bloodadvances.2019000572>.

Appendix A

#	COBRR - VTE trial definitions	Implementation in routine care	References/Rationale	Color coding
		Please use the following Google Drive for further details or any missing information: https://drive.google.com/drive/folders/2W0558arpe7aG0L7oac-VCObb8-gY?usp=sharing		
		RCT-18 codes are not listed in the document because of cost (off site distribution) and a cover number of RCT-18 index. Full RCT-18 code list will be available in the above Google Drive Folder (link above). RCT-9 to RCT-18 code conversions were completed using a SAS macro that implements forward/backward mapping based on the CMS (RCT-9) to RCT-18 mapping.		
		TRIAL DETAILS		Green
		EXPOSURE vs. COMPARISON		Can be replicated in claims Using dummy definitions for measuring outcomes
	Random 20 mg PO BID for 1 week, then 3 mg PO BID for 3 months of treatment N Desaruban 15 mg PO BID for 3 weeks, then 20 mg PO QD for 3 months of treatment	Location: All generic vs. Desaruban_40 generic		Can't be measured in claims
		PRIMARY OUTCOME		
	The rate of adjudicated clinically relevant bleeding (CRB) events [Time Frame: For the duration of the study, 3 months]. CRB events are defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events	Measured [0,90] in an inpatient setting in any diagnosis position (with translation codes for non-critical sites) Major Bleeding: See "Major Bleeding" Sheet Measured [0,90] in an inpatient setting in any diagnosis position (translation codes NOT included for non-critical sites) Clinically Relevant Non-Major Bleeding Events: See Sheet "CRNMB Sheet"	Graham DJ, Reichman ME, Wernicke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. <i>JAMA Intern Med.</i> 2016;176(2):156-162. doi:10.1001/jamainternmed.2016.1954	Can't be measured in claims but not important for the analysis
		INCLUSION CRITERIA		
1	Confirmed newly diagnosed asymptomatic acute VTE (proximal lower extremity DVT or segmental or greater PE)	Measured [1,4, 0] in any diagnosis position in an inpatient setting Polymyoma Embolism: ICD-9-CM Diagnosis: I71.7, 415.10, 415.11, 415.12, 415.13, 415.14, 415.15, 415.16, 415.17, 415.19, 415.199 ICD-10-CM Diagnosis: I71.01, I71.02, I71.03, I71.04, I71.05, I71.06, I71.07, I71.08, I71.09, I71.10, I71.11, I71.12, I71.13, I71.14, I71.15, I71.16, I71.17, I71.18, I71.19, I71.20, I71.21, I71.22, I71.23, I71.24, I71.25, I71.26, I71.27, I71.28, I71.29, I71.30, I71.31, I71.32, I71.33, I71.34, I71.35, I71.36, I71.37, I71.38, I71.39, I71.40, I71.41, I71.42, I71.43, I71.44, I71.45, I71.46, I71.47, I71.48, I71.49, I71.50, I71.51, I71.52, I71.53, I71.54, I71.55, I71.56, I71.57, I71.58, I71.59, I71.60, I71.61, I71.62, I71.63, I71.64, I71.65, I71.66, I71.67, I71.68, I71.69, I71.70, I71.71, I71.72, I71.73, I71.74, I71.75, I71.76, I71.77, I71.78, I71.79, I71.80, I71.81, I71.82, I71.83, I71.84, I71.85, I71.86, I71.87, I71.88, I71.89, I71.90, I71.91, I71.92, I71.93, I71.94, I71.95, I71.96, I71.97, I71.98, I71.99, I72.00, I72.01, I72.02, I72.03, I72.04, I72.05, I72.06, I72.07, I72.08, I72.09, I72.10, I72.11, I72.12, I72.13, I72.14, I72.15, I72.16, I72.17, I72.18, I72.19, I72.20, I72.21, I72.22, I72.23, I72.24, I72.25, I72.26, I72.27, I72.28, I72.29, I72.30, I72.31, I72.32, I72.33, I72.34, I72.35, I72.36, I72.37, I72.38, I72.39, I72.40, I72.41, I72.42, I72.43, I72.44, I72.45, I72.46, I72.47, I72.48, I72.49, I72.50, I72.51, I72.52, I72.53, I72.54, I72.55, I72.56, I72.57, I72.58, I72.59, I72.60, I72.61, I72.62, I72.63, I72.64, I72.65, I72.66, I72.67, I72.68, I72.69, I72.70, I72.71, I72.72, I72.73, I72.74, I72.75, I72.76, I72.77, I72.78, I72.79, I72.80, I72.81, I72.82, I72.83, I72.84, I72.85, I72.86, I72.87, I72.88, I72.89, I72.90, I72.91, I72.92, I72.93, I72.94, I72.95, I72.96, I72.97, I72.98, I72.99, I73.00, I73.01, I73.02, I73.03, I73.04, I73.05, I73.06, I73.07, I73.08, I73.09, I73.10, I73.11, I73.12, I73.13, I73.14, I73.15, I73.16, I73.17, I73.18, I73.19, I73.20, I73.21, I73.22, I73.23, I73.24, I73.25, I73.26, I73.27, I73.28, I73.29, I73.30, I73.31, I73.32, I73.33, I73.34, I73.35, I73.36, I73.37, I73.38, I73.39, I73.40, I73.41, I73.42, I73.43, I73.44, I73.45, I73.46, I73.47, I73.48, I73.49, I73.50, I73.51, I73.52, I73.53, I73.54, I73.55, I73.56, I73.57, I73.58, I73.59, I73.60, I73.61, I73.62, I73.63, I73.64, I73.65, I73.66, I73.67, I73.68, I73.69, I73.70, I73.71, I73.72, I73.73, I73.74, I73.75, I73.76, I73.77, I73.78, I73.79, I73.80, I73.81, I73.82, I73.83, I73.84, I73.85, I73.86, I73.87, I73.88, I73.89, I73.90, I73.91, I73.92, I73.93, I73.94, I73.95, I73.96, I73.97, I73.98, I73.99, I74.00, I74.01, I74.02, I74.03, I74.04, I74.05, I74.06, I74.07, I74.08, I74.09, I74.10, I74.11, I74.12, I74.13, I74.14, I74.15, I74.16, I74.17, I74.18, I74.19, I74.20, I74.21, I74.22, I74.23, I74.24, I74.25, I74.26, I74.27, I74.28, I74.29, I74.30, I74.31, I74.32, I74.33, I74.34, I74.35, I74.36, I74.37, I74.38, I74.39, I74.40, I74.41, I74.42, I74.43, I74.44, I74.45, I74.46, I74.47, I74.48, I74.49, I74.50, I74.51, I74.52, I74.53, I74.54, I74.55, I74.56, I74.57, I74.58, I74.59, I74.60, I74.61, I74.62, I74.63, I74.64, I74.65, I74.66, I74.67, I74.68, I74.69, I74.70, I74.71, I74.72, I74.73, I74.74, I74.75, I74.76, I74.77, I74.78, I74.79, I74.80, I74.81, I74.82, I74.83, I74.84, I74.85, I74.86, I74.87, I74.88, I74.89, I74.90, I74.91, I74.92, I74.93, I74.94, I74.95, I74.96, I74.97, I74.98, I74.99, I75.00, I75.01, I75.02, I75.03, I75.04, I75.05, I75.06, I75.07, I75.08, I75.09, I75.10, I75.11, I75.12, I75.13, I75.14, I75.15, I75.16, I75.17, I75.18, I75.19, I75.20, I75.21, I75.22, I75.23, I75.24, I75.25, I75.26, I75.27, I75.28, I75.29, I75.30, I75.31, I75.32, I75.33, I75.34, I75.35, I75.36, I75.37, I75.38, I75.39, I75.40, I75.41, I75.42, I75.43, I75.44, I75.45, I75.46, I75.47, I75.48, I75.49, I75.50, I75.51, I75.52, I75.53, I75.54, I75.55, I75.56, I75.57, I75.58, I75.59, I75.60, I75.61, I75.62, I75.63, I75.64, I75.65, I75.66, I75.67, I75.68, I75.69, I75.70, I75.71, I75.72, I75.73, I75.74, I75.75, I75.76, I75.77, I75.78, I75.79, I75.80, I75.81, I75.82, I75.83, I75.84, I75.85, I75.86, I75.87, I75.88, I75.89, I75.90, I75.91, I75.92, I75.93, I75.94, I75.95, I75.96, I75.97, I75.98, I75.99, I76.00, I76.01, I76.02, I76.03, I76.04, I76.05, I76.06, I76.07, I76.08, I76.09, I76.10, I76.11, I76.12, I76.13, I76.14, I76.15, I76.16, I76.17, I76.18, I76.19, I76.20, I76.21, I76.22, I76.23, I76.24, I76.25, I76.26, I76.27, I76.28, I76.29, I76.30, I76.31, I76.32, I76.33, I76.34, I76.35, I76.36, I76.37, I76.38, I76.39, I76.40, I76.41, I76.42, I76.43, I76.44, I76.45, I76.46, I76.47, I76.48, I76.49, I76.50, I76.51, I76.52, I76.53, I76.54, I76.55, I76.56, I76.57, I76.58, I76.59, I76.60, I76.61, I76.62, I76.63, I76.64, I76.65, I76.66, I76.67, I76.68, I76.69, I76.70, I76.71, I76.72, I76.73, I76.74, I76.75, I76.76, I76.77, I76.78, I76.79, I76.80, I76.81, I76.82, I76.83, I76.84, I76.85, I76.86, I76.87, I76.88, I76.89, I76.90, I76.91, I76.92, I76.93, I76.94, I76.95, I76.96, I76.97, I76.98, I76.99, I77.00, I77.01, I77.02, I77.03, I77.04, I77.05, I77.06, I77.07, I77.08, I77.09, I77.10, I77.11, I77.12, I77.13, I77.14, I77.15, I77.16, I77.17, I77.18, I77.19, I77.20, I77.21, I77.22, I77.23, I77.24, I77.25, I77.26, I77.27, I77.28, I77.29, I77.30, I77.31, I77.32, I77.33, I77.34, I77.35, I77.36, I77.37, I77.38, I77.39, I77.40, I77.41, I77.42, I77.43, I77.44, I77.45, I77.46, I77.47, I77.48, I77.49, I77.50, I77.51, I77.52, I77.53, I77.54, I77.55, I77.56, I77.57, I77.58, I77.59, I77.60, I77.61, I77.62, I77.63, I77.64, I77.65, I77.66, I77.67, I77.68, I77.69, I77.70, I77.71, I77.72, I77.73, I77.74, I77.75, I77.76, I77.77, I77.78, I77.79, I77.80, I77.81, I77.82, I77.83, I77.84, I77.85, I77.86, I77.87, I77.88, I77.89, I77.90, I77.91, I77.92, I77.93, I77.94, I77.95, I77.96, I77.97, I77.98, I77.99, I78.00, I78.01, I78.02, I78.03, I78.04, I78.05, I78.06, I78.07, I78.08, I78.09, I78.10, I78.11, I78.12, I78.13, I78.14, I78.15, I78.16, I78.17, I78.18, I78.19, I78.20, I78.21, I78.22, I78.23, I78.24, I78.25, I78.26, I78.27, I78.28, I78.29, I78.30, I78.31, I78.32, I78.33, I78.34, I78.35, I78.36, I78.37, I78.38, I78.39, I78.40, I78.41, I78.42, I78.43, I78.44, I78.45, I78.46, I78.47, I78.48, I78.49, I78.50, I78.51, I78.52, I78.53, I78.54, I78.55, I78.56, I78.57, I78.58, I78.59, I78.60, I78.61, I78.62, I78.63, I78.64, I78.65, I78.66, I78.67, I78.68, I78.69, I78.70, I78.71, I78.72, I78.73, I78.74, I78.75, I78.76, I78.77, I78.78, I78.79, I78.80, I78.81, I78.82, I78.83, I78.84, I78.85, I78.86, I78.87, I78.88, I78.89, I78.90, I78.91, I78.92, I78.93, I78.94, I78.95, I78.96, I78.97, I78.98, I78.99, I79.00, I79.01, I79.02, I79.03, I79.04, I79.05, I79.06, I79.07, I79.08, I79.09, I79.10, I79.11, I79.12, I79.13, I79.14, I79.15, I79.16, I79.17, I79.18, I79.19, I79.20, I79.21, I79.22, I79.23, I79.24, I79.25, I79.26, I79.27, I79.28, I79.29, I79.30, I79.31, I79.32, I79.33, I79.34, I79.35, I79.36, I79.37, I79.38, I79.39, I79.40, I79.41, I79.42, I79.43, I79.44, I79.45, I79.46, I79.47, I79.48, I79.49, I79.50, I79.51, I79.52, I79.53, I79.54, I79.55, I79.56, I79.57, I79.58, I79.59, I79.60, I79.61, I79.62, I79.63, I79.64, I79.65, I79.66, I79.67, I79.68, I79.69, I79.70, I79.71, I79.72, I79.73, I79.74, I79.75, I79.76, I79.77, I79.78, I79.79, I79.80, I79.81, I79.82, I79.83, I79.84, I79.85, I79.86, I79.87, I79.88, I79.89, I79.90, I79.91, I79.92, I79.93, I79.94, I79.95, I79.96, I79.97, I79.98, I79.99, I80.00, I80.01, I80.02, I80.03, I80.04, I80.05, I80.06, I80.07, I80.08, I80.09, I80.10, I80.11, I80.12, I80.13, I80.14, I80.15, I80.16, I80.17, I80.18, I80.19, I80.20, I80.21, I80.22, I80.23, I80.24, I80.25, I80.26, I80.27, I80.28, I80.29, I80.30, I80.31, I80.32, I80.33, I80.34, I80.35, I80.36, I80.37, I80.38, I80.39, I80.40, I80.41, I80.42, I80.43, I80.44, I80.45, I80.46, I80.47, I80.48, I80.49, I80.50, I80.51, I80.52, I80.53, I80.54, I80.55, I80.56, I80.57, I80.58, I80.59, I80.60, I80.61, I80.62, I80.63, I80.64, I80.65, I80.66, I80.67, I80.68, I80.69, I80.70, I80.71, I80.72, I80.73, I80.74, I80.75, I80.76, I80.77, I80.78, I80.79, I80.80, I80.81, I80.82, I80.83, I80.84, I80.85, I80.86, I80.87, I80.88, I80.89, I80.90, I80.91, I80.92, I80.93, I80.94, I80.95, I80.96, I80.97, I80.98, I80.99, I81.00, I81.01, I81.02, I81.03, I81.04, I81.05, I81.06, I81.07, I81.08, I81.09, I81.10, I81.11, I81.12, I81.13, I81.14, I81.15, I81.16, I81.17, I81.18, I81.19, I81.20, I81.21, I81.22, I81.23, I81.24, I81.25, I81.26, I81.27, I81.28, I81.29, I81.30, I81.31, I81.32, I81.33, I81.34, I81.35, I81.36, I81.37, I81.38, I81.39, I81.40, I81.41, I81.42, I81.43, I81.44, I81.45, I81.46, I81.47, I81.48, I81.49, I81.50, I81.51, I81.52, I81.53, I81.54, I81.55, I81.56, I81.57, I81.58, I81.59, I81.60, I81.61, I81.62, I81.63, I81.64, I81.65, I81.66, I81.67, I81.68, I81.69, I81.70, I81.71, I81.72, I81.73, I81.74, I81.75, I81.76, I81.77, I81.78, I81.79, I81.80, I81.81, I81.82, I81.83, I81.84, I81.85, I81.86, I81.87, I81.88, I81.89, I81.90, I81.91, I81.92, I81.93, I81.94, I81.95, I81.96, I81.97, I81.98, I81.99, I82.00, I82.01, I82.02, I82.03, I82.04, I82.05, I82.06, I82.07, I82.08, I82.09, I82.10, I82.11, I82.12, I82.13, I82.14, I82.15, I82.16, I82.17, I82.18, I82.19, I82.20, I82.21, I82.22, I82.23, I82.24, I82.25, I82.26, I82.27, I82.28, I82.29, I82.30, I82.31, I82.32, I82.33, I82.34, I82.35, I82.36, I82.37, I82.38, I82.39, I82.40, I82.41, I82.42, I82.43, I82.44, I82.45, I82.46, I82.47, I82.48, I82.49, I82.50, I82.51, I82.52, I82.53, I82.54, I82.55, I82.56, I82.57, I82.58, I82.59, I82.60, I82.61, I82.62, I82.63, I82.64, I82.65, I82.66, I82.67, I82.68, I82.69, I82.70, I82.71, I82.72, I82.73, I82.74, I82.75, I82.76, I82.77, I82.78, I82.79, I82.80, I82.81, I82.82, I82.83, I82.84, I82.85, I82.86, I82.87, I82.88, I82.89, I82.90, I82.91, I82.92, I82.93, I82.94, I82.95, I82.96, I82.97, I82.98, I82.99, I83.00, I83.01, I83.02, I83.03, I83.04, I83.05, I83.06, I83.07, I83.08, I83.09, I83.10, I83.11, I83.12, I83.13, I83.14, I83.15, I83.16, I83.17, I83.18, I83.19, I83.20, I83.21, I83.22, I83.23, I83.24, I83.25, I83.26, I83.27, I83.28, I83.29, I83.30, I83.31, I83.32, I83.33, I83.34, I83.35, I83.36, I83.37, I83.38, I83.39, I83.40, I83.41, I83.42, I83.43, I83.44, I83.45, I83.46, I83.47, I83.48, I83.49, I83.50, I83.51, I83.52, I83.53, I83.54, I83.55, I83.56, I83.57, I83.58, I83.59, I83.60, I83.61, I83.62, I83.63, I83.64, I83.65, I83.66, I83.67, I83.68, I83.69, I83.70, I83.71, I83.72, I83.73, I83.74, I83.75, I83.76, I83.77, I83.78, I83.79, I83.80, I83.81, I83.82, I83.83, I83.84, I83.85, I83.86, I83.87, I83.88, I83.89, I83.90, I83.91, I83.92, I83.93, I83.94, I83.95, I83.96, I83.97, I83.98, I83.99, I84.00, I84.01, I84.02, I84.03, I84.04, I84.05, I84.06, I84.07, I84.08, I84.09, I84.10, I84.11, I84.12, I84.13, I84.14, I84.15, I84.16, I84.17, I84.18, I84.19, I84.20, I84.21, I84.22, I84.23, I84.24, I84.25, I84.26, I84.27, I84.28, I84.29, I84.30, I84.31, I84.32, I84.33, I84.34, I84.35, I84.36, I84.37, I84.38, I84.39, I84.40, I84.41, I84.42, I84.43, I84.44, I84.45, I84.46, I84.47, I84.48, I84.49, I84.50, I84.51, I84.52, I84.53, I84.54, I84.55, I84.56, I84.57, I84.58, I84.59, I84.60, I84.61, I84.62, I84.63, I84.64, I84.65, I84.66, I84.67, I84.68, I84.69, I84.70, I84.71, I84.72, I84.73, I84.74, I84.75, I84.76, I84.77, I84.78, I84.79, I84.80, I84.81, I84.82, I84.83, I84.84, I84.85, I84.86, I84.87, I84.88, I84.89, I84.90, I84.91, I84.92, I84.93, I84.94, I84.95, I84.96, I84.97, I84.98, I84.99, I85.00, I85.01, I85.02, I85.03, I85.04, I85.05, I85.06, I85.07, I85.08, I85.09, I85.10, I85.11, I85.12, I85.13, I85.14, I85.15, I85.16, I85.17, I85.18, I85.19, I85.20, I85.21, I85.22, I85.23, I85.24, I85.25, I85.26, I85.27, I85.28, I85.29, I85.30, I85.31, I85.32, I85.33, I85.34, I85.35, I85.36, I85.37, I85.38, I85.39, I85.40, I85.41, I85.42, I85.43, I85.44, I85.45, I85.46, I85.47, I85.48, I85.49, I85.50, I85.51, I85.52, I85.53, I85.54, I85.55, I85.56, I85.57, I85.58, I85.59, I85.60, I85.61, I85.62, I85.63, I85.64, I85.65, I85.66, I85.67, I85.68, I85.69, I85.70, I85.71, I85.72, I85.73, I85.74, I85.75, I85.76, I85.77, I85.78, I85.79, I85.80, I85.81, I85.82, I85.83, I85.84, I85.85, I85.86, I85.87, I85.88, I85.89, I85.90, I85.91, I85.92, I85.93, I85.94, I85.95, I85.96, I85.97, I85.98, I85.99, I86.00, I86.01, I86.02, I86.03, I86.04, I86.05, I86.06, I86.07, I86.08, I86.09, I86.10, I86.11, I86.12, I86.13, I86.14, I86.15, I86.16, I86.17, I86.18, I86.19, I86.20, I86.21, I86.22, I86.23, I86.24, I86.25, I86.26, I86.27, I86.28, I86.29, I86.30, I86.31, I86.32, I86.33, I86.34, I86.35, I86.36, I86.37, I86.38, I86.39, I86.40, I86.41, I86.42, I86.43, I86.44, I86.45, I86.46, I86.47, I86.48, I86.49, I86.50, I86.51, I86.52, I86.53, I86.54, I86.55, I86.56, I86.57, I86.58, I86.59, I86.60, I86.61, I86.62, I86.63, I86.64, I86.65, I86.66, I86.67, I86.68, I86.69, I86.70, I86.71, I86.72, I86.73, I86.74, I86.75, I86.76, I86.77, I86.78, I86.79, I86.80, I86.81, I86.82, I86.83, I86.84, I86.85, I86.86, I86.87, I86.88, I86.89, I86.90, I86.91, I86.92, I86.93, I86.94, I86.95, I86.96, I86.97, I86.98, I86.99, I87.00, I87.01,		

Appendix A

Information from Trial

Trial Name: COBBRA clinicaltrials.gov/ct2/show/NCT0462430

NCT: NCT04642430

Therapeutic Area: Cardiology

RCT Category: Equivalence/Superiority

Brand Name: Eliquis and Xarelto

Generic Name: Apixaban and Rivaroxaban

Sponsor: Ottwa Hospital Research Institute

Year: 2020 - Present

Measurable Endpoint: Major Bleeding

Exposure: Apixaban

Comparator: Rivaroxaban

Populuation: Men and women ages 18 and older presenting with acute VTE

No. of Patients: 3,018

Power: TBD

Appendix A

ICD-9 Dx	
336.1	VASCULAR MYELOPATHIES
363.61	CHOROIDAL HEMORRHAGE UNSPECIFIED
363.62	EXPULSIVE CHOROIDAL HEMORRHAGE
376.32	ORBITAL HEMORRHAGE
377.42	HEMORRHAGE IN OPTIC NERVE SHEATHS
379.23	VITREOUS HEMORRHAGE
431	INTRACEREBRAL HEMORRHAGE
432	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE
432	NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1	SUBDURAL HEMORRHAGE
432.9	UNSPECIFIED INTRACRANIAL HEMORRHAGE
719.1	HEMARTHROSIS
719.11	HEMARTHROSIS INVOLVING SHOULDER REGION
719.12	HEMARTHROSIS INVOLVING UPPER ARM
719.14	HEMARTHROSIS INVOLVING HAND
719.15	HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.17	HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.19	HEMARTHROSIS INVOLVING MULTIPLE SITES
729.92	NONTRAUMATIC HEMATOMA OF SOFT TISSUE
852	SUBARACHNOID SUBDURAL AND EXTRADURAL HEMORRHAGE FOLLOWING INJURY
852	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.01	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.03	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1 - 24 HOURS) LOSS OF CONSCIOUSNESS
852.05	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.06	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.09	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.1	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.11	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.12	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.15	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.19	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.2	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.22	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.25	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.3	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.3	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.31	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.32	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.33	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.34	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.35	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.42	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN 1 HOUR) LOSS OF CONSCIOUSNESS
852.43	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE
852.45	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-24 HOURS) LOSS OF CONSCIOUSNESS-EXISTING CONSCIOUS LEVEL
852.49	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.54	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY
853	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
853.01	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
853.03	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
853.04	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853.05	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853.1	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
853.11	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
853.12	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
853.13	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
853.14	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED(MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853.15	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
866.02	LACERATION OF KIDNEY WITHOUT OPEN WOUND INTO CAVITY

Appendix A

363.72	HEMORRHAGIC CHOROICAL DETACH
423	HEMOPERICARDIUM
430	SUBARACHNOID HEMORRHAGE
568.81	HEMOPERITONEUM (NONTRAUMATIC)
719.1	HEMARTHROSIS SITE UNSPECIFIED
719.13	HEMARTHROSIS INVOLVING FOREARM
719.16	HEMARTHROSIS INVOLVING LOWER LEG
719.18	HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
852	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
852.02	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.04	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.1	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.13	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.14	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.16	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.2	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
852.21	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.23	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.24	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.26	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.29	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.36	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.39	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.4	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
852.4	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.41	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.44	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.46	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.5	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.5	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.51	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.52	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.53	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.55	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.56	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.59	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
853	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
853.02	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
853.06	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED
853.09	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
853.1	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
853.16	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
853.19	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
866.01	HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITHOUT OPEN WOUND INTO CAVITY
866.11	HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITH OPEN WOUND INTO CAVITY
866.12	LACERATION OF KIDNEY WITH OPEN WOUND INTO CAVIT

The occurrence of Inpatient Confinement with the following attributes:

Procedure Code (Any Confinement Position)	is any of: { "99.05", "99.03", "99.04", "99.06" }
99.05	TRANSFUSION OF PLATELETS
99.03	OTHER TRANSFUSION OF WHOLE BLOOD
99.04	TRANSFUSION OF PACKED CELLS
99.06	TRANSFUSION OF COAGULATION FACTORS

AND
ICD-9 Dx

Appendix A

455.1	INTERNAL THROMBOSED HEMORRHOIDS
455.7	UNSPECIFIED THROMBOSED HEMORRHOIDS
455.8	UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION
455.9	RESIDUAL HEMORRHOIDAL SKIN TAGS
459	HEMORRHAGE UNSPECIFIED
530.1	ESOPHAGITIS
530.1	ESOPHAGITIS UNSPECIFIED
530.13	EOSINOPHILIC ESOPHAGITIS
530.19	OTHER ESOPHAGITIS
530.7	GASTROESOPHAGEAL LACERATION-HEMORRHAGE SYNDROME
530.82	ESOPHAGEAL HEMORRHAGE
531	ACUTE GASTRIC ULCER WITH HEMORRHAGE
531.01	ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2	ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21	ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.3	ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
531.4	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.5	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION
531.6	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.61	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.7	CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
531.9	GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
532	ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01	ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.1	ACUTE DUODENAL ULCER WITH PERFORATION
532.3	ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
532.4	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.41	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.5	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION
532.9	DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
533.1	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION
533.2	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.21	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.5	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION
533.6	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.9	PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
534	ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.2	ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.21	ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.6	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.9	GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
535.11	ATROPHIC GASTRITIS WITH HEMORRHAGE
535.31	ALCOHOLIC GASTRITIS WITH HEMORRHAGE
535.4	OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE)
535.51	UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE
535.61	DUODENITIS WITH HEMORRHAGE
562.01	DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
562.03	DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.11	DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE)
562.12	DIVERTICULOSIS OF COLON WITH HEMORRHAGE
569.85	ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
578.1	BLOOD IN STOOL
599.71	GROSS HEMATURIA
623.8	OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA
626.8	OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT

Appendix A

784.7	EPISTAXIS
784.8	HEMORRHAGE FROM THROAT
786.3	HEMOPTYSIS
786.39	OTHER HEMOPTYSIS
280	IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC)
285.1	ACUTE POSTHEMORRHAGIC ANEMIA
455.2	INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.4	EXTERNAL THROMBOSED HEMORRHOIDS
455.5	EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.6	UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION
456	ESOPHAGEAL VARICES WITH BLEEDING
456.2	ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE WITH BLEEDING
530.11	REFLUX ESOPHAGITIS
530.12	ACUTE ESOPHAGITIS
531	ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.1	ACUTE GASTRIC ULCER WITH PERFORATION
531.2	ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.4	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.41	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6	CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
532	ACUTE DUODENAL ULCER WITH HEMORRHAGE
532.2	ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2	ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21	ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.6	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.61	CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.7	CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
533	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.3	ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION
533.4	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.6	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.61	CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.7	CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
534	ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.01	ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.1	ACUTE GASTROJEJUNAL ULCER WITH PERFORATION
534.2	ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.3	ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
534.41	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.5	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION
534.61	CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.7	CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
535	ACUTE GASTRITIS (WITHOUT HEMORRHAGE)
535.01	ACUTE GASTRITIS WITH HEMORRHAGE
535.1	ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE)
535.2	GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE)
535.21	GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE
535.3	ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE)
535.41	OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE
535.5	UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE)
535.6	DUODENITIS (WITHOUT HEMORRHAGE)
537.83	ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE
562	DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
562.02	DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.1	DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE)

Appendix A

562.13	DIVERTICULITIS OF COLON WITH HEMORRHAGE
569.3	HEMORRHAGE OF RECTUM AND ANUS
578	HEMATEMESIS
578.9	HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
593.81	VASCULAR DISORDERS OF KIDNEY
599.7	HEMATURIA UNSPECIFIED
623.6	VAGINAL HEMATOMA
626.6	METORRHAGIA
786.3	HEMOPTYSIS UNSPECIFIED
786.31	ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS

ICD-10 Dx

G95.19	Other vascular myelopathies
H05.232	Hemorrhage of left orbit
H05.239	Hemorrhage of unspecified orbit
H31.30	Unspecified choroidal hemorrhage
H31.301	Unspecified choroidal hemorrhage, right eye
H31.303	Unspecified choroidal hemorrhage, bilateral
H31.312	Expulsive choroidal hemorrhage, left eye
H31.313	Expulsive choroidal hemorrhage, bilateral
H31.411	Hemorrhagic choroidal detachment, right eye
H31.419	Hemorrhagic choroidal detachment, unspecified eye
H43.1	Vitreous hemorrhage
H43.10	Vitreous hemorrhage, unspecified eye
H43.11	Vitreous hemorrhage, right eye
H43.13	Vitreous hemorrhage, bilateral
H47.022	Hemorrhage in optic nerve sheath, left eye
H47.023	Hemorrhage in optic nerve sheath, bilateral
H47.029	Hemorrhage in optic nerve sheath, unspecified eye
I60.0	Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.1	Nontraumatic subarachnoid hemorrhage from middle cerebral artery
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8	Other nontraumatic subarachnoid hemorrhage
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3	Nontraumatic intracerebral hemorrhage in brain stem
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized
I61.8	Other nontraumatic intracerebral hemorrhage
I62	Other and unspecified nontraumatic intracranial hemorrhage
I62.0	Nontraumatic subdural hemorrhage
I62.00	Nontraumatic subdural hemorrhage, unspecified
I62.01	Nontraumatic acute subdural hemorrhage
I62.02	Nontraumatic subacute subdural hemorrhage
I62.9	Nontraumatic intracranial hemorrhage, unspecified
K66.1	Hemoperitoneum
M25.0	Hemarthrosis
M25.01	Hemarthrosis, shoulder
M25.012	Hemarthrosis, left shoulder
M25.019	Hemarthrosis, unspecified shoulder
M25.021	Hemarthrosis, right elbow
M25.029	Hemarthrosis, unspecified elbow
M25.03	Hemarthrosis, wrist
M25.039	Hemarthrosis, unspecified wrist
M25.05	Hemarthrosis, hip

Appendix A

M25.051	Hemarthrosis, right hip
M25.052	Hemarthrosis, left hip
M25.06	Hemarthrosis, knee
M25.061	Hemarthrosis, right knee
M25.07	Hemarthrosis, ankle and foot
M25.071	Hemarthrosis, right ankle
M25.073	Hemarthrosis, unspecified ankle
M25.074	Hemarthrosis, right foot
M25.075	Hemarthrosis, left foot
M25.08	Hemarthrosis, other specified site
M79.81	Nontraumatic hematoma of soft tissue
S06.4	Epidural hemorrhage
S06.4X	Epidural hemorrhage
S06.4X0	Epidural hemorrhage without loss of consciousness
S06.4X0D	Epidural hemorrhage without loss of consciousness, subsequent encounter
S06.4X1A	Epidural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
S06.4X2S	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela
S06.4X3	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
S06.4X3A	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
S06.4X4	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours
S06.4X4A	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.4X5D	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
S06.4X5S	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
S06.4X6D	Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
S06.4X7	Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness
S06.4X7A	Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter
S06.4X9	Epidural hemorrhage with loss of consciousness of unspecified duration
S06.4X9A	Epidural hemorrhage with loss of consciousness of unspecified duration, initial encounter
S06.5	Traumatic subdural hemorrhage
S06.5X	Traumatic subdural hemorrhage
S06.5X0	Traumatic subdural hemorrhage without loss of consciousness
S06.5X2	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.5X2A	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.5X3A	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
S06.5X3D	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.5X3S	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.5X4S	Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela
S06.5X5	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level
S06.5X5A	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
S06.5X5S	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
S06.5X6A	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
S06.5X6D	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
S06.5X6S	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
S06.5X8	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness
S06.5X9A	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, initial encounter
S06.5X9D	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
S06.5X9S	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, sequela
S06.6X	Traumatic subarachnoid hemorrhage
S06.6X0	Traumatic subarachnoid hemorrhage without loss of consciousness
S06.6X0A	Traumatic subarachnoid hemorrhage without loss of consciousness, initial encounter
S06.6X0D	Traumatic subarachnoid hemorrhage without loss of consciousness, subsequent encounter
S06.6X1	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less
S06.6X1A	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
S06.6X1S	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.6X2D	Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.6X3D	Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.6X4	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours
S06.6X4A	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.6X4S	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela
S06.6X5	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level

Appendix A

S06.6X5S	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
S06.6X6	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
S06.6X6A	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
S06.6X6S	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
S06.6X7	Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness
S06.6X8A	Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, initial encounter
S06.6X9S	Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, sequela
S26.0	Injury of heart with hemopericardium
S26.01	Contusion of heart with hemopericardium
S26.01XA	Contusion of heart with hemopericardium, initial encounter
S26.020	Mild laceration of heart with hemopericardium
S26.020A	Mild laceration of heart with hemopericardium, initial encounter
S26.021D	Moderate laceration of heart with hemopericardium, subsequent encounter
S26.021S	Moderate laceration of heart with hemopericardium, sequela
S26.022	Major laceration of heart with hemopericardium
S26.022D	Major laceration of heart with hemopericardium, subsequent encounter
S26.09	Other injury of heart with hemopericardium
S26.09XD	Other injury of heart with hemopericardium, subsequent encounter
S26.09XS	Other injury of heart with hemopericardium, sequela
S37.01	Minor contusion of kidney
S37.011D	Minor contusion of right kidney, subsequent encounter
S37.011S	Minor contusion of right kidney, sequela
S37.012A	Minor contusion of left kidney, initial encounter
S37.012D	Minor contusion of left kidney, subsequent encounter
S37.012S	Minor contusion of left kidney, sequela
S37.02	Major contusion of kidney
S37.021	Major contusion of right kidney
S37.021D	Major contusion of right kidney, subsequent encounter
S37.021S	Major contusion of right kidney, sequela
S37.022D	Major contusion of left kidney, subsequent encounter
S37.022S	Major contusion of left kidney, sequela
S37.029	Major contusion of unspecified kidney
S37.031A	Laceration of right kidney, unspecified degree, initial encounter
S37.031D	Laceration of right kidney, unspecified degree, subsequent encounter
S37.032	Laceration of left kidney, unspecified degree
S37.032D	Laceration of left kidney, unspecified degree, subsequent encounter
S37.032S	Laceration of left kidney, unspecified degree, sequela
S37.039	Laceration of unspecified kidney, unspecified degree
S37.039D	Laceration of unspecified kidney, unspecified degree, subsequent encounter
S37.04	Minor laceration of kidney
S37.041	Minor laceration of right kidney
S37.041A	Minor laceration of right kidney, initial encounter
S37.041D	Minor laceration of right kidney, subsequent encounter
S37.041S	Minor laceration of right kidney, sequela
S37.042A	Minor laceration of left kidney, initial encounter
S37.042D	Minor laceration of left kidney, subsequent encounter
S37.042S	Minor laceration of left kidney, sequela
S37.051	Moderate laceration of right kidney
S37.051A	Moderate laceration of right kidney, initial encounter
S37.051S	Moderate laceration of right kidney, sequela
S37.052S	Moderate laceration of left kidney, sequela
S37.059D	Moderate laceration of unspecified kidney, subsequent encounter
S37.059S	Moderate laceration of unspecified kidney, sequela
S37.061S	Major laceration of right kidney, sequela
S37.062	Major laceration of left kidney
S37.062S	Major laceration of left kidney, sequela
S37.069A	Major laceration of unspecified kidney, initial encounter
S37.069S	Major laceration of unspecified kidney, sequela
H05.23	Hemorrhage of orbit
H05.231	Hemorrhage of right orbit

Appendix A

H05.233	Hemorrhage of bilateral orbit
H31.302	Unspecified choroidal hemorrhage, left eye
H31.309	Unspecified choroidal hemorrhage, unspecified eye
H31.31	Expulsive choroidal hemorrhage
H31.311	Expulsive choroidal hemorrhage, right eye
H31.319	Expulsive choroidal hemorrhage, unspecified eye
H31.41	Hemorrhagic choroidal detachment
H31.412	Hemorrhagic choroidal detachment, left eye
H31.413	Hemorrhagic choroidal detachment, bilateral
H43.12	Vitreous hemorrhage, left eye
H47.02	Hemorrhage in optic nerve sheath
H47.021	Hemorrhage in optic nerve sheath, right eye
I23.0	Hemopericardium as current complication following acute myocardial infarction
I31.2	Hemopericardium, not elsewhere classified
I60	Nontraumatic subarachnoid hemorrhage
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.5	Nontraumatic subarachnoid hemorrhage from vertebral artery
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified
I61	Nontraumatic intracerebral hemorrhage
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum
I61.9	Nontraumatic intracerebral hemorrhage, unspecified
I62.03	Nontraumatic chronic subdural hemorrhage
I62.1	Nontraumatic extradural hemorrhage
M25.00	Hemarthrosis, unspecified joint
M25.011	Hemarthrosis, right shoulder
M25.02	Hemarthrosis, elbow
M25.022	Hemarthrosis, left elbow
M25.031	Hemarthrosis, right wrist
M25.032	Hemarthrosis, left wrist
M25.04	Hemarthrosis, hand
M25.041	Hemarthrosis, right hand
M25.042	Hemarthrosis, left hand
M25.049	Hemarthrosis, unspecified hand
M25.059	Hemarthrosis, unspecified hip
M25.062	Hemarthrosis, left knee
M25.069	Hemarthrosis, unspecified knee
M25.072	Hemarthrosis, left ankle
M25.076	Hemarthrosis, unspecified foot
S06.4X0A	Epidural hemorrhage without loss of consciousness, initial encounter
S06.4X0S	Epidural hemorrhage without loss of consciousness, sequela
S06.4X1	Epidural hemorrhage with loss of consciousness of 30 minutes or less
S06.4X1D	Epidural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.4X1S	Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.4X2	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.4X2A	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.4X2D	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.4X3D	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.4X3S	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.4X4D	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06.4X4S	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela

Appendix A

S06.4X5	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level
S06.4X5A	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
S06.4X6	Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
S06.4X6A	Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
S06.4X6S	Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
S06.4X8	Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness
S06.4X8A	Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness, initial encounter
S06.4X9D	Epidural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
S06.4X9S	Epidural hemorrhage with loss of consciousness of unspecified duration, sequela
S06.5X0A	Traumatic subdural hemorrhage without loss of consciousness, initial encounter
S06.5X0D	Traumatic subdural hemorrhage without loss of consciousness, subsequent encounter
S06.5X0S	Traumatic subdural hemorrhage without loss of consciousness, sequela
S06.5X1	Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less
S06.5X1A	Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
S06.5X1D	Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.5X1S	Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.5X2D	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.5X2S	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela
S06.5X3	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
S06.5X4	Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours
S06.5X4A	Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.5X4D	Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06.5X5D	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
S06.5X6	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
S06.5X7	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness
S06.5X7A	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness, initial encounter
S06.5X8A	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness, initial encounter
S06.5X9	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration
S06.6	Traumatic subarachnoid hemorrhage
S06.6X0S	Traumatic subarachnoid hemorrhage without loss of consciousness, sequela
S06.6X1D	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.6X2	Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.6X2A	Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.6X2S	Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela
S06.6X3	Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
S06.6X3A	Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
S06.6X3S	Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.6X4D	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06.6X5A	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
S06.6X5D	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
S06.6X6D	Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
S06.6X7A	Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter
S06.6X8	Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness
S06.6X9	Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration
S06.6X9A	Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, initial encounter
S06.6X9D	Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
S26.00	Unspecified injury of heart with hemopericardium
S26.00XA	Unspecified injury of heart with hemopericardium, initial encounter
S26.00XD	Unspecified injury of heart with hemopericardium, subsequent encounter
S26.00XS	Unspecified injury of heart with hemopericardium, sequela
S26.01XD	Contusion of heart with hemopericardium, subsequent encounter
S26.01XS	Contusion of heart with hemopericardium, sequela
S26.02	Laceration of heart with hemopericardium
S26.020D	Mild laceration of heart with hemopericardium, subsequent encounter
S26.020S	Mild laceration of heart with hemopericardium, sequela
S26.021	Moderate laceration of heart with hemopericardium
S26.021A	Moderate laceration of heart with hemopericardium, initial encounter
S26.022A	Major laceration of heart with hemopericardium, initial encounter
S26.022S	Major laceration of heart with hemopericardium, sequela
S26.09XA	Other injury of heart with hemopericardium, initial encounter

Appendix A

S37.011	Minor contusion of right kidney
S37.011A	Minor contusion of right kidney, initial encounter
S37.012	Minor contusion of left kidney
S37.019	Minor contusion of unspecified kidney
S37.019A	Minor contusion of unspecified kidney, initial encounter
S37.019D	Minor contusion of unspecified kidney, subsequent encounter
S37.019S	Minor contusion of unspecified kidney, sequela
S37.021A	Major contusion of right kidney, initial encounter
S37.022	Major contusion of left kidney
S37.022A	Major contusion of left kidney, initial encounter
S37.029A	Major contusion of unspecified kidney, initial encounter
S37.029D	Major contusion of unspecified kidney, subsequent encounter
S37.029S	Major contusion of unspecified kidney, sequela
S37.03	Laceration of kidney, unspecified degree
S37.031	Laceration of right kidney, unspecified degree
S37.031S	Laceration of right kidney, unspecified degree, sequela
S37.032A	Laceration of left kidney, unspecified degree, initial encounter
S37.039A	Laceration of unspecified kidney, unspecified degree, initial encounter
S37.039S	Laceration of unspecified kidney, unspecified degree, sequela
S37.042	Minor laceration of left kidney
S37.049	Minor laceration of unspecified kidney
S37.049A	Minor laceration of unspecified kidney, initial encounter
S37.049D	Minor laceration of unspecified kidney, subsequent encounter
S37.049S	Minor laceration of unspecified kidney, sequela
S37.05	Moderate laceration of kidney
S37.051D	Moderate laceration of right kidney, subsequent encounter
S37.052	Moderate laceration of left kidney
S37.052A	Moderate laceration of left kidney, initial encounter
S37.052D	Moderate laceration of left kidney, subsequent encounter
S37.059	Moderate laceration of unspecified kidney
S37.059A	Moderate laceration of unspecified kidney, initial encounter
S37.06	Major laceration of kidney
S37.061	Major laceration of right kidney
S37.061A	Major laceration of right kidney, initial encounter
S37.061D	Major laceration of right kidney, subsequent encounter
S37.062A	Major laceration of left kidney, initial encounter
S37.062D	Major laceration of left kidney, subsequent encounter
S37.069	Major laceration of unspecified kidney
S37.069D	Major laceration of unspecified kidney, subsequent encounter

The occurrence of Inpatient Confinement with the following attributes:

Procedure Code (Any Confinement Position)	is any of: { "30230H1", "30230M1", "30230N1", "30230P1", "30230T1", "30230V1", "30230W1", "30233H1", "30233M1", "30233R1", "30233T1", "30240H1", "30240K1", "30240P1", "30240R1", "30243L1", "30243M1", "30243N1", "30243R1", "30243W1", "30230K1", "30230L1", "30230R1", "30233K1", "30233L1", "30233N1", "30233P1", "30233V1", "30233W1", "30240L1", "30240M1", "30240N1", "30240T1", "30240V1", "30240W1", "30243H1", "30243K1", "30243P1", "30243T1", "30243V1" }
AND	
D50.0	Iron deficiency anemia secondary to blood loss (chronic)
D62	Acute posthemorrhagic anemia
I85.11	Secondary esophageal varices with bleeding
K20	Esophagitis
K20.0	Eosinophilic esophagitis
K20.8	Other esophagitis
K20.9	Esophagitis, unspecified
K21.0	Gastro-esophageal reflux disease with esophagitis
K22.11	Ulcer of esophagus with bleeding
K25.1	Acute gastric ulcer with perforation
K25.2	Acute gastric ulcer with both hemorrhage and perforation
K25.4	Chronic or unspecified gastric ulcer with hemorrhage
K25.5	Chronic or unspecified gastric ulcer with perforation

Appendix A

K26.2	Acute duodenal ulcer with both hemorrhage and perforation
K26.4	Chronic or unspecified duodenal ulcer with hemorrhage
K26.6	Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.4	Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.5	Chronic or unspecified peptic ulcer, site unspecified, with perforation
K27.6	Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.1	Acute gastrojejunal ulcer with perforation
K28.2	Acute gastrojejunal ulcer with both hemorrhage and perforation
K29.31	Chronic superficial gastritis with bleeding
K29.91	Gastroduodenitis, unspecified, with bleeding
K57.11	Diverticulosis of small intestine without perforation or abscess with bleeding
K57.21	Diverticulitis of large intestine with perforation and abscess with bleeding
K57.51	Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53	Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.93	Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5	Hemorrhage of anus and rectum
K64.1	Second degree hemorrhoids
K64.3	Fourth degree hemorrhoids
K64.9	Unspecified hemorrhoids
K92.0	Hematemesis
K92.1	Melena
N89.7	Hematocolpos
N92.1	Excessive and frequent menstruation with irregular cycle
N93.8	Other specified abnormal uterine and vaginal bleeding
R04.0	Epistaxis
R31.0	Gross hematuria
R31.9	Hematuria, unspecified
R58	Hemorrhage, not elsewhere classified
I85.01	Esophageal varices with bleeding
K22.6	Gastro-esophageal laceration-hemorrhage syndrome
K25.0	Acute gastric ulcer with hemorrhage
K25.6	Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0	Acute duodenal ulcer with hemorrhage
K26.1	Acute duodenal ulcer with perforation
K26.5	Chronic or unspecified duodenal ulcer with perforation
K27.0	Acute peptic ulcer, site unspecified, with hemorrhage
K27.1	Acute peptic ulcer, site unspecified, with perforation
K27.2	Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0	Acute gastrojejunal ulcer with hemorrhage
K28.4	Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.5	Chronic or unspecified gastrojejunal ulcer with perforation
K28.6	Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K29.01	Acute gastritis with bleeding
K29.21	Alcoholic gastritis with bleeding
K29.41	Chronic atrophic gastritis with bleeding
K29.51	Unspecified chronic gastritis with bleeding
K29.61	Other gastritis with bleeding
K29.71	Gastritis, unspecified, with bleeding
K29.81	Duodenitis with bleeding
K31.811	Angiodysplasia of stomach and duodenum with bleeding
K55.21	Angiodysplasia of colon with hemorrhage
K57.01	Diverticulitis of small intestine with perforation and abscess with bleeding
K57.31	Diverticulosis of large intestine without perforation or abscess with bleeding
K57.41	Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.81	Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91	Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K64.0	First degree hemorrhoids
K64.2	Third degree hemorrhoids
K64.4	Residual hemorrhoidal skin tags
K64.5	Perianal venous thrombosis

Appendix A

K64.8	Other hemorrhoids
K92.2	Gastrointestinal hemorrhage, unspecified
N89.8	Other specified noninflammatory disorders of vagina
N93.9	Abnormal uterine and vaginal bleeding, unspecified
R04.1	Hemorrhage from throat
R04.2	Hemoptysis

Appendix A

Inpatient, Primary Diagnosis: ICD-9 Codes

280.0 - IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS
(CHRONIC)

455.7 - UNSPECIFIED THROMBOSED HEMORRHOIDS

459.0 - HEMORRHAGE UNSPECIFIED

530.10 - ESOPHAGITIS UNSPECIFIED

530.13 - EOSINOPHILIC ESOPHAGITIS

531.0 - ACUTE GASTRIC ULCER WITH HEMORRHAGE

531.1 - ACUTE GASTRIC ULCER WITH PERFORATION

531.2 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND
PERFORATION

531.20 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND
PERFORATION WITHOUT OBSTRUCTION

531.3 - ACUTE GASTRIC ULCER WITHOUT MENTION OF
HEMORRHAGE OR PERFORATION

531.4 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH
HEMORRHAGE

531.6 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH
HEMORRHAGE AND PERFORATION

531.61 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH
HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

531.9 - GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC
WITHOUT MENTION OF HEMORRHAGE OR PERFORATION

532.0 - ACUTE DUODENAL ULCER WITH HEMORRHAGE

532.00 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT
OBSTRUCTION

532.01 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH
OBSTRUCTION

532.2 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND
PERFORATION

532.20 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND
PERFORATION WITHOUT OBSTRUCTION

532.3 - ACUTE DUODENAL ULCER WITHOUT MENTION OF
HEMORRHAGE OR PERFORATION

Appendix A

532.4 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE

532.41 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION

532.5 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION

532.61 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

533.0 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE

533.00 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION

533.01 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION

533.1 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION

533.2 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION

533.20 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

533.3 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION

533.6 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION

533.60 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

533.7 - CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION

534.00 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION

534.01 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION

534.20 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

Appendix A

- 534.3 - ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 534.40 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
- 534.41 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION

- 534.61 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
- 534.7 - CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 534.9 - GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 535.00 - ACUTE GASTRITIS (WITHOUT HEMORRHAGE)
- 535.01 - ACUTE GASTRITIS WITH HEMORRHAGE
- 535.10 - ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE)
- 535.20 - GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE)

- 535.21 - GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE
- 535.31 - ALCOHOLIC GASTRITIS WITH HEMORRHAGE

- 535.40 - OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE)
- 535.41 - OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE
- 562.00 - DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
- 562.01 - DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)

- 562.03 - DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE

- 562.11 - DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE)
- 562.13 - DIVERTICULITIS OF COLON WITH HEMORRHAGE
- 569.85 - ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE

Appendix A

578.0 - HEMATEMESIS
578.1 - BLOOD IN STOOL
578.9 - HEMORRHAGE OF GASTROINTESTINAL TRACT
UNSPECIFIED
593.81 - VASCULAR DISORDERS OF KIDNEY
599.70 - HEMATURIA UNSPECIFIED
599.71 - GROSS HEMATURIA
623.6 - VAGINAL HEMATOMA
626.6 - METRORRHAGIA
784.7 - EPISTAXIS
784.8 - HEMORRHAGE FROM THROAT
786.31 - ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN
INFANTS
285.1 - ACUTE POSTHEMORRHAGIC ANEMIA
455.1 - INTERNAL THROMBOSED HEMORRHOIDS

455.2 - INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.4 - EXTERNAL THROMBOSED HEMORRHOIDS

455.5 - EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION

455.6 - UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION

455.8 - UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION
455.9 - RESIDUAL HEMORRHOIDAL SKIN TAGS
456.0 - ESOPHAGEAL VARICES WITH BLEEDING
456.20 - ESOPHAGEAL VARICES IN DISEASES CLASSIFIED
ELSEWHERE WITH BLEEDING
530.1 - ESOPHAGITIS
530.11 - REFLUX ESOPHAGITIS
530.12 - ACUTE ESOPHAGITIS
530.19 - OTHER ESOPHAGITIS
530.7 - GASTROESOPHAGEAL LACERATION-HEMORRHAGE
SYNDROME
530.82 - ESOPHAGEAL HEMORRHAGE

Appendix A

531.00 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION

531.01 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION

531.21 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

531.40 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION

531.41 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION

531.5 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION

531.60 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

531.7 - CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION

532.1 - ACUTE DUODENAL ULCER WITH PERFORATION

532.21 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

532.40 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION

532.6 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION

532.60 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

532.7 - CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION

532.9 - DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION

533.21 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

533.4 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE

Appendix A

533.40 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION

533.41 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION

533.5 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION

533.61 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

533.9 - PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION

534.0 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE

534.1 - ACUTE GASTROJEJUNAL ULCER WITH PERFORATION

534.2 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION

534.21 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION

534.4 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE

534.5 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION

534.6 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION

534.60 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

535.11 - ATROPHIC GASTRITIS WITH HEMORRHAGE

535.30 - ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE)

535.50 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE)

535.51 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE

535.60 - DUODENITIS (WITHOUT HEMORRHAGE)

Appendix A

535.61 - DUODENITIS WITH HEMORRHAGE
537.83 - ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE
562.02 - DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE

562.10 - DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE)
562.12 - DIVERTICULOSIS OF COLON WITH HEMORRHAGE
569.3 - HEMORRHAGE OF RECTUM AND ANUS
623.8 - OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA
626.8 - OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT
786.3 - HEMOPTYSIS
786.30 - HEMOPTYSIS UNSPECIFIED
786.39 - OTHER HEMOPTYSIS
285.9 - ANEMIA UNSPECIFIED
790.92 - ABNORMAL COAGULATION PROFILE
363.63 - CHOROIDAL RUPTURE
626.2 - EXCESSIVE OR FREQUENT MENSTRUATION
372.72 - CONJUNCTIVAL HEMORRHAGE

Inpatient, Primary Diagnosis: ICD-10 Codes

D50.0 - Iron deficiency anemia secondary to blood loss (chronic)
D62 - Acute posthemorrhagic anemia
I85.01 - Esophageal varices with bleeding
I85.11 - Secondary esophageal varices with bleeding
K20.0 - Eosinophilic esophagitis
K20.8 - Other esophagitis
K22.11 - Ulcer of esophagus with bleeding
K22.6 - Gastro-esophageal laceration-hemorrhage syndrome
K25.0 - Acute gastric ulcer with hemorrhage
K25.1 - Acute gastric ulcer with perforation
K25.2 - Acute gastric ulcer with both hemorrhage and perforation

Appendix A

K25.4 - Chronic or unspecified gastric ulcer with hemorrhage
K25.5 - Chronic or unspecified gastric ulcer with perforation
K26.1 - Acute duodenal ulcer with perforation
K26.2 - Acute duodenal ulcer with both hemorrhage and perforation
K26.4 - Chronic or unspecified duodenal ulcer with hemorrhage
K27.1 - Acute peptic ulcer, site unspecified, with perforation
K27.2 - Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.5 - Chronic or unspecified peptic ulcer, site unspecified, with perforation
K27.6 - Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0 - Acute gastrojejunal ulcer with hemorrhage
K28.4 - Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6 - Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K29.01 - Acute gastritis with bleeding
K29.31 - Chronic superficial gastritis with bleeding
K29.41 - Chronic atrophic gastritis with bleeding
K29.51 - Unspecified chronic gastritis with bleeding
K29.71 - Gastritis, unspecified, with bleeding
K57.11 - Diverticulosis of small intestine without perforation or abscess with bleeding
K57.21 - Diverticulitis of large intestine with perforation and abscess with bleeding
K57.41 - Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.51 - Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.81 - Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91 - Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93 - Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding

Appendix A

K62.5 - Hemorrhage of anus and rectum
K64.0 - First degree hemorrhoids
K64.5 - Perianal venous thrombosis
K64.8 - Other hemorrhoids
K64.9 - Unspecified hemorrhoids
K92.0 - Hematemesis
K92.2 - Gastrointestinal hemorrhage, unspecified
N89.7 - Hematocolpos
N93.8 - Other specified abnormal uterine and vaginal bleeding
R04.2 - Hemoptysis
R31.0 - Gross hematuria
K20 - Esophagitis
K20.9 - Esophagitis, unspecified
K21.0 - Gastro-esophageal reflux disease with esophagitis
K25.6 - Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0 - Acute duodenal ulcer with hemorrhage
K26.5 - Chronic or unspecified duodenal ulcer with perforation
K26.6 - Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0 - Acute peptic ulcer, site unspecified, with hemorrhage
K27.4 - Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K28.1 - Acute gastrojejunal ulcer with perforation

K28.2 - Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.5 - Chronic or unspecified gastrojejunal ulcer with perforation
K29.21 - Alcoholic gastritis with bleeding
K29.61 - Other gastritis with bleeding
K29.81 - Duodenitis with bleeding
K29.91 - Gastroduodenitis, unspecified, with bleeding
K31.811 - Angiodysplasia of stomach and duodenum with bleeding
K55.21 - Angiodysplasia of colon with hemorrhage

Appendix A

K57.01 - Diverticulitis of small intestine with perforation and abscess with bleeding

K57.31 - Diverticulosis of large intestine without perforation or abscess with bleeding

K57.53 - Diverticulitis of both small and large intestine without perforation or abscess with bleeding

K64.1 - Second degree hemorrhoids

K64.2 - Third degree hemorrhoids

K64.3 - Fourth degree hemorrhoids

K64.4 - Residual hemorrhoidal skin tags

K92.1 - Melena

N89.8 - Other specified noninflammatory disorders of vagina

N93.9 - Abnormal uterine and vaginal bleeding, unspecified

R04.0 - Epistaxis

R04.1 - Hemorrhage from throat

R58 - Hemorrhage, not elsewhere classified

D64.9 - Anemia, unspecified

R79.1 - Abnormal coagulation profile

H11.30 - Conjunctival hemorrhage, unspecified eye

H11.31 - Conjunctival hemorrhage, right eye

H11.32 - Conjunctival hemorrhage, left eye

H11.33 - Conjunctival hemorrhage, bilateral

H31.321 - Choroidal rupture, right eye

H31.322 - Choroidal rupture, left eye

H31.323 - Choroidal rupture, bilateral

H31.329 - Choroidal rupture, unspecified eye

N92.1 - Excessive and frequent menstruation with irregular cycle

R31.1 - Benign essential microscopic hematuria

R31.2 - Other microscopic hematuria

R31.29 - Other microscopic hematuria

N92.0 - Excessive and frequent menstruation with regular cycle

R31.21 - Asymptomatic microscopic hematuria

R31.9 - Hematuria, unspecified

Appendix A

Cancer - ICD-9

140.0 - MALIGNANT NEOPLASM OF UPPER LIP
VERMILION BORDER

140.3 - MALIGNANT NEOPLASM OF UPPER LIP
INNER ASPECT

140.6 - MALIGNANT NEOPLASM OF
COMMISSURE OF LIP

140.8 - MALIGNANT NEOPLASM OF OTHER
SITES OF LIP

140.9 - MALIGNANT NEOPLASM OF LIP
UNSPECIFIED VERMILION BORDER

141.0 - MALIGNANT NEOPLASM OF BASE OF
TONGUE

141.3 - MALIGNANT NEOPLASM OF VENTRAL
SURFACE OF TONGUE

141.5 - MALIGNANT NEOPLASM OF JUNCTIONAL
ZONE OF TONGUE

141.6 - MALIGNANT NEOPLASM OF LINGUAL
TONSIL

141.9 - MALIGNANT NEOPLASM OF TONGUE
UNSPECIFIED

142.0 - MALIGNANT NEOPLASM OF PAROTID
GLAND

142.1 - MALIGNANT NEOPLASM OF
SUBMANDIBULAR GLAND

142.9 - MALIGNANT NEOPLASM OF SALIVARY
GLAND UNSPECIFIED

143.8 - MALIGNANT NEOPLASM OF OTHER
SITES OF GUM

144.1 - MALIGNANT NEOPLASM OF LATERAL
PORTION OF FLOOR OF MOUTH

144.8 - MALIGNANT NEOPLASM OF OTHER
SITES OF FLOOR OF MOUTH

144.9 - MALIGNANT NEOPLASM OF FLOOR OF
MOUTH PART UNSPECIFIED

Cancer - ICD-10

C00.0 - Malignant neoplasm of external upper lip

C00.1 - Malignant neoplasm of external lower lip

C00.4 - Malignant neoplasm of lower lip, inner aspect

C00.5 - Malignant neoplasm of lip, unspecified, inner
aspect

C00.6 - Malignant neoplasm of commissure of lip,
unspecified

C00.9 - Malignant neoplasm of lip, unspecified

C01 - Malignant neoplasm of base of tongue

C02 - Malignant neoplasm of other and unspecified parts
of tongue

C02.1 - Malignant neoplasm of border of tongue

C02.2 - Malignant neoplasm of ventral surface of tongue

C02.3 - Malignant neoplasm of anterior two-thirds of
tongue, part unspecified

C02.4 - Malignant neoplasm of lingual tonsil

C02.8 - Malignant neoplasm of overlapping sites of tongue

C02.9 - Malignant neoplasm of tongue, unspecified

C03 - Malignant neoplasm of gum

C03.0 - Malignant neoplasm of upper gum

C04 - Malignant neoplasm of floor of mouth

Appendix A

145.3 - MALIGNANT NEOPLASM OF SOFT PALATE

145.5 - MALIGNANT NEOPLASM OF PALATE UNSPECIFIED

145.9 - MALIGNANT NEOPLASM OF MOUTH UNSPECIFIED

146 - MALIGNANT NEOPLASM OF OROPHARYNX

146.3 - MALIGNANT NEOPLASM OF VALLECULA EPIGLOTTICA

146.4 - MALIGNANT NEOPLASM OF ANTERIOR ASPECT OF EPIGLOTTIS

146.6 - MALIGNANT NEOPLASM OF LATERAL WALL OF OROPHARYNX

146.7 - MALIGNANT NEOPLASM OF POSTERIOR WALL OF OROPHARYNX

146.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF OROPHARYNX

146.9 - MALIGNANT NEOPLASM OF OROPHARYNX UNSPECIFIED SITE

147 - MALIGNANT NEOPLASM OF NASOPHARYNX

147.0 - MALIGNANT NEOPLASM OF SUPERIOR WALL OF NASOPHARYNX

147.2 - MALIGNANT NEOPLASM OF LATERAL WALL OF NASOPHARYNX

147.9 - MALIGNANT NEOPLASM OF NASOPHARYNX UNSPECIFIED SITE

148 - MALIGNANT NEOPLASM OF HYPOPHARYNX

148.2 - MALIGNANT NEOPLASM OF ARYEPIGLOTTIC FOLD HYPOPHARYNGEAL ASPECT

148.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF HYPOPHARYNX

C04.1 - Malignant neoplasm of lateral floor of mouth

C04.8 - Malignant neoplasm of overlapping sites of floor of mouth

C05 - Malignant neoplasm of palate

C05.2 - Malignant neoplasm of uvula

C05.9 - Malignant neoplasm of palate, unspecified

C06 - Malignant neoplasm of other and unspecified parts of mouth

C06.0 - Malignant neoplasm of cheek mucosa

C06.2 - Malignant neoplasm of retromolar area

C06.8 - Malignant neoplasm of overlapping sites of other and unspecified parts of mouth

C06.89 - Malignant neoplasm of overlapping sites of other parts of mouth

C07 - Malignant neoplasm of parotid gland

C08 - Malignant neoplasm of other and unspecified major salivary glands

C08.0 - Malignant neoplasm of submandibular gland

C08.9 - Malignant neoplasm of major salivary gland, unspecified

C09.0 - Malignant neoplasm of tonsillar fossa

C10 - Malignant neoplasm of oropharynx

C10.0 - Malignant neoplasm of vallecula

Appendix A

148.9 - MALIGNANT NEOPLASM OF HYPOPHARYNX UNSPECIFIED SITE	C10.2 - Malignant neoplasm of lateral wall of oropharynx
149.0 - MALIGNANT NEOPLASM OF PHARYNX UNSPECIFIED	C10.3 - Malignant neoplasm of posterior wall of oropharynx
149.8 - MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE LIP AND ORAL CAVITY	C10.9 - Malignant neoplasm of oropharynx, unspecified
150.1 - MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS	C11 - Malignant neoplasm of nasopharynx
150.2 - MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS	C11.0 - Malignant neoplasm of superior wall of nasopharynx
150.4 - MALIGNANT NEOPLASM OF MIDDLE THIRD OF ESOPHAGUS	C11.1 - Malignant neoplasm of posterior wall of nasopharynx
150.5 - MALIGNANT NEOPLASM OF LOWER THIRD OF ESOPHAGUS	C11.2 - Malignant neoplasm of lateral wall of nasopharynx
150.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED PART OF ESOPHAGUS	C11.8 - Malignant neoplasm of overlapping sites of nasopharynx
150.9 - MALIGNANT NEOPLASM OF ESOPHAGUS UNSPECIFIED SITE	C11.9 - Malignant neoplasm of nasopharynx, unspecified
151.0 - MALIGNANT NEOPLASM OF CARDIA	C13 - Malignant neoplasm of hypopharynx
151.2 - MALIGNANT NEOPLASM OF PYLORIC ANTRUM	C13.1 - Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
151.3 - MALIGNANT NEOPLASM OF FUNDUS OF STOMACH	C14.2 - Malignant neoplasm of Waldeyer's ring
151.5 - MALIGNANT NEOPLASM OF LESSER CURVATURE OF STOMACH UNSPECIFIED	C15.4 - Malignant neoplasm of middle third of esophagus
151.6 - MALIGNANT NEOPLASM OF GREATER CURVATURE OF STOMACH UNSPECIFIED	C15.8 - Malignant neoplasm of overlapping sites of esophagus
151.9 - MALIGNANT NEOPLASM OF STOMACH UNSPECIFIED SITE	C15.9 - Malignant neoplasm of esophagus, unspecified
152 - MALIGNANT NEOPLASM OF SMALL INTESTINE INCLUDING DUODENUM	C16.0 - Malignant neoplasm of cardia
152.0 - MALIGNANT NEOPLASM OF DUODENUM	C16.2 - Malignant neoplasm of body of stomach

Appendix A

152.3 - MALIGNANT NEOPLASM OF MECKEL'S DIVERTICULUM	C16.3 - Malignant neoplasm of pyloric antrum
152.9 - MALIGNANT NEOPLASM OF SMALL INTESTINE UNSPECIFIED SITE	C17.3 - Meckel's diverticulum, malignant
153.1 - MALIGNANT NEOPLASM OF TRANSVERSE COLON	C18.2 - Malignant neoplasm of ascending colon
153.4 - MALIGNANT NEOPLASM OF CECUM	C18.3 - Malignant neoplasm of hepatic flexure
153.5 - MALIGNANT NEOPLASM OF APPENDIX VERMIFORMIS	C18.4 - Malignant neoplasm of transverse colon
153.7 - MALIGNANT NEOPLASM OF SPLENIC FLEXURE	C21.8 - Malignant neoplasm of overlapping sites of rectum, anus and anal canal
153.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARGE INTESTINE	C22 - Malignant neoplasm of liver and intrahepatic bile ducts
154.0 - MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION	C22.1 - Intrahepatic bile duct carcinoma
154.2 - MALIGNANT NEOPLASM OF ANAL CANAL	C22.3 - Angiosarcoma of liver
154.3 - MALIGNANT NEOPLASM OF ANUS UNSPECIFIED SITE	C22.4 - Other sarcomas of liver
155 - MALIGNANT NEOPLASM OF LIVER AND INTRAHEPATIC BILE DUCTS	C22.8 - Malignant neoplasm of liver, primary, unspecified as to type
155.0 - MALIGNANT NEOPLASM OF LIVER PRIMARY	C24.0 - Malignant neoplasm of extrahepatic bile duct
155.2 - MALIGNANT NEOPLASM OF LIVER NOT SPECIFIED AS PRIMARY OR SECONDARY	C24.9 - Malignant neoplasm of biliary tract, unspecified
156 - MALIGNANT NEOPLASM OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS	C25.0 - Malignant neoplasm of head of pancreas
156.0 - MALIGNANT NEOPLASM OF GALLBLADDER	C25.3 - Malignant neoplasm of pancreatic duct
156.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS	C25.7 - Malignant neoplasm of other parts of pancreas

Appendix A

157.0 - MALIGNANT NEOPLASM OF HEAD OF PANCREAS	C25.8 - Malignant neoplasm of overlapping sites of pancreas
157.2 - MALIGNANT NEOPLASM OF TAIL OF PANCREAS	C26 - Malignant neoplasm of other and ill-defined digestive organs
157.9 - MALIGNANT NEOPLASM OF PANCREAS PART UNSPECIFIED	C26.0 - Malignant neoplasm of intestinal tract, part unspecified
158.8 - MALIGNANT NEOPLASM OF SPECIFIED PARTS OF PERITONEUM	C26.1 - Malignant neoplasm of spleen
158.9 - MALIGNANT NEOPLASM OF PERITONEUM UNSPECIFIED	C31.1 - Malignant neoplasm of ethmoidal sinus
159.0 - MALIGNANT NEOPLASM OF INTESTINAL TRACT PART UNSPECIFIED	C31.3 - Malignant neoplasm of sphenoid sinus
160 - MALIGNANT NEOPLASM OF NASAL CAVITIES MIDDLE EAR AND ACCESSORY SINUSES	C31.8 - Malignant neoplasm of overlapping sites of accessory sinuses
160.1 - MALIGNANT NEOPLASM OF AUDITORY TUBE MIDDLE EAR AND MASTOID AIR CELLS	C31.9 - Malignant neoplasm of accessory sinus, unspecified
160.9 - MALIGNANT NEOPLASM OF ACCESSORY SINUS UNSPECIFIED	C32.0 - Malignant neoplasm of glottis
161 - MALIGNANT NEOPLASM OF LARYNX	C33 - Malignant neoplasm of trachea
161.0 - MALIGNANT NEOPLASM OF GLOTTIS	C34 - Malignant neoplasm of bronchus and lung
161.1 - MALIGNANT NEOPLASM OF SUPRAGLOTTIS	C34.0 - Malignant neoplasm of main bronchus
161.2 - MALIGNANT NEOPLASM OF SUBGLOTTIS	C34.01 - Malignant neoplasm of right main bronchus
161.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARYNX	C34.02 - Malignant neoplasm of left main bronchus
162 - MALIGNANT NEOPLASM OF TRACHEA BRONCHUS AND LUNG	C34.1 - Malignant neoplasm of upper lobe, bronchus or lung
162.0 - MALIGNANT NEOPLASM OF TRACHEA	C34.10 - Malignant neoplasm of upper lobe, unspecified bronchus or lung
162.2 - MALIGNANT NEOPLASM OF MAIN BRONCHUS	C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung

Appendix A

162.8 - MALIGNANT NEOPLASM OF OTHER PARTS OF BRONCHUS OR LUNG

163 - MALIGNANT NEOPLASM OF PLEURA
163.0 - MALIGNANT NEOPLASM OF PARIETAL PLEURA

163.9 - MALIGNANT NEOPLASM OF PLEURA UNSPECIFIED

164 - MALIGNANT NEOPLASM OF THYMUS HEART AND MEDIASTINUM

164.1 - MALIGNANT NEOPLASM OF HEART
164.8 - MALIGNANT NEOPLASM OF OTHER PARTS OF MEDIASTINUM

164.9 - MALIGNANT NEOPLASM OF MEDIASTINUM PART UNSPECIFIED

170.1 - MALIGNANT NEOPLASM OF MANDIBLE

170.2 - MALIGNANT NEOPLASM OF VERTEBRAL COLUMN EXCLUDING SACRUM AND COCCYX

170.5 - MALIGNANT NEOPLASM OF SHORT BONES OF UPPER LIMB

170.8 - MALIGNANT NEOPLASM OF SHORT BONES OF LOWER LIMB

170.9 - MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE SITE UNSPECIFIED

171 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE

171.0 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF HEAD FACE AND NECK

171.2 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF UPPER LIMB INCLUDING SHOULDER

C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung

C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung

C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung

C34.80 - Malignant neoplasm of overlapping sites of unspecified bronchus and lung

C34.92 - Malignant neoplasm of unspecified part of left bronchus or lung

C37 - Malignant neoplasm of thymus

C38.1 - Malignant neoplasm of anterior mediastinum

C38.2 - Malignant neoplasm of posterior mediastinum

C39.0 - Malignant neoplasm of upper respiratory tract, part unspecified

C40 - Malignant neoplasm of bone and articular cartilage of limbs

C40.0 - Malignant neoplasm of scapula and long bones of upper limb

C40.01 - Malignant neoplasm of scapula and long bones of right upper limb

C40.10 - Malignant neoplasm of short bones of unspecified upper limb

C40.12 - Malignant neoplasm of short bones of left upper limb

C40.2 - Malignant neoplasm of long bones of lower limb

C40.20 - Malignant neoplasm of long bones of unspecified lower limb

Appendix A

171.4 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF THORAX	C40.22 - Malignant neoplasm of long bones of left lower limb
171.7 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF TRUNK UNSPECIFIED	C40.3 - Malignant neoplasm of short bones of lower limb
171.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CONNECTIVE AND OTHER SOFT TISSUE	C40.8 - Malignant neoplasm of overlapping sites of bone and articular cartilage of limb C40.80 - Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb C40.90 - Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb C40.91 - Malignant neoplasm of unspecified bones and articular cartilage of right limb C40.92 - Malignant neoplasm of unspecified bones and articular cartilage of left limb
172 - MALIGNANT MELANOMA OF SKIN	C41 - Malignant neoplasm of bone and articular cartilage of other and unspecified sites
172.1 - MALIGNANT MELANOMA OF SKIN OF EYELID INCLUDING CANTHUS	C41.0 - Malignant neoplasm of bones of skull and face
172.2 - MALIGNANT MELANOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL	C41.1 - Malignant neoplasm of mandible
172.3 - MALIGNANT MELANOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE	C41.2 - Malignant neoplasm of vertebral column
174 - MALIGNANT NEOPLASM OF FEMALE BREAST	C41.3 - Malignant neoplasm of ribs, sternum and clavicle C41.4 - Malignant neoplasm of pelvic bones, sacrum and coccyx
174.1 - MALIGNANT NEOPLASM OF CENTRAL PORTION OF FEMALE BREAST	C43.1 - Malignant melanoma of eyelid, including canthus
174.2 - MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST	C43.11 - Malignant melanoma of right eyelid, including canthus
174.4 - MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST	C43.111 - Malignant melanoma of right upper eyelid, including canthus
174.5 - MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST	
174.6 - MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST	
174.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE BREAST	
174.9 - MALIGNANT NEOPLASM OF BREAST (FEMALE) UNSPECIFIED SITE	
175 - MALIGNANT NEOPLASM OF MALE BREAST	

Appendix A

175.9 - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES OF MALE BREAST	C43.122 - Malignant melanoma of left lower eyelid, including canthus
176 - KAPOSII'S SARCOMA	C43.2 - Malignant melanoma of ear and external auricular canal
176.0 - KAPOSII'S SARCOMA SKIN	C43.22 - Malignant melanoma of left ear and external auricular canal
176.2 - KAPOSII'S SARCOMA PALATE	C43.39 - Malignant melanoma of other parts of face
176.4 - KAPOSII'S SARCOMA LUNG	C43.51 - Malignant melanoma of anal skin
176.5 - KAPOSII'S SARCOMA LYMPH NODES	C43.59 - Malignant melanoma of other part of trunk
176.9 - KAPOSII'S SARCOMA UNSPECIFIED SITE	C43.61 - Malignant melanoma of right upper limb, including shoulder
180 - MALIGNANT NEOPLASM OF CERVIX UTERI	C43.71 - Malignant melanoma of right lower limb, including hip
180.0 - MALIGNANT NEOPLASM OF ENDOCERVIX	C43.9 - Malignant melanoma of skin, unspecified
180.1 - MALIGNANT NEOPLASM OF EXOCERVIX	C45 - Mesothelioma
181 - MALIGNANT NEOPLASM OF PLACENTA	C45.0 - Mesothelioma of pleura
182 - MALIGNANT NEOPLASM OF BODY OF UTERUS	C45.2 - Mesothelioma of pericardium
182.0 - MALIGNANT NEOPLASM OF CORPUS UTERI EXCEPT ISTHMUS	C46.51 - Kaposi's sarcoma of right lung
182.1 - MALIGNANT NEOPLASM OF ISTHMUS	C46.52 - Kaposi's sarcoma of left lung
182.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BODY OF UTERUS	C46.9 - Kaposi's sarcoma, unspecified
183 - MALIGNANT NEOPLASM OF OVARY AND OTHER UTERINE ADNEXA	C47.10 - Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
183.2 - MALIGNANT NEOPLASM OF FALLOPIAN TUBE	C47.12 - Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
183.3 - MALIGNANT NEOPLASM OF BROAD LIGAMENT OF UTERUS	C47.20 - Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
184.0 - MALIGNANT NEOPLASM OF VAGINA	C47.21 - Malignant neoplasm of peripheral nerves of right lower limb, including hip
184.3 - MALIGNANT NEOPLASM OF CLITORIS	C47.22 - Malignant neoplasm of peripheral nerves of left lower limb, including hip

Appendix A

184.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE GENITAL ORGANS

186 - MALIGNANT NEOPLASM OF TESTIS

186.0 - MALIGNANT NEOPLASM OF UNDESCENDED TESTIS

187 - MALIGNANT NEOPLASM OF PENIS AND OTHER MALE GENITAL ORGANS

187.1 - MALIGNANT NEOPLASM OF PREPUCE

187.3 - MALIGNANT NEOPLASM OF BODY OF PENIS

187.5 - MALIGNANT NEOPLASM OF EPIDIDYMIS

187.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF MALE GENITAL ORGANS

188 - MALIGNANT NEOPLASM OF BLADDER

188.1 - MALIGNANT NEOPLASM OF DOME OF URINARY BLADDER

188.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BLADDER

189.2 - MALIGNANT NEOPLASM OF URETER

190.0 - MALIGNANT NEOPLASM OF EYEBALL EXCEPT CONJUNCTIVA CORNEA RETINA AND CHOROID

190.1 - MALIGNANT NEOPLASM OF ORBIT

190.2 - MALIGNANT NEOPLASM OF LACRIMAL GLAND

190.5 - MALIGNANT NEOPLASM OF RETINA

C47.4 - Malignant neoplasm of peripheral nerves of abdomen

C47.8 - Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system

C47.9 - Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified

C48.0 - Malignant neoplasm of retroperitoneum

C48.2 - Malignant neoplasm of peritoneum, unspecified

C48.8 - Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum

C49 - Malignant neoplasm of other connective and soft tissue

C49.10 - Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder

C49.2 - Malignant neoplasm of connective and soft tissue of lower limb, including hip

C49.20 - Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip

C49.4 - Malignant neoplasm of connective and soft tissue of abdomen

C49.5 - Malignant neoplasm of connective and soft tissue of pelvis

C49.6 - Malignant neoplasm of connective and soft tissue of trunk, unspecified

C49.8 - Malignant neoplasm of overlapping sites of connective and soft tissue

C49.A - Gastrointestinal stromal tumor

C49.A2 - Gastrointestinal stromal tumor of stomach

Appendix A

190.7 - MALIGNANT NEOPLASM OF LACRIMAL DUCT	C49.A3 - Gastrointestinal stromal tumor of small intestine
190.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF EYE	C49.A5 - Gastrointestinal stromal tumor of rectum
191 - MALIGNANT NEOPLASM OF BRAIN	C49.A9 - Gastrointestinal stromal tumor of other sites
191.1 - MALIGNANT NEOPLASM OF FRONTAL LOBE	C50 - Malignant neoplasm of breast
191.3 - MALIGNANT NEOPLASM OF PARIETAL LOBE	C50.012 - Malignant neoplasm of nipple and areola, left female breast
191.4 - MALIGNANT NEOPLASM OF OCCIPITAL LOBE	C50.02 - Malignant neoplasm of nipple and areola, male
191.7 - MALIGNANT NEOPLASM OF BRAIN STEM	C50.021 - Malignant neoplasm of nipple and areola, right male breast
191.9 - MALIGNANT NEOPLASM OF BRAIN UNSPECIFIED SITE	C50.029 - Malignant neoplasm of nipple and areola, unspecified male breast
192 - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED PARTS OF NERVOUS SYSTEM	C50.1 - Malignant neoplasm of central portion of breast
192.0 - MALIGNANT NEOPLASM OF CRANIAL NERVES	C50.119 - Malignant neoplasm of central portion of unspecified female breast
192.2 - MALIGNANT NEOPLASM OF SPINAL CORD	C50.12 - Malignant neoplasm of central portion of breast, male
192.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NERVOUS SYSTEM	C50.122 - Malignant neoplasm of central portion of left male breast
193 - MALIGNANT NEOPLASM OF THYROID GLAND	C50.21 - Malignant neoplasm of upper-inner quadrant of breast, female
194 - MALIGNANT NEOPLASM OF OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES	C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast
194.1 - MALIGNANT NEOPLASM OF PARATHYROID GLAND	C50.22 - Malignant neoplasm of upper-inner quadrant of breast, male
194.3 - MALIGNANT NEOPLASM OF PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT	C50.221 - Malignant neoplasm of upper-inner quadrant of right male breast

Appendix A

194.4 - MALIGNANT NEOPLASM OF PINEAL GLAND	C50.3 - Malignant neoplasm of lower-inner quadrant of breast
194.6 - MALIGNANT NEOPLASM OF AORTIC BODY AND OTHER PARAGANGLIA	C50.312 - Malignant neoplasm of lower-inner quadrant of left female breast
194.8 - MALIGNANT NEOPLASM OF OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES	C50.32 - Malignant neoplasm of lower-inner quadrant of breast, male
194.9 - MALIGNANT NEOPLASM OF ENDOCRINE GLAND SITE UNSPECIFIED	C50.322 - Malignant neoplasm of lower-inner quadrant of left male breast
195 - MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES	C50.329 - Malignant neoplasm of lower-inner quadrant of unspecified male breast
195.2 - MALIGNANT NEOPLASM OF ABDOMEN	C50.4 - Malignant neoplasm of upper-outer quadrant of breast
195.3 - MALIGNANT NEOPLASM OF PELVIS	C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast
195.4 - MALIGNANT NEOPLASM OF UPPER LIMB	C50.419 - Malignant neoplasm of upper-outer quadrant of unspecified female breast
195.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES	C50.51 - Malignant neoplasm of lower-outer quadrant of breast, female
196.8 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF MULTIPLE SITES	C50.522 - Malignant neoplasm of lower-outer quadrant of left male breast
197.1 - SECONDARY MALIGNANT NEOPLASM OF MEDIASTINUM	C50.6 - Malignant neoplasm of axillary tail of breast
197.2 - SECONDARY MALIGNANT NEOPLASM OF PLEURA	C50.61 - Malignant neoplasm of axillary tail of breast, female
197.5 - SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM	C50.612 - Malignant neoplasm of axillary tail of left female breast
197.7 - MALIGNANT NEOPLASM OF LIVER SECONDARY	C50.619 - Malignant neoplasm of axillary tail of unspecified female breast
197.8 - SECONDARY MALIGNANT NEOPLASM OF OTHER DIGESTIVE ORGANS AND SPLEEN	C50.621 - Malignant neoplasm of axillary tail of right male breast

Appendix A

198.1 - SECONDARY MALIGNANT NEOPLASM OF OTHER URINARY ORGANS	C50.629 - Malignant neoplasm of axillary tail of unspecified male breast
198.2 - SECONDARY MALIGNANT NEOPLASM OF SKIN	C50.81 - Malignant neoplasm of overlapping sites of breast, female
198.5 - SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW	C50.811 - Malignant neoplasm of overlapping sites of right female breast
198.8 - SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES	C50.812 - Malignant neoplasm of overlapping sites of left female breast
198.82 - SECONDARY MALIGNANT NEOPLASM OF GENITAL ORGANS	C50.829 - Malignant neoplasm of overlapping sites of unspecified male breast
199 - MALIGNANT NEOPLASM WITHOUT SPECIFICATION OF SITE	C50.912 - Malignant neoplasm of unspecified site of left female breast
199.0 - DISSEMINATED MALIGNANT NEOPLASM	C50.92 - Malignant neoplasm of breast of unspecified site, male
200.0 - RETICULOSARCOMA	C50.921 - Malignant neoplasm of unspecified site of right male breast
200.01 - RETICULOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C50.922 - Malignant neoplasm of unspecified site of left male breast
200.03 - RETICULOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES	C50.929 - Malignant neoplasm of unspecified site of unspecified male breast
200.05 - RETICULOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C51 - Malignant neoplasm of vulva
200.06 - RETICULOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES	C51.0 - Malignant neoplasm of labium majus
200.1 - LYMPHOSARCOMA	C51.1 - Malignant neoplasm of labium minus
200.10 - LYMPHOSARCOMA UNSPECIFIED SITE	C51.2 - Malignant neoplasm of clitoris
200.11 - LYMPHOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C51.8 - Malignant neoplasm of overlapping sites of vulva
200.14 - LYMPHOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C51.9 - Malignant neoplasm of vulva, unspecified
200.16 - LYMPHOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES	C53.0 - Malignant neoplasm of endocervix

Appendix A

200.17 - LYMPHOSARCOMA INVOLVING SPLEEN	C54.1 - Malignant neoplasm of endometrium
200.18 - LYMPHOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES	C54.2 - Malignant neoplasm of myometrium
200.2 - BURKITT'S TUMOR OR LYMPHOMA	C54.3 - Malignant neoplasm of fundus uteri
200.20 - BURKITT'S TUMOR OR LYMPHOMA UNSPECIFIED SITE	C56 - Malignant neoplasm of ovary
200.22 - BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES	C57.00 - Malignant neoplasm of unspecified fallopian tube
200.25 - BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C57.02 - Malignant neoplasm of left fallopian tube
200.28 - BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES	C57.1 - Malignant neoplasm of broad ligament
200.3 - MARGINAL ZONE LYMPHOMA	C57.11 - Malignant neoplasm of right broad ligament
200.31 - MARGINAL ZONE LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C57.12 - Malignant neoplasm of left broad ligament
200.34 - MARGINAL ZONE LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C57.8 - Malignant neoplasm of overlapping sites of female genital organs
200.36 - MARGINAL ZONE LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES	C57.9 - Malignant neoplasm of female genital organ, unspecified
200.37 - MARGINAL ZONE LYMPHOMA INVOLVING SPLEEN	C60.0 - Malignant neoplasm of prepuce
200.38 - MARGINAL ZONE LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES	C60.1 - Malignant neoplasm of glans penis
200.4 - MANTLE CELL LYMPHOMA	C60.9 - Malignant neoplasm of penis, unspecified
200.40 - MANTLE CELL LYMPHOMA UNSPECIFIED SITE	C61 - Malignant neoplasm of prostate
200.41 - MANTLE CELL LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C62.00 - Malignant neoplasm of unspecified undescended testis

Appendix A

200.42 - MANTLE CELL LYMPHOMA INVOLVING
INTRATHORACIC LYMPH NODES

200.46 - MANTLE CELL LYMPHOMA INVOLVING
INTRAPELVIC LYMPH NODES

200.48 - MANTLE CELL LYMPHOMA INVOLVING
LYMPH NODES OF MULTIPLE SITES

200.5 - PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA

200.51 - PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA INVOLVING LYMPH NODES OF
HEAD FACE AND NECK

200.52 - PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA INVOLVING INTRATHORACIC
LYMPH NODES

200.54 - PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA INVOLVING LYMPH NODES OF
AXILLA AND UPPER LIMB

200.55 - PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA INVOLVING LYMPH NODES OF
INGUINAL REGION AND LOWER LIMB

200.57 - PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA INVOLVING SPLEEN

200.60 - ANAPLASTIC LARGE CELL LYMPHOMA
UNSPECIFIED SITE

200.61 - ANAPLASTIC LARGE CELL LYMPHOMA
INVOLVING LYMPH NODES OF HEAD FACE AND
NECK

200.62 - ANAPLASTIC LARGE CELL LYMPHOMA
INVOLVING INTRATHORACIC LYMPH NODES

200.64 - ANAPLASTIC LARGE CELL LYMPHOMA
INVOLVING LYMPH NODES OF AXILLA AND
UPPER LIMB

C62.01 - Malignant neoplasm of undescended right testis

C62.02 - Malignant neoplasm of undescended left testis

C62.12 - Malignant neoplasm of descended left testis

C62.9 - Malignant neoplasm of testis, unspecified whether
descended or undescended

C62.90 - Malignant neoplasm of unspecified testis,
unspecified whether descended or undescended

C62.92 - Malignant neoplasm of left testis, unspecified
whether descended or undescended

C63.02 - Malignant neoplasm of left epididymis

C63.2 - Malignant neoplasm of scrotum

C63.8 - Malignant neoplasm of overlapping sites of male
genital organs

C64 - Malignant neoplasm of kidney, except renal pelvis

C64.2 - Malignant neoplasm of left kidney, except renal
pelvis

C65.2 - Malignant neoplasm of left renal pelvis

C65.9 - Malignant neoplasm of unspecified renal pelvis

Appendix A

200.66 - ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES

200.67 - ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING SPLEEN

200.7 - LARGE CELL LYMPHOMA

200.71 - LARGE CELL LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK

200.72 - LARGE CELL LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES

200.73 - LARGE CELL LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES

200.76 - LARGE CELL LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES

200.77 - LARGE CELL LYMPHOMA INVOLVING SPLEEN

200.78 - LARGE CELL LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES

200.8 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA

200.80 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA UNSPECIFIED SITE

200.83 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES

C66 - Malignant neoplasm of ureter

C66.1 - Malignant neoplasm of right ureter

C66.2 - Malignant neoplasm of left ureter

C67 - Malignant neoplasm of bladder

C67.2 - Malignant neoplasm of lateral wall of bladder

C67.3 - Malignant neoplasm of anterior wall of bladder

C67.6 - Malignant neoplasm of ureteric orifice

C68 - Malignant neoplasm of other and unspecified urinary organs

C68.9 - Malignant neoplasm of urinary organ, unspecified

C69.1 - Malignant neoplasm of cornea

C69.12 - Malignant neoplasm of left cornea

C69.21 - Malignant neoplasm of right retina

Appendix A

200.85 - OTHER NAMED VARIANTS OF
LYMPHOSARCOMA AND RETICULOSARCOMA
INVOLVING LYMPH NODES OF INGUINAL
REGION AND LOWER LIMB

201 - HODGKIN'S DISEASE

201.00 - HODGKIN'S PARAGRANULOMA
UNSPECIFIED SITE

201.01 - HODGKIN'S PARAGRANULOMA
INVOLVING LYMPH NODES OF HEAD FACE AND
NECK

201.02 - HODGKIN'S PARAGRANULOMA
INVOLVING INTRATHORACIC LYMPH NODES

201.03 - HODGKIN'S PARAGRANULOMA
INVOLVING INTRA-ABDOMINAL LYMPH NODES

201.05 - HODGKIN'S PARAGRANULOMA
INVOLVING LYMPH NODES OF INGUINAL
REGION AND LOWER LIMB

201.07 - HODGKIN'S PARAGRANULOMA
INVOLVING SPLEEN

201.1 - HODGKIN'S GRANULOMA

201.14 - HODGKIN'S GRANULOMA INVOLVING
LYMPH NODES OF AXILLA AND UPPER LIMB

201.15 - HODGKIN'S GRANULOMA INVOLVING
LYMPH NODES OF INGUINAL REGION AND
LOWER LIMB

201.17 - HODGKIN'S GRANULOMA INVOLVING
SPLEEN

201.18 - HODGKIN'S GRANULOMA INVOLVING
LYMPH NODES OF MULTIPLE SITES

C69.3 - Malignant neoplasm of choroid

C69.30 - Malignant neoplasm of unspecified choroid

C69.32 - Malignant neoplasm of left choroid

C69.5 - Malignant neoplasm of lacrimal gland and duct

C69.51 - Malignant neoplasm of right lacrimal gland and
duct

C69.52 - Malignant neoplasm of left lacrimal gland and
duct

C69.60 - Malignant neoplasm of unspecified orbit

C69.81 - Malignant neoplasm of overlapping sites of right
eye and adnexa

C69.82 - Malignant neoplasm of overlapping sites of left
eye and adnexa

C69.91 - Malignant neoplasm of unspecified site of right
eye

C69.92 - Malignant neoplasm of unspecified site of left eye

C70 - Malignant neoplasm of meninges

C70.0 - Malignant neoplasm of cerebral meninges

Appendix A

201.20 - HODGKIN'S SARCOMA UNSPECIFIED SITE

201.22 - HODGKIN'S SARCOMA INVOLVING INTRATHORACIC LYMPH NODES

201.23 - HODGKIN'S SARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES

201.25 - HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

201.4 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE

201.40 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE UNSPECIFIED SITE

201.46 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRAPELVIC LYMPH NODES

201.50 - HODGKIN'S DISEASE NODULAR SCLEROSIS UNSPECIFIED SITE

201.52 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRATHORACIC LYMPH NODES

201.54 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

201.55 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

201.56 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRAPELVIC LYMPH NODES

201.57 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING SPLEEN

C70.1 - Malignant neoplasm of spinal meninges

C70.9 - Malignant neoplasm of meninges, unspecified

C71 - Malignant neoplasm of brain

C71.2 - Malignant neoplasm of temporal lobe

C71.3 - Malignant neoplasm of parietal lobe

C71.4 - Malignant neoplasm of occipital lobe

C71.5 - Malignant neoplasm of cerebral ventricle

C71.6 - Malignant neoplasm of cerebellum

C71.7 - Malignant neoplasm of brain stem

C71.8 - Malignant neoplasm of overlapping sites of brain

C71.9 - Malignant neoplasm of brain, unspecified

C72 - Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system

C72.0 - Malignant neoplasm of spinal cord

Appendix A

201.61 - HODGKIN'S DISEASE MIXED
CELLULARITY INVOLVING LYMPH NODES OF
HEAD FACE AND NECK

C72.3 - Malignant neoplasm of optic nerve

201.62 - HODGKIN'S DISEASE MIXED
CELLULARITY INVOLVING INTRATHORACIC
LYMPH NODES

C72.30 - Malignant neoplasm of unspecified optic nerve

201.65 - HODGKIN'S DISEASE MIXED
CELLULARITY INVOLVING LYMPH NODES OF
INGUINAL REGION AND LOWER LIMB

C72.32 - Malignant neoplasm of left optic nerve

201.66 - HODGKIN'S DISEASE MIXED
CELLULARITY INVOLVING INTRAPELVIC LYMPH
NODES

C72.4 - Malignant neoplasm of acoustic nerve

201.67 - HODGKIN'S DISEASE MIXED
CELLULARITY INVOLVING SPLEEN

C72.40 - Malignant neoplasm of unspecified acoustic
nerve

201.68 - HODGKIN'S DISEASE MIXED
CELLULARITY INVOLVING LYMPH NODES OF
MULTIPLE SITES

C72.41 - Malignant neoplasm of right acoustic nerve

201.7 - HODGKIN'S DISEASE LYMPHOCYTIC
DEPLETION

C72.50 - Malignant neoplasm of unspecified cranial nerve

201.72 - HODGKIN'S DISEASE LYMPHOCYTIC
DEPLETION INVOLVING INTRATHORACIC
LYMPH NODES

C72.59 - Malignant neoplasm of other cranial nerves

201.73 - HODGKIN'S DISEASE LYMPHOCYTIC
DEPLETION INVOLVING INTRA-ABDOMINAL
LYMPH NODES

C72.9 - Malignant neoplasm of central nervous system,
unspecified

201.75 - HODGKIN'S DISEASE LYMPHOCYTIC
DEPLETION INVOLVING LYMPH NODES OF
INGUINAL REGION AND LOWER LIMB

C73 - Malignant neoplasm of thyroid gland

201.76 - HODGKIN'S DISEASE LYMPHOCYTIC
DEPLETION INVOLVING INTRAPELVIC LYMPH
NODES

C74 - Malignant neoplasm of adrenal gland

201.78 - HODGKIN'S DISEASE LYMPHOCYTIC
DEPLETION INVOLVING LYMPH NODES OF
MULTIPLE SITES

C74.00 - Malignant neoplasm of cortex of unspecified
adrenal gland

Appendix A

201.9 - HODGKIN'S DISEASE UNSPECIFIED TYPE

201.90 - HODGKIN'S DISEASE UNSPECIFIED TYPE UNSPECIFIED SITE

201.92 - HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRATHORACIC LYMPH NODES

201.93 - HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRA-ABDOMINAL LYMPH NODES

201.96 - HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRAPELVIC LYMPH NODES

202.0 - NODULAR LYMPHOMA

202.01 - NODULAR LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK

202.03 - NODULAR LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES

202.06 - NODULAR LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES

202.11 - MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF HEAD FACE AND NECK

202.12 - MYCOSIS FUNGOIDES INVOLVING INTRATHORACIC LYMPH NODES

202.13 - MYCOSIS FUNGOIDES INVOLVING INTRA-ABDOMINAL LYMPH NODES

202.14 - MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

202.15 - MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

202.17 - MYCOSIS FUNGOIDES INVOLVING SPLEEN

202.18 - MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF MULTIPLE SITES

C74.01 - Malignant neoplasm of cortex of right adrenal gland

C74.10 - Malignant neoplasm of medulla of unspecified adrenal gland

C74.92 - Malignant neoplasm of unspecified part of left adrenal gland

C75 - Malignant neoplasm of other endocrine glands and related structures

C75.0 - Malignant neoplasm of parathyroid gland

C75.4 - Malignant neoplasm of carotid body

C75.8 - Malignant neoplasm with pluriglandular involvement, unspecified

C75.9 - Malignant neoplasm of endocrine gland, unspecified

C76.40 - Malignant neoplasm of unspecified upper limb

C76.41 - Malignant neoplasm of right upper limb

C76.42 - Malignant neoplasm of left upper limb

C76.5 - Malignant neoplasm of lower limb

C76.50 - Malignant neoplasm of unspecified lower limb

C76.51 - Malignant neoplasm of right lower limb

C76.52 - Malignant neoplasm of left lower limb

C76.8 - Malignant neoplasm of other specified ill-defined sites

Appendix A

202.2 - SEZARY'S DISEASE	C77.0 - Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
202.22 - SEZARY'S DISEASE INVOLVING INTRATHORACIC LYMPH NODES	C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
202.25 - SEZARY'S DISEASE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
202.27 - SEZARY'S DISEASE INVOLVING SPLEEN	C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified
202.28 - SEZARY'S DISEASE INVOLVING LYMPH NODES OF MULTIPLE SITES	C78 - Secondary malignant neoplasm of respiratory and digestive organs
202.3 - MALIGNANT HISTIOCYTOSIS	C78.00 - Secondary malignant neoplasm of unspecified lung
202.31 - MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C78.1 - Secondary malignant neoplasm of mediastinum
202.33 - MALIGNANT HISTIOCYTOSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES	C78.2 - Secondary malignant neoplasm of pleura
202.34 - MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C78.30 - Secondary malignant neoplasm of unspecified respiratory organ
202.36 - MALIGNANT HISTIOCYTOSIS INVOLVING INTRAPELVIC LYMPH NODES	C78.39 - Secondary malignant neoplasm of other respiratory organs
202.37 - MALIGNANT HISTIOCYTOSIS INVOLVING SPLEEN	C78.5 - Secondary malignant neoplasm of large intestine and rectum
202.38 - MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF MULTIPLE SITES	C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum
202.4 - LEUKEMIC RETICULOENDOTHELIOSIS	C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
202.41 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C78.80 - Secondary malignant neoplasm of unspecified digestive organ

Appendix A

202.46 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRAPELVIC LYMPH NODES	C78.89 - Secondary malignant neoplasm of other digestive organs
202.47 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING SPLEEN	C79.02 - Secondary malignant neoplasm of left kidney and renal pelvis
202.5 - LETTERER-SIWE DISEASE	C79.11 - Secondary malignant neoplasm of bladder
202.50 - LETTERER-SIWE DISEASE UNSPECIFIED SITE	C79.2 - Secondary malignant neoplasm of skin
202.51 - LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C79.3 - Secondary malignant neoplasm of brain and cerebral meninges
202.54 - LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C79.31 - Secondary malignant neoplasm of brain
202.55 - LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C79.5 - Secondary malignant neoplasm of bone and bone marrow
202.58 - LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF MULTIPLE SITES	C79.6 - Secondary malignant neoplasm of ovary
202.65 - MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C79.62 - Secondary malignant neoplasm of left ovary
202.66 - MALIGNANT MAST CELL TUMORS INVOLVING INTRAPELVIC LYMPH NODES	C79.7 - Secondary malignant neoplasm of adrenal gland
202.70 - PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED SITE	C79.70 - Secondary malignant neoplasm of unspecified adrenal gland
202.71 - PERIPHERAL T-CELL LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C79.72 - Secondary malignant neoplasm of left adrenal gland
202.72 - PERIPHERAL T-CELL LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES	C79.8 - Secondary malignant neoplasm of other specified sites

Appendix A

202.75 - PERIPHERAL T-CELL LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

C79.81 - Secondary malignant neoplasm of breast

202.76 - PERIPHERAL T-CELL LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES

C79.9 - Secondary malignant neoplasm of unspecified site

202.78 - PERIPHERAL T-CELL LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES

C80 - Malignant neoplasm without specification of site

202.80 - OTHER MALIGNANT LYMPHOMAS UNSPECIFIED SITE

C81 - Hodgkin lymphoma

202.81 - OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF HEAD FACE AND NECK

C81.0 - Nodular lymphocyte predominant Hodgkin lymphoma

202.83 - OTHER MALIGNANT LYMPHOMAS INVOLVING INTRA-ABDOMINAL LYMPH NODES

C81.01 - Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck

202.84 - OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

C81.02 - Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes

202.90 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE UNSPECIFIED SITE

C81.04 - Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb

202.91 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF HEAD FACE AND NECK

C81.06 - Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes

202.92 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRATHORACIC LYMPH NODES

C81.07 - Nodular lymphocyte predominant Hodgkin lymphoma, spleen

202.97 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING SPLEEN

C81.09 - Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites

Appendix A

202.98 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF MULTIPLE SITES

203.00 - MULTIPLE MYELOMA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

203.01 - MULTIPLE MYELOMA IN REMISSION

203.02 - MULTIPLE MYELOMA IN RELAPSE

203.10 - PLASMA CELL LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

203.11 - PLASMA CELL LEUKEMIA IN REMISSION

203.12 - PLASMA CELL LEUKEMIA IN RELAPSE

203.8 - OTHER IMMUNOPROLIFERATIVE NEOPLASMS

203.80 - OTHER IMMUNOPROLIFERATIVE NEOPLASMS WITHOUT MENTION OF HAVING ACHIEVED REMISSION

204 - LYMPHOID LEUKEMIA

204.0 - ACUTE LYMPHOID LEUKEMIA

204.01 - ACUTE LYMPHOID LEUKEMIA IN REMISSION

204.1 - CHRONIC LYMPHOID LEUKEMIA

204.10 - CHRONIC LYMPHOID LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

204.12 - CHRONIC LYMPHOID LEUKEMIA IN RELAPSE

C81.1 - Nodular sclerosis Hodgkin lymphoma

C81.12 - Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes

C81.14 - Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.15 - Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.16 - Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes

C81.17 - Nodular sclerosis Hodgkin lymphoma, spleen

C81.18 - Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites

C81.19 - Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites

C81.2 - Mixed cellularity Hodgkin lymphoma

C81.20 - Mixed cellularity Hodgkin lymphoma, unspecified site

C81.22 - Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes

C81.24 - Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.26 - Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes

C81.27 - Mixed cellularity Hodgkin lymphoma, spleen

C81.30 - Lymphocyte depleted Hodgkin lymphoma, unspecified site

Appendix A

204.22 - SUBACUTE LYMPHOID LEUKEMIA IN RELAPSE	C81.31 - Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck
204.8 - OTHER LYMPHOID LEUKEMIA	C81.34 - Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
204.80 - OTHER LYMPHOID LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C81.36 - Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes
204.81 - OTHER LYMPHOID LEUKEMIA IN REMISSION	C81.38 - Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
204.82 - OTHER LYMPHOID LEUKEMIA IN RELAPSE	C81.4 - Lymphocyte-rich Hodgkin lymphoma
204.91 - UNSPECIFIED LYMPHOID LEUKEMIA IN REMISSION	C81.41 - Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck
204.92 - UNSPECIFIED LYMPHOID LEUKEMIA IN RELAPSE	C81.42 - Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes
205.0 - ACUTE MYELOID LEUKEMIA	C81.43 - Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes
205.01 - ACUTE MYELOID LEUKEMIA IN REMISSION	C81.44 - Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb
205.02 - ACUTE MYELOID LEUKEMIA IN RELAPSE	C81.7 - Other Hodgkin lymphoma
205.1 - CHRONIC MYELOID LEUKEMIA	C81.70 - Other Hodgkin lymphoma, unspecified site
205.12 - CHRONIC MYELOID LEUKEMIA IN RELAPSE	C81.71 - Other Hodgkin lymphoma, lymph nodes of head, face, and neck
205.2 - SUBACUTE MYELOID LEUKEMIA	C81.72 - Other Hodgkin lymphoma, intrathoracic lymph nodes
205.80 - OTHER MYELOID LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C81.73 - Other Hodgkin lymphoma, intra-abdominal lymph nodes
205.82 - OTHER MYELOID LEUKEMIA IN RELAPSE	C81.75 - Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
205.9 - UNSPECIFIED MYELOID LEUKEMIA	C81.79 - Other Hodgkin lymphoma, extranodal and solid organ sites

Appendix A

205.90 - UNSPECIFIED MYELOID LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

205.91 - UNSPECIFIED MYELOID LEUKEMIA IN
REMISSION

205.92 - UNSPECIFIED MYELOID LEUKEMIA IN
RELAPSE

206 - MONOCYTIC LEUKEMIA

206.00 - ACUTE MONOCYTIC LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

206.1 - CHRONIC MONOCYTIC LEUKEMIA

206.11 - CHRONIC MONOCYTIC LEUKEMIA IN
REMISSION

206.2 - SUBACUTE MONOCYTIC LEUKEMIA

206.21 - SUBACUTE MONOCYTIC LEUKEMIA IN
REMISSION

206.8 - OTHER MONOCYTIC LEUKEMIA

206.80 - OTHER MONOCYTIC LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

206.9 - UNSPECIFIED MONOCYTIC LEUKEMIA

207.0 - ACUTE ERYTHREMIA AND
ERYTHROLEUKEMIA

207.00 - ACUTE ERYTHREMIA AND
ERYTHROLEUKEMIA WITHOUT MENTION OF
HAVING ACHIEVED REMISSION

207.11 - CHRONIC ERYTHREMIA IN REMISSION

207.81 - OTHER SPECIFIED LEUKEMIA IN
REMISSION

C81.90 - Hodgkin lymphoma, unspecified, unspecified site

C81.91 - Hodgkin lymphoma, unspecified, lymph nodes of
head, face, and neck

C81.94 - Hodgkin lymphoma, unspecified, lymph nodes of
axilla and upper limb

C81.96 - Hodgkin lymphoma, unspecified, intrapelvic
lymph nodes

C81.97 - Hodgkin lymphoma, unspecified, spleen

C81.98 - Hodgkin lymphoma, unspecified, lymph nodes of
multiple sites

C82 - Follicular lymphoma

C82.05 - Follicular lymphoma grade I, lymph nodes of
inguinal region and lower limb

C82.06 - Follicular lymphoma grade I, intrapelvic lymph
nodes

C82.07 - Follicular lymphoma grade I, spleen

C82.08 - Follicular lymphoma grade I, lymph nodes of
multiple sites

C82.09 - Follicular lymphoma grade I, extranodal and solid
organ sites

C82.1 - Follicular lymphoma grade II

C82.12 - Follicular lymphoma grade II, intrathoracic lymph
nodes

C82.14 - Follicular lymphoma grade II, lymph nodes of
axilla and upper limb

C82.15 - Follicular lymphoma grade II, lymph nodes of
inguinal region and lower limb

Appendix A

208 - LEUKEMIA OF UNSPECIFIED CELL TYPE	C82.18 - Follicular lymphoma grade II, lymph nodes of multiple sites
208.0 - ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE	C82.19 - Follicular lymphoma grade II, extranodal and solid organ sites
208.1 - CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE	C82.2 - Follicular lymphoma grade III, unspecified
208.10 - CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C82.20 - Follicular lymphoma grade III, unspecified, unspecified site
208.12 - CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE IN RELAPSE	C82.21 - Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
208.2 - SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE	C82.24 - Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
208.20 - SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C82.25 - Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
208.21 - SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE IN REMISSION	C82.28 - Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
208.22 - SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE IN RELAPSE	C82.29 - Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
208.82 - OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE IN RELAPSE	C82.32 - Follicular lymphoma grade IIIa, intrathoracic lymph nodes
209 - NEUROENDOCRINE TUMORS	C82.33 - Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
209.00 - MALIGNANT CARCINOID TUMOR OF THE SMALL INTESTINE UNSPECIFIED PORTION	C82.35 - Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
209.01 - MALIGNANT CARCINOID TUMOR OF THE DUODENUM	C82.39 - Follicular lymphoma grade IIIa, extranodal and solid organ sites
209.02 - MALIGNANT CARCINOID TUMOR OF THE JEJUNUM	C82.44 - Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
209.11 - MALIGNANT CARCINOID TUMOR OF THE APPENDIX	C82.46 - Follicular lymphoma grade IIIb, intrapelvic lymph nodes
209.12 - MALIGNANT CARCINOID TUMOR OF THE CECUM	C82.47 - Follicular lymphoma grade IIIb, spleen

Appendix A

209.17 - MALIGNANT CARCINOID TUMOR OF THE RECTUM

209.22 - MALIGNANT CARCINOID TUMOR OF THE THYMUS

209.25 - MALIGNANT CARCINOID TUMOR OF THE FOREGUT NOT OTHERWISE SPECIFIED

209.29 - MALIGNANT CARCINOID TUMOR OF OTHER SITES

209.3 - MALIGNANT POORLY DIFFERENTIATED NEUROENDOCRINE TUMORS

209.30 - MALIGNANT POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA ANY SITE

209.31 - MERKEL CELL CARCINOMA OF THE FACE

209.32 - MERKEL CELL CARCINOMA OF THE SCALP AND NECK

209.33 - MERKEL CELL CARCINOMA OF THE UPPER LIMB

209.34 - MERKEL CELL CARCINOMA OF THE LOWER LIMB

209.70 - SECONDARY NEUROENDOCRINE TUMOR UNSPECIFIED SITE

209.72 - SECONDARY NEUROENDOCRINE TUMOR OF LIVER

209.75 - SECONDARY MERKEL CELL CARCINOMA

209.79 - SECONDARY NEUROENDOCRINE TUMOR OF OTHER SITES

140 - MALIGNANT NEOPLASM OF LIP

140.1 - MALIGNANT NEOPLASM OF LOWER LIP VERMILION BORDER

C82.51 - Diffuse follicle center lymphoma, lymph nodes of head, face, and neck

C82.52 - Diffuse follicle center lymphoma, intrathoracic lymph nodes

C82.55 - Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb

C82.56 - Diffuse follicle center lymphoma, intrapelvic lymph nodes

C82.59 - Diffuse follicle center lymphoma, extranodal and solid organ sites

C82.60 - Cutaneous follicle center lymphoma, unspecified site

C82.61 - Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck

C82.62 - Cutaneous follicle center lymphoma, intrathoracic lymph nodes

C82.63 - Cutaneous follicle center lymphoma, intra-abdominal lymph nodes

C82.68 - Cutaneous follicle center lymphoma, lymph nodes of multiple sites

C82.69 - Cutaneous follicle center lymphoma, extranodal and solid organ sites

C82.8 - Other types of follicular lymphoma

C82.80 - Other types of follicular lymphoma, unspecified site

C82.86 - Other types of follicular lymphoma, intrapelvic lymph nodes

C82.87 - Other types of follicular lymphoma, spleen

C82.89 - Other types of follicular lymphoma, extranodal and solid organ sites

Appendix A

140.4 - MALIGNANT NEOPLASM OF LOWER LIP INNER ASPECT	C82.92 - Follicular lymphoma, unspecified, intrathoracic lymph nodes
140.5 - MALIGNANT NEOPLASM OF LIP UNSPECIFIED INNER ASPECT	C82.95 - Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
141 - MALIGNANT NEOPLASM OF TONGUE	C82.96 - Follicular lymphoma, unspecified, intrapelvic lymph nodes
141.1 - MALIGNANT NEOPLASM OF DORSAL SURFACE OF TONGUE	C82.97 - Follicular lymphoma, unspecified, spleen
141.2 - MALIGNANT NEOPLASM OF TIP AND LATERAL BORDER OF TONGUE	C82.98 - Follicular lymphoma, unspecified, lymph nodes of multiple sites
141.4 - MALIGNANT NEOPLASM OF ANTERIOR TWO-THIRDS OF TONGUE PART UNSPECIFIED	C82.99 - Follicular lymphoma, unspecified, extranodal and solid organ sites
141.8 - MALIGNANT NEOPLASM OF OTHER SITES OF TONGUE	C83.00 - Small cell B-cell lymphoma, unspecified site
142 - MALIGNANT NEOPLASM OF MAJOR SALIVARY GLANDS	C83.01 - Small cell B-cell lymphoma, lymph nodes of head, face, and neck
142.2 - MALIGNANT NEOPLASM OF SUBLINGUAL GLAND	C83.02 - Small cell B-cell lymphoma, intrathoracic lymph nodes
142.8 - MALIGNANT NEOPLASM OF OTHER MAJOR SALIVARY GLANDS	C83.03 - Small cell B-cell lymphoma, intra-abdominal lymph nodes
143 - MALIGNANT NEOPLASM OF GUM	C83.06 - Small cell B-cell lymphoma, intrapelvic lymph nodes
143.0 - MALIGNANT NEOPLASM OF UPPER GUM	C83.07 - Small cell B-cell lymphoma, spleen
143.1 - MALIGNANT NEOPLASM OF LOWER GUM	C83.08 - Small cell B-cell lymphoma, lymph nodes of multiple sites
143.9 - MALIGNANT NEOPLASM OF GUM UNSPECIFIED	C83.11 - Mantle cell lymphoma, lymph nodes of head, face, and neck
144 - MALIGNANT NEOPLASM OF FLOOR OF MOUTH	C83.12 - Mantle cell lymphoma, intrathoracic lymph nodes
144.0 - MALIGNANT NEOPLASM OF ANTERIOR PORTION OF FLOOR OF MOUTH	C83.14 - Mantle cell lymphoma, lymph nodes of axilla and upper limb
145 - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED PARTS OF MOUTH	C83.17 - Mantle cell lymphoma, spleen

Appendix A

145.0 - MALIGNANT NEOPLASM OF CHEEK MUCOSA	C83.18 - Mantle cell lymphoma, lymph nodes of multiple sites
145.1 - MALIGNANT NEOPLASM OF VESTIBULE OF MOUTH	C83.19 - Mantle cell lymphoma, extranodal and solid organ sites
145.2 - MALIGNANT NEOPLASM OF HARD PALATE	
145.4 - MALIGNANT NEOPLASM OF UVULA	C83.30 - Diffuse large B-cell lymphoma, unspecified site
145.6 - MALIGNANT NEOPLASM OF RETROMOLAR AREA	C83.31 - Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
145.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED PARTS OF MOUTH	C83.34 - Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
	C83.35 - Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
146.0 - MALIGNANT NEOPLASM OF TONSIL	C83.36 - Diffuse large B-cell lymphoma, intrapelvic lymph nodes
146.1 - MALIGNANT NEOPLASM OF TONSILLAR FOSSA	C83.37 - Diffuse large B-cell lymphoma, spleen
146.2 - MALIGNANT NEOPLASM OF TONSILLAR PILLARS (ANTERIOR) (POSTERIOR)	C83.38 - Diffuse large B-cell lymphoma, lymph nodes of multiple sites
146.5 - MALIGNANT NEOPLASM OF JUNCTIONAL REGION OF OROPHARYNX	C83.5 - Lymphoblastic (diffuse) lymphoma
147.1 - MALIGNANT NEOPLASM OF POSTERIOR WALL OF NASOPHARYNX	C83.50 - Lymphoblastic (diffuse) lymphoma, unspecified site
147.3 - MALIGNANT NEOPLASM OF ANTERIOR WALL OF NASOPHARYNX	C83.52 - Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
147.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NASOPHARYNX	C83.53 - Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
148.0 - MALIGNANT NEOPLASM OF POSTCRICOID REGION OF HYPOPHARYNX	C83.56 - Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
148.1 - MALIGNANT NEOPLASM OF PYRIFORM SINUS	C83.58 - Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
148.3 - MALIGNANT NEOPLASM OF POSTERIOR HYPOPHARYNGEAL WALL	C83.59 - Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites

Appendix A

149 - MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES WITHIN THE LIP ORAL CAVITY AND PHARYNX

149.1 - MALIGNANT NEOPLASM OF WALDEYER'S RING

C83.72 - Burkitt lymphoma, intrathoracic lymph nodes

C83.76 - Burkitt lymphoma, intrapelvic lymph nodes

149.9 - MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE LIP AND ORAL CAVITY

C83.77 - Burkitt lymphoma, spleen

C83.79 - Burkitt lymphoma, extranodal and solid organ sites

150 - MALIGNANT NEOPLASM OF ESOPHAGUS

150.0 - MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS

C83.8 - Other non-follicular lymphoma

150.3 - MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS

C83.80 - Other non-follicular lymphoma, unspecified site

C83.83 - Other non-follicular lymphoma, intra-abdominal lymph nodes

151 - MALIGNANT NEOPLASM OF STOMACH

C83.84 - Other non-follicular lymphoma, lymph nodes of axilla and upper limb

151.1 - MALIGNANT NEOPLASM OF PYLORUS

151.4 - MALIGNANT NEOPLASM OF BODY OF STOMACH

C83.89 - Other non-follicular lymphoma, extranodal and solid organ sites

151.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF STOMACH

C83.9 - Non-follicular (diffuse) lymphoma, unspecified

C83.90 - Non-follicular (diffuse) lymphoma, unspecified, unspecified site

152.1 - MALIGNANT NEOPLASM OF JEJUNUM

C83.92 - Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes

152.2 - MALIGNANT NEOPLASM OF ILEUM

152.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SMALL INTESTINE

C83.93 - Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes

153 - MALIGNANT NEOPLASM OF COLON

C83.95 - Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb

153.0 - MALIGNANT NEOPLASM OF HEPATIC FLEXURE

C84.02 - Mycosis fungoides, intrathoracic lymph nodes

153.2 - MALIGNANT NEOPLASM OF DESCENDING COLON

C84.07 - Mycosis fungoides, spleen

Appendix A

153.3 - MALIGNANT NEOPLASM OF SIGMOID COLON	C84.11 - Sezary disease, lymph nodes of head, face, and neck
153.6 - MALIGNANT NEOPLASM OF ASCENDING COLON	C84.13 - Sezary disease, intra-abdominal lymph nodes
153.9 - MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE	C84.15 - Sezary disease, lymph nodes of inguinal region and lower limb
154 - MALIGNANT NEOPLASM OF RECTUM RECTOSIGMOID JUNCTION AND ANUS	C84.17 - Sezary disease, spleen
154.1 - MALIGNANT NEOPLASM OF RECTUM	C84.18 - Sezary disease, lymph nodes of multiple sites
154.8 - MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM RECTOSIGMOID JUNCTION AND ANUS	C84.4 - Peripheral T-cell lymphoma, not classified
155.1 - MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS	C84.41 - Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck
156.1 - MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCTS	C84.42 - Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes
156.2 - MALIGNANT NEOPLASM OF AMPULLA OF VATER	C84.43 - Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes
156.9 - MALIGNANT NEOPLASM OF BILIARY TRACT PART UNSPECIFIED SITE	C84.44 - Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb
157 - MALIGNANT NEOPLASM OF PANCREAS	C84.45 - Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb
157.1 - MALIGNANT NEOPLASM OF BODY OF PANCREAS	C84.48 - Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites
157.3 - MALIGNANT NEOPLASM OF PANCREATIC DUCT	C84.49 - Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites
157.4 - MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS	C84.61 - Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck
157.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PANCREAS	C84.66 - Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes
158 - MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM	C84.7 - Anaplastic large cell lymphoma, ALK-negative
158.0 - MALIGNANT NEOPLASM OF RETROPERITONEUM	C84.71 - Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck

Appendix A

159 - MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND PERITONEUM	C84.74 - Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb
159.1 - MALIGNANT NEOPLASM OF SPLEEN NOT ELSEWHERE CLASSIFIED	C84.75 - Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb
159.8 - MALIGNANT NEOPLASM OF OTHER SITES OF DIGESTIVE SYSTEM AND INTRA-ABDOMINAL ORGANS	C84.76 - Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes
159.9 - MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND PERITONEUM	C84.79 - Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
160.0 - MALIGNANT NEOPLASM OF NASAL CAVITIES	C84.9 - Mature T/NK-cell lymphomas, unspecified
160.2 - MALIGNANT NEOPLASM OF MAXILLARY SINUS	C84.93 - Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes
160.3 - MALIGNANT NEOPLASM OF ETHMOIDAL SINUS	C84.94 - Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb
160.4 - MALIGNANT NEOPLASM OF FRONTAL SINUS	C84.95 - Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb
160.5 - MALIGNANT NEOPLASM OF SPHENOIDAL SINUS	C84.96 - Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes
160.8 - MALIGNANT NEOPLASM OF OTHER ACCESSORY SINUSES	C84.97 - Mature T/NK-cell lymphomas, unspecified, spleen
161.3 - MALIGNANT NEOPLASM OF LARYNGEAL CARTILAGES	C84.98 - Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites
161.9 - MALIGNANT NEOPLASM OF LARYNX UNSPECIFIED	C84.99 - Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
162.3 - MALIGNANT NEOPLASM OF UPPER LOBE BRONCHUS OR LUNG	C84.A - Cutaneous T-cell lymphoma, unspecified
162.4 - MALIGNANT NEOPLASM OF MIDDLE LOBE BRONCHUS OR LUNG	C84.A4 - Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb
162.5 - MALIGNANT NEOPLASM OF LOWER LOBE BRONCHUS OR LUNG	C84.A6 - Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes

Appendix A

162.9 - MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED	C84.A8 - Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites
163.1 - MALIGNANT NEOPLASM OF VISCERAL PLEURA	C84.A9 - Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites
163.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PLEURA	C84.Z0 - Other mature T/NK-cell lymphomas, unspecified site
164.0 - MALIGNANT NEOPLASM OF THYMUS	C84.Z2 - Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
164.2 - MALIGNANT NEOPLASM OF ANTERIOR MEDIASTINUM	C84.Z3 - Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
164.3 - MALIGNANT NEOPLASM OF POSTERIOR MEDIASTINUM	C84.Z5 - Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
165 - MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES WITHIN THE RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS	C84.Z7 - Other mature T/NK-cell lymphomas, spleen
165.0 - MALIGNANT NEOPLASM OF UPPER RESPIRATORY TRACT PART UNSPECIFIED	C84.Z9 - Other mature T/NK-cell lymphomas, extranodal and solid organ sites
165.8 - MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS	C85 - Other specified and unspecified types of non-Hodgkin lymphoma
165.9 - MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE RESPIRATORY SYSTEM	C85.10 - Unspecified B-cell lymphoma, unspecified site
170 - MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE	C85.11 - Unspecified B-cell lymphoma, lymph nodes of head, face, and neck
170.0 - MALIGNANT NEOPLASM OF BONES OF SKULL AND FACE EXCEPT MANDIBLE	C85.14 - Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb
170.3 - MALIGNANT NEOPLASM OF RIBS STERNUM AND CLAVICLE	C85.16 - Unspecified B-cell lymphoma, intrapelvic lymph nodes
170.4 - MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF UPPER LIMB	C85.2 - Mediastinal (thymic) large B-cell lymphoma
170.6 - MALIGNANT NEOPLASM OF PELVIC BONES SACRUM AND COCCYX	C85.20 - Mediastinal (thymic) large B-cell lymphoma, unspecified site

Appendix A

170.7 - MALIGNANT NEOPLASM OF LONG BONES OF LOWER LIMB	C85.21 - Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
171.3 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF LOWER LIMB INCLUDING HIP	C85.23 - Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
171.5 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF ABDOMEN	C85.24 - Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
171.6 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF PELVIS	C85.25 - Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
171.9 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE SITE UNSPECIFIED	C85.27 - Mediastinal (thymic) large B-cell lymphoma, spleen
172.0 - MALIGNANT MELANOMA OF SKIN OF LIP	C85.28 - Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
172.4 - MALIGNANT MELANOMA OF SKIN OF SCALP AND NECK	C85.29 - Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
172.5 - MALIGNANT MELANOMA OF SKIN OF TRUNK EXCEPT SCROTUM	C85.81 - Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck
172.6 - MALIGNANT MELANOMA OF SKIN OF UPPER LIMB INCLUDING SHOULDER	C85.82 - Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
172.7 - MALIGNANT MELANOMA OF SKIN OF LOWER LIMB INCLUDING HIP	C85.83 - Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
172.8 - MALIGNANT MELANOMA OF OTHER SPECIFIED SITES OF SKIN	C85.84 - Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
172.9 - MELANOMA OF SKIN SITE UNSPECIFIED	C85.85 - Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
174.0 - MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST	C85.88 - Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
174.3 - MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST	C85.9 - Non-Hodgkin lymphoma, unspecified
175.0 - MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST	C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site

Appendix A

176.1 - KAPOSI'S SARCOMA SOFT TISSUE	C85.94 - Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
176.3 - KAPOSI'S SARCOMA GASTROINTESTINAL SITES	C85.95 - Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
176.8 - KAPOSI'S SARCOMA OTHER SPECIFIED SITES	C86.1 - Hepatosplenic T-cell lymphoma
179 - MALIGNANT NEOPLASM OF UTERUS-PART UNS	C86.2 - Enteropathy-type (intestinal) T-cell lymphoma
180.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CERVIX	C88 - Malignant immunoproliferative diseases and certain other B-cell lymphomas
180.9 - MALIGNANT NEOPLASM OF CERVIX UTERI UNSPECIFIED SITE	C88.3 - Immunoproliferative small intestinal disease
183.0 - MALIGNANT NEOPLASM OF OVARY	C88.9 - Malignant immunoproliferative disease, unspecified
183.4 - MALIGNANT NEOPLASM OF PARAMETRIUM	C90.0 - Multiple myeloma
183.5 - MALIGNANT NEOPLASM OF ROUND LIGAMENT OF UTERUS	C90.01 - Multiple myeloma in remission
183.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF UTERINE ADNEXA	C90.11 - Plasma cell leukemia in remission
183.9 - MALIGNANT NEOPLASM OF UTERINE ADNEXA UNSPECIFIED SITE	C90.2 - Extramedullary plasmacytoma
184 - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS	C90.20 - Extramedullary plasmacytoma not having achieved remission
184.1 - MALIGNANT NEOPLASM OF LABIA MAJORA	C90.3 - Solitary plasmacytoma
184.2 - MALIGNANT NEOPLASM OF LABIA MINORA	C90.30 - Solitary plasmacytoma not having achieved remission
184.4 - MALIGNANT NEOPLASM OF VULVA UNSPECIFIED SITE	C91.0 - Acute lymphoblastic leukemia [ALL]
184.9 - MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN SITE UNSPECIFIED	C91.00 - Acute lymphoblastic leukemia not having achieved remission
185 - MALIGNANT NEOPLASM OF PROSTATE	C91.11 - Chronic lymphocytic leukemia of B-cell type in remission

Appendix A

186.9 - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED TESTIS	C91.3 - Prolymphocytic leukemia of B-cell type
187.2 - MALIGNANT NEOPLASM OF GLANS PENIS	C91.31 - Prolymphocytic leukemia of B-cell type, in remission
187.4 - MALIGNANT NEOPLASM OF PENIS PART UNSPECIFIED	C91.4 - Hairy cell leukemia
187.6 - MALIGNANT NEOPLASM OF SPERMATIC CORD	C91.40 - Hairy cell leukemia not having achieved remission
187.7 - MALIGNANT NEOPLASM OF SCROTUM	C91.41 - Hairy cell leukemia, in remission
187.9 - MALIGNANT NEOPLASM OF MALE GENITAL ORGAN SITE UNSPECIFIED	C91.5 - Adult T-cell lymphoma/leukemia (HTLV-1-associated)
188.0 - MALIGNANT NEOPLASM OF TRIGONE OF URINARY BLADDER	C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
188.2 - MALIGNANT NEOPLASM OF LATERAL WALL OF URINARY BLADDER	C91.6 - Prolymphocytic leukemia of T-cell type
188.3 - MALIGNANT NEOPLASM OF ANTERIOR WALL OF URINARY BLADDER	C91.60 - Prolymphocytic leukemia of T-cell type not having achieved remission
188.4 - MALIGNANT NEOPLASM OF POSTERIOR WALL OF URINARY BLADDER	C91.61 - Prolymphocytic leukemia of T-cell type, in remission
188.5 - MALIGNANT NEOPLASM OF BLADDER NECK	C91.91 - Lymphoid leukemia, unspecified, in remission
188.6 - MALIGNANT NEOPLASM OF URETERIC ORIFICE	C91.A1 - Mature B-cell leukemia Burkitt-type, in remission
188.7 - MALIGNANT NEOPLASM OF URACHUS	C91.Z - Other lymphoid leukemia
188.9 - MALIGNANT NEOPLASM OF BLADDER PART UNSPECIFIED	C91.Z2 - Other lymphoid leukemia, in relapse
189 - MALIGNANT NEOPLASM OF KIDNEY AND OTHER AND UNSPECIFIED URINARY ORGANS	C92.00 - Acute myeloblastic leukemia, not having achieved remission
189.0 - MALIGNANT NEOPLASM OF KIDNEY EXCEPT PELVIS	C92.01 - Acute myeloblastic leukemia, in remission
189.1 - MALIGNANT NEOPLASM OF RENAL PELVIS	C92.02 - Acute myeloblastic leukemia, in relapse

Appendix A

189.3 - MALIGNANT NEOPLASM OF URETHRA	C92.1 - Chronic myeloid leukemia, BCR/ABL-positive
189.4 - MALIGNANT NEOPLASM OF PARAURETHRAL GLANDS	C92.11 - Chronic myeloid leukemia, BCR/ABL-positive, in remission
189.8 - MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF URINARY ORGANS	C92.21 - Atypical chronic myeloid leukemia, BCR/ABL- negative, in remission
189.9 - MALIGNANT NEOPLASM OF URINARY ORGAN SITE UNSPECIFIED	C92.3 - Myeloid sarcoma
190 - MALIGNANT NEOPLASM OF EYE	C92.30 - Myeloid sarcoma, not having achieved remission
190.3 - MALIGNANT NEOPLASM OF CONJUNCTIVA	C92.4 - Acute promyelocytic leukemia
190.4 - MALIGNANT NEOPLASM OF CORNEA	C92.41 - Acute promyelocytic leukemia, in remission
190.6 - MALIGNANT NEOPLASM OF CHOROID	C92.42 - Acute promyelocytic leukemia, in relapse
190.9 - MALIGNANT NEOPLASM OF EYE PART UNSPECIFIED	C92.60 - Acute myeloid leukemia with 11q23-abnormality not having achieved remission
191.0 - MALIGNANT NEOPLASM OF CEREBRUM EXCEPT LOBES AND VENTRICLES	C92.61 - Acute myeloid leukemia with 11q23-abnormality in remission
191.2 - MALIGNANT NEOPLASM OF TEMPORAL LOBE	C92.9 - Myeloid leukemia, unspecified
191.5 - MALIGNANT NEOPLASM OF VENTRICLES	C92.90 - Myeloid leukemia, unspecified, not having achieved remission
191.6 - MALIGNANT NEOPLASM OF CEREBELLUM NOT OTHERWISE SPECIFIED	C92.91 - Myeloid leukemia, unspecified in remission
191.8 - MALIGNANT NEOPLASM OF OTHER PARTS OF BRAIN	C92.A0 - Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
192.1 - MALIGNANT NEOPLASM OF CEREBRAL MENINGES	C92.A1 - Acute myeloid leukemia with multilineage dysplasia, in remission
192.3 - MALIGNANT NEOPLASM OF SPINAL MENINGES	C92.A2 - Acute myeloid leukemia with multilineage dysplasia, in relapse
192.9 - MALIGNANT NEOPLASM OF NERVOUS SYSTEM PART UNSPECIFIED	C92.Z - Other myeloid leukemia

Appendix A

194.0 - MALIGNANT NEOPLASM OF ADRENAL GLAND	C92.Z0 - Other myeloid leukemia not having achieved remission
194.5 - MALIGNANT NEOPLASM OF CAROTID BODY	C93.0 - Acute monoblastic/monocytic leukemia
195.0 - MALIGNANT NEOPLASM OF HEAD FACE AND NECK	C93.01 - Acute monoblastic/monocytic leukemia, in remission
195.1 - MALIGNANT NEOPLASM OF THORAX	C93.1 - Chronic myelomonocytic leukemia
195.5 - MALIGNANT NEOPLASM OF LOWER LIMB	C93.12 - Chronic myelomonocytic leukemia, in relapse
196 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES	C93.3 - Juvenile myelomonocytic leukemia
196.0 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF HEAD FACE AND NECK	C93.30 - Juvenile myelomonocytic leukemia, not having achieved remission
196.1 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRATHORACIC LYMPH NODES	C93.31 - Juvenile myelomonocytic leukemia, in remission
196.2 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRA-ABDOMINAL LYMPH NODES	C93.32 - Juvenile myelomonocytic leukemia, in relapse
196.3 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF AXILLA AND UPPER LIMB	C93.90 - Monocytic leukemia, unspecified, not having achieved remission
196.5 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C93.92 - Monocytic leukemia, unspecified in relapse
196.6 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRAPELVIC LYMPH NODES	C93.Z - Other monocytic leukemia
196.9 - SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES SITE UNSPECIFIED	C93.Z1 - Other monocytic leukemia, in remission
197 - SECONDARY MALIGNANT NEOPLASM OF RESPIRATORY AND DIGESTIVE SYSTEMS	C94.0 - Acute erythroid leukemia

Appendix A

197.0 - SECONDARY MALIGNANT NEOPLASM OF LUNG	C94.20 - Acute megakaryoblastic leukemia not having achieved remission
197.3 - SECONDARY MALIGNANT NEOPLASM OF OTHER RESPIRATORY ORGANS	C94.21 - Acute megakaryoblastic leukemia, in remission
197.4 - SECONDARY MALIGNANT NEOPLASM OF SMALL INTESTINE INCLUDING DUODENUM	C94.22 - Acute megakaryoblastic leukemia, in relapse
197.6 - SECONDARY MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM	C94.3 - Mast cell leukemia
198 - SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES	C94.4 - Acute panmyelosis with myelofibrosis
198.0 - SECONDARY MALIGNANT NEOPLASM OF KIDNEY	C94.40 - Acute panmyelosis with myelofibrosis not having achieved remission
198.3 - SECONDARY MALIGNANT NEOPLASM OF BRAIN AND SPINAL CORD	C94.42 - Acute panmyelosis with myelofibrosis, in relapse
198.4 - SECONDARY MALIGNANT NEOPLASM OF OTHER PARTS OF NERVOUS SYSTEM	C94.6 - Myelodysplastic disease, not classified
198.6 - SECONDARY MALIGNANT NEOPLASM OF OVARY	C95 - Leukemia of unspecified cell type
198.7 - SECONDARY MALIGNANT NEOPLASM OF ADRENAL GLAND	C95.0 - Acute leukemia of unspecified cell type
198.81 - SECONDARY MALIGNANT NEOPLASM OF BREAST	C95.1 - Chronic leukemia of unspecified cell type
198.89 - SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES	C95.90 - Leukemia, unspecified not having achieved remission
199.1 - OTHER MALIGNANT NEOPLASM OF UNSPECIFIED SITE	C95.92 - Leukemia, unspecified, in relapse
199.2 - MALIGNANT NEOPLASM ASSOCIATED WITH TRANSPLANTED ORGAN	C96 - Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue

Appendix A

200 - LYMPHOSARCOMA AND
RETICULOSARCOMA AND OTHER SPECIFIED
MALIGNANT TUMORS OF LYMPHATIC TISSUE

200.00 - RETICULOSARCOMA UNSPECIFIED
SITE

200.02 - RETICULOSARCOMA INVOLVING
INTRATHORACIC LYMPH NODES

200.04 - RETICULOSARCOMA INVOLVING
LYMPH NODES OF AXILLA AND UPPER LIMB

200.07 - RETICULOSARCOMA INVOLVING
SPLEEN

200.08 - RETICULOSARCOMA INVOLVING
LYMPH NODES OF MULTIPLE SITES

200.12 - LYMPHOSARCOMA INVOLVING
INTRATHORACIC LYMPH NODES

200.13 - LYMPHOSARCOMA INVOLVING INTRA-
ABDOMINAL LYMPH NODES

200.15 - LYMPHOSARCOMA INVOLVING LYMPH
NODES OF INGUINAL REGION AND LOWER
LIMB

200.21 - BURKITT'S TUMOR OR LYMPHOMA
INVOLVING LYMPH NODES OF HEAD FACE AND
NECK

200.23 - BURKITT'S TUMOR OR LYMPHOMA
INVOLVING INTRA-ABDOMINAL LYMPH NODES

200.24 - BURKITT'S TUMOR OR LYMPHOMA
INVOLVING LYMPH NODES OF AXILLA AND
UPPER LIMB

200.26 - BURKITT'S TUMOR OR LYMPHOMA
INVOLVING INTRAPELVIC LYMPH NODES

200.27 - BURKITT'S TUMOR OR LYMPHOMA
INVOLVING SPLEEN

C96.20 - Malignant mast cell neoplasm, unspecified

C96.21 - Aggressive systemic mastocytosis

C96.22 - Mast cell sarcoma

D45 - Polycythemia vera

C00 - Malignant neoplasm of lip

C00.2 - Malignant neoplasm of external lip, unspecified

C00.3 - Malignant neoplasm of upper lip, inner aspect

C00.8 - Malignant neoplasm of overlapping sites of lip

C02.0 - Malignant neoplasm of dorsal surface of tongue

C03.1 - Malignant neoplasm of lower gum

C03.9 - Malignant neoplasm of gum, unspecified

C04.0 - Malignant neoplasm of anterior floor of mouth

C04.9 - Malignant neoplasm of floor of mouth, unspecified

C05.0 - Malignant neoplasm of hard palate

Appendix A

200.30 - MARGINAL ZONE LYMPHOMA UNSPECIFIED SITE	C05.1 - Malignant neoplasm of soft palate
200.32 - MARGINAL ZONE LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES	C05.8 - Malignant neoplasm of overlapping sites of palate
200.33 - MARGINAL ZONE LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES	C06.1 - Malignant neoplasm of vestibule of mouth
200.35 - MARGINAL ZONE LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C06.80 - Malignant neoplasm of overlapping sites of unspecified parts of mouth
200.43 - MANTLE CELL LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES	C06.9 - Malignant neoplasm of mouth, unspecified
200.44 - MANTLE CELL LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C08.1 - Malignant neoplasm of sublingual gland
200.45 - MANTLE CELL LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C09 - Malignant neoplasm of tonsil
200.47 - MANTLE CELL LYMPHOMA INVOLVING SPLEEN	C09.1 - Malignant neoplasm of tonsillar pillar (anterior) (posterior)
200.50 - PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA UNSPECIFIED SITE	C09.8 - Malignant neoplasm of overlapping sites of tonsil
200.53 - PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES	C09.9 - Malignant neoplasm of tonsil, unspecified
200.56 - PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES	C10.1 - Malignant neoplasm of anterior surface of epiglottis
200.58 - PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES	C10.4 - Malignant neoplasm of branchial cleft C10.8 - Malignant neoplasm of overlapping sites of oropharynx
200.6 - ANAPLASTIC LARGE CELL LYMPHOMA	

Appendix A

200.63 - ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES	C11.3 - Malignant neoplasm of anterior wall of nasopharynx
200.65 - ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C12 - Malignant neoplasm of pyriform sinus
200.68 - ANAPLASTIC LARGE CELL LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES	C13.0 - Malignant neoplasm of postcricoid region
200.70 - LARGE CELL LYMPHOMA UNSPECIFIED SITE	C13.2 - Malignant neoplasm of posterior wall of hypopharynx
200.74 - LARGE CELL LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C13.8 - Malignant neoplasm of overlapping sites of hypopharynx
200.75 - LARGE CELL LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C13.9 - Malignant neoplasm of hypopharynx, unspecified
200.81 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C14 - Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
200.82 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES	C14.0 - Malignant neoplasm of pharynx, unspecified
200.84 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C14.8 - Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
200.86 - OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES	C15 - Malignant neoplasm of esophagus

Appendix A

200.87 - OTHER NAMED VARIANTS OF
LYMPHOSARCOMA AND RETICULOSARCOMA
INVOLVING SPLEEN

C15.3 - Malignant neoplasm of upper third of esophagus

200.88 - OTHER NAMED VARIANTS OF
LYMPHOSARCOMA AND RETICULOSARCOMA
INVOLVING LYMPH NODES OF MULTIPLE SITES

C15.5 - Malignant neoplasm of lower third of esophagus

201.0 - HODGKIN'S PARAGRANULOMA

C16 - Malignant neoplasm of stomach

201.04 - HODGKIN'S PARAGRANULOMA
INVOLVING LYMPH NODES OF AXILLA AND
UPPER LIMB

C16.1 - Malignant neoplasm of fundus of stomach

201.06 - HODGKIN'S PARAGRANULOMA
INVOLVING INTRAPELVIC LYMPH NODES

C16.4 - Malignant neoplasm of pylorus

201.08 - HODGKIN'S PARAGRANULOMA
INVOLVING LYMPH NODES OF MULTIPLE SITES

C16.5 - Malignant neoplasm of lesser curvature of
stomach, unspecified

201.10 - HODGKIN'S GRANULOMA UNSPECIFIED
SITE

C16.6 - Malignant neoplasm of greater curvature of
stomach, unspecified

201.11 - HODGKIN'S GRANULOMA INVOLVING
LYMPH NODES OF HEAD FACE AND NECK

C16.8 - Malignant neoplasm of overlapping sites of
stomach

201.12 - HODGKIN'S GRANULOMA INVOLVING
INTRATHORACIC LYMPH NODES

C16.9 - Malignant neoplasm of stomach, unspecified

201.13 - HODGKIN'S GRANULOMA INVOLVING
INTRA-ABDOMINAL LYMPH NODES

C17 - Malignant neoplasm of small intestine

201.16 - HODGKIN'S GRANULOMA INVOLVING
INTRAPELVIC LYMPH NODES

C17.0 - Malignant neoplasm of duodenum

201.2 - HODGKIN'S SARCOMA

C17.1 - Malignant neoplasm of jejunum

201.21 - HODGKIN'S SARCOMA INVOLVING
LYMPH NODES OF HEAD FACE AND NECK

C17.2 - Malignant neoplasm of ileum

201.24 - HODGKIN'S SARCOMA INVOLVING
LYMPH NODES OF AXILLA AND UPPER LIMB

C17.8 - Malignant neoplasm of overlapping sites of small
intestine

201.26 - HODGKIN'S SARCOMA INVOLVING
INTRAPELVIC LYMPH NODES

C17.9 - Malignant neoplasm of small intestine, unspecified

Appendix A

201.27 - HODGKIN'S SARCOMA INVOLVING SPLEEN

C18 - Malignant neoplasm of colon

201.28 - HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES

C18.0 - Malignant neoplasm of cecum

201.41 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF HEAD FACE AND NECK

C18.1 - Malignant neoplasm of appendix

201.42 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRATHORACIC LYMPH NODES

C18.5 - Malignant neoplasm of splenic flexure

201.43 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRA-ABDOMINAL LYMPH NODES

C18.6 - Malignant neoplasm of descending colon

201.44 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

C18.7 - Malignant neoplasm of sigmoid colon

201.45 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

C18.8 - Malignant neoplasm of overlapping sites of colon

201.47 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING SPLEEN

C18.9 - Malignant neoplasm of colon, unspecified

201.48 - HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF MULTIPLE SITES

C19 - Malignant neoplasm of rectosigmoid junction

201.5 - HODGKIN'S DISEASE NODULAR SCLEROSIS

C20 - Malignant neoplasm of rectum

Appendix A

201.51 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK

201.53 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES

201.58 - HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF MULTIPLE SITES

201.6 - HODGKIN'S DISEASE MIXED CELLULARITY

201.60 - HODGKIN'S DISEASE MIXED CELLULARITY UNSPECIFIED SITE

201.63 - HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRA-ABDOMINAL LYMPH NODES

201.64 - HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

201.70 - HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION UNSPECIFIED SITE

201.71 - HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF HEAD FACE AND NECK

201.74 - HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

201.77 - HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING SPLEEN

201.91 - HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF HEAD FACE AND NECK

C21 - Malignant neoplasm of anus and anal canal

C21.0 - Malignant neoplasm of anus, unspecified

C21.1 - Malignant neoplasm of anal canal

C21.2 - Malignant neoplasm of cloacogenic zone

C22.0 - Liver cell carcinoma

C22.2 - Hepatoblastoma

C22.7 - Other specified carcinomas of liver

C22.9 - Malignant neoplasm of liver, not specified as primary or secondary

C23 - Malignant neoplasm of gallbladder

C24 - Malignant neoplasm of other and unspecified parts of biliary tract

C24.1 - Malignant neoplasm of ampulla of Vater

C24.8 - Malignant neoplasm of overlapping sites of biliary tract

Appendix A

201.94 - HODGKIN'S DISEASE UNSPECIFIED
TYPE INVOLVING LYMPH NODES OF AXILLA
AND UPPER LIMB

C25 - Malignant neoplasm of pancreas

201.95 - HODGKIN'S DISEASE UNSPECIFIED
TYPE INVOLVING LYMPH NODES OF INGUINAL
REGION AND LOWER LIMB

C25.1 - Malignant neoplasm of body of pancreas

201.97 - HODGKIN'S DISEASE UNSPECIFIED
TYPE INVOLVING SPLEEN

C25.2 - Malignant neoplasm of tail of pancreas

201.98 - HODGKIN'S DISEASE UNSPECIFIED
TYPE INVOLVING LYMPH NODES OF MULTIPLE
SITES

C25.4 - Malignant neoplasm of endocrine pancreas

202 - OTHER MALIGNANT NEOPLASMS OF
LYMPHOID AND HISTIOCYTIC TISSUE

C25.9 - Malignant neoplasm of pancreas, unspecified

202.00 - NODULAR LYMPHOMA UNSPECIFIED
SITE

C26.9 - Malignant neoplasm of ill-defined sites within the
digestive system

202.02 - NODULAR LYMPHOMA INVOLVING
INTRATHORACIC LYMPH NODES

C30 - Malignant neoplasm of nasal cavity and middle ear

202.04 - NODULAR LYMPHOMA INVOLVING
LYMPH NODES OF AXILLA AND UPPER LIMB

C30.0 - Malignant neoplasm of nasal cavity

202.05 - NODULAR LYMPHOMA INVOLVING
LYMPH NODES OF INGUINAL REGION AND
LOWER LIMB

C30.1 - Malignant neoplasm of middle ear

202.07 - NODULAR LYMPHOMA INVOLVING
SPLEEN

C31 - Malignant neoplasm of accessory sinuses

202.08 - NODULAR LYMPHOMA INVOLVING
LYMPH NODES OF MULTIPLE SITES

C31.0 - Malignant neoplasm of maxillary sinus

202.1 - MYCOSIS FUNGOIDES

C31.2 - Malignant neoplasm of frontal sinus

202.10 - MYCOSIS FUNGOIDES UNSPECIFIED
SITE

C32 - Malignant neoplasm of larynx

202.16 - MYCOSIS FUNGOIDES INVOLVING
INTRAPELVIC LYMPH NODES

C32.1 - Malignant neoplasm of supraglottis

202.20 - SEZARY'S DISEASE UNSPECIFIED SITE

C32.2 - Malignant neoplasm of subglottis

202.21 - SEZARY'S DISEASE INVOLVING LYMPH
NODES OF HEAD FACE AND NECK

C32.3 - Malignant neoplasm of laryngeal cartilage

Appendix A

202.23 - SEZARY'S DISEASE INVOLVING INTRA-ABDOMINAL LYMPH NODES	C32.8 - Malignant neoplasm of overlapping sites of larynx
202.24 - SEZARY'S DISEASE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C32.9 - Malignant neoplasm of larynx, unspecified
202.26 - SEZARY'S DISEASE INVOLVING INTRAPELVIC LYMPH NODES	C34.00 - Malignant neoplasm of unspecified main bronchus
202.30 - MALIGNANT HISTIOCYTOSIS UNSPECIFIED SITE	C34.2 - Malignant neoplasm of middle lobe, bronchus or lung
202.32 - MALIGNANT HISTIOCYTOSIS INVOLVING INTRATHORACIC LYMPH NODES	C34.3 - Malignant neoplasm of lower lobe, bronchus or lung
202.35 - MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C34.30 - Malignant neoplasm of lower lobe, unspecified bronchus or lung
202.40 - LEUKEMIC RETICULOENDOTHELIOSIS UNSPECIFIED SITE	C34.8 - Malignant neoplasm of overlapping sites of bronchus and lung
202.42 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRATHORACIC LYMPH NODES	C34.81 - Malignant neoplasm of overlapping sites of right bronchus and lung
202.43 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES	C34.82 - Malignant neoplasm of overlapping sites of left bronchus and lung
202.44 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER ARM	C34.9 - Malignant neoplasm of unspecified part of bronchus or lung
202.45 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB	C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung
202.48 - LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF MULTIPLE SITES	C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung
202.52 - LETTERER-SIWE DISEASE INVOLVING INTRATHORACIC LYMPH NODES	C38 - Malignant neoplasm of heart, mediastinum and pleura

Appendix A

202.53 - LETTERER-SIWE DISEASE INVOLVING INTRA-ABDOMINAL LYMPH NODES	C38.0 - Malignant neoplasm of heart
202.56 - LETTERER-SIWE DISEASE INVOLVING INTRAPELVIC LYMPH NODES	C38.3 - Malignant neoplasm of mediastinum, part unspecified
202.57 - LETTERER-SIWE DISEASE INVOLVING SPLEEN	C38.4 - Malignant neoplasm of pleura
202.6 - MALIGNANT MAST CELL TUMORS	C38.8 - Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
202.60 - MALIGNANT MAST CELL TUMORS UNSPECIFIED SITE	C39 - Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs
202.61 - MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF HEAD FACE AND NECK	C39.9 - Malignant neoplasm of lower respiratory tract, part unspecified
202.62 - MALIGNANT MAST CELL TUMORS INVOLVING INTRATHORACIC LYMPH NODES	C40.00 - Malignant neoplasm of scapula and long bones of unspecified upper limb
202.63 - MALIGNANT MAST CELL TUMORS INVOLVING INTRA-ABDOMINAL LYMPH NODES	C40.02 - Malignant neoplasm of scapula and long bones of left upper limb
202.64 - MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB	C40.1 - Malignant neoplasm of short bones of upper limb
202.67 - MALIGNANT MAST CELL TUMORS INVOLVING SPLEEN	C40.11 - Malignant neoplasm of short bones of right upper limb
202.68 - MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF MULTIPLE SITES	C40.21 - Malignant neoplasm of long bones of right lower limb
202.7 - PERIPHERAL T-CELL LYMPHOMA	C40.30 - Malignant neoplasm of short bones of unspecified lower limb
202.73 - PERIPHERAL T-CELL LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES	C40.31 - Malignant neoplasm of short bones of right lower limb

Appendix A

202.74 - PERIPHERAL T-CELL LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

202.77 - PERIPHERAL T-CELL LYMPHOMA INVOLVING SPLEEN

202.8 - OTHER MALIGNANT LYMPHOMAS

202.82 - OTHER MALIGNANT LYMPHOMAS INVOLVING INTRATHORACIC LYMPH NODES

202.85 - OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

202.86 - OTHER MALIGNANT LYMPHOMAS INVOLVING INTRAPELVIC LYMPH NODES

202.87 - OTHER MALIGNANT LYMPHOMAS INVOLVING SPLEEN

202.88 - OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF MULTIPLE SITES

202.9 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE

202.93 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRA-ABDOMINAL LYMPH NODES

202.94 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB

202.95 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB

C40.32 - Malignant neoplasm of short bones of left lower limb

C40.81 - Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb

C40.82 - Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb

C40.9 - Malignant neoplasm of unspecified bones and articular cartilage of limb

C41.9 - Malignant neoplasm of bone and articular cartilage, unspecified

C43 - Malignant melanoma of skin

C43.0 - Malignant melanoma of lip

C43.10 - Malignant melanoma of unspecified eyelid, including canthus

C43.112 - Malignant melanoma of right lower eyelid, including canthus

C43.12 - Malignant melanoma of left eyelid, including canthus

C43.121 - Malignant melanoma of left upper eyelid, including canthus

C43.20 - Malignant melanoma of unspecified ear and external auricular canal

Appendix A

202.96 - OTHER AND UNSPECIFIED MALIGNANT
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC
TISSUE INVOLVING INTRAPELVIC LYMPH
NODES

203 - MULTIPLE MYELOMA AND
IMMUNOPROLIFERATIVE NEOPLASMS

203.0 - MULTIPLE MYELOMA

203.1 - PLASMA CELL LEUKEMIA

203.81 - OTHER IMMUNOPROLIFERATIVE
NEOPLASMS IN REMISSION

203.82 - OTHER IMMUNOPROLIFERATIVE
NEOPLASMS IN RELAPSE

204.00 - ACUTE LYMPHOID LEUKEMIA WITHOUT
MENTION OF HAVING ACHIEVED REMISSION

204.02 - ACUTE LYMPHOID LEUKEMIA IN
RELAPSE

204.11 - CHRONIC LYMPHOID LEUKEMIA IN
REMISSION

204.2 - SUBACUTE LYMPHOID LEUKEMIA

204.20 - SUBACUTE LYMPHOID LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

204.21 - SUBACUTE LYMPHOID LEUKEMIA IN
REMISSION

204.9 - UNSPECIFIED LYMPHOID LEUKEMIA

204.90 - UNSPECIFIED LYMPHOID LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

205 - MYELOID LEUKEMIA

C43.21 - Malignant melanoma of right ear and external
auricular canal

C43.3 - Malignant melanoma of other and unspecified
parts of face

C43.30 - Malignant melanoma of unspecified part of face

C43.31 - Malignant melanoma of nose

C43.4 - Malignant melanoma of scalp and neck

C43.5 - Malignant melanoma of trunk

C43.52 - Malignant melanoma of skin of breast

C43.6 - Malignant melanoma of upper limb, including
shoulder

C43.60 - Malignant melanoma of unspecified upper limb,
including shoulder

C43.62 - Malignant melanoma of left upper limb, including
shoulder

C43.7 - Malignant melanoma of lower limb, including hip

C43.70 - Malignant melanoma of unspecified lower limb,
including hip

C43.72 - Malignant melanoma of left lower limb, including
hip

C43.8 - Malignant melanoma of overlapping sites of skin

C45.1 - Mesothelioma of peritoneum

Appendix A

205.00 - ACUTE MYELOID LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

205.10 - CHRONIC MYELOID LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

205.11 - CHRONIC MYELOID LEUKEMIA IN REMISSION

205.20 - SUBACUTE MYELOID LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

205.21 - SUBACUTE MYELOID LEUKEMIA IN REMISSION

205.22 - SUBACUTE MYELOID LEUKEMIA IN RELAPSE

205.3 - MYELOID SARCOMA

205.30 - MYELOID SARCOMA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

205.31 - MYELOID SARCOMA IN REMISSION

205.32 - MYELOID SARCOMA IN RELAPSE

205.8 - OTHER MYELOID LEUKEMIA

205.81 - OTHER MYELOID LEUKEMIA IN REMISSION

206.0 - ACUTE MONOCYTTIC LEUKEMIA

206.01 - ACUTE MONOCYTTIC LEUKEMIA IN REMISSION

206.02 - ACUTE MONOCYTTIC LEUKEMIA IN RELAPSE

206.10 - CHRONIC MONOCYTTIC LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION

206.12 - CHRONIC MONOCYTTIC LEUKEMIA IN RELAPSE

C45.7 - Mesothelioma of other sites

C45.9 - Mesothelioma, unspecified

C46 - Kaposi's sarcoma

C46.0 - Kaposi's sarcoma of skin

C46.1 - Kaposi's sarcoma of soft tissue

C46.2 - Kaposi's sarcoma of palate

C46.3 - Kaposi's sarcoma of lymph nodes

C46.4 - Kaposi's sarcoma of gastrointestinal sites

C46.5 - Kaposi's sarcoma of lung

C46.50 - Kaposi's sarcoma of unspecified lung

C46.7 - Kaposi's sarcoma of other sites

C47 - Malignant neoplasm of peripheral nerves and autonomic nervous system

C47.0 - Malignant neoplasm of peripheral nerves of head, face and neck

C47.1 - Malignant neoplasm of peripheral nerves of upper limb, including shoulder

C47.11 - Malignant neoplasm of peripheral nerves of right upper limb, including shoulder

C47.2 - Malignant neoplasm of peripheral nerves of lower limb, including hip

C47.3 - Malignant neoplasm of peripheral nerves of thorax

Appendix A

206.20 - SUBACUTE MONOCYTIC LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

206.22 - SUBACUTE MONOCYTIC LEUKEMIA IN
RELAPSE

206.81 - OTHER MONOCYTIC LEUKEMIA IN
REMISSION

206.82 - OTHER MONOCYTIC LEUKEMIA IN
RELAPSE

206.90 - UNSPECIFIED MONOCYTIC LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

206.91 - UNSPECIFIED MONOCYTIC LEUKEMIA
IN REMISSION

206.92 - UNSPECIFIED MONOCYTIC LEUKEMIA
IN RELAPSE

207 - OTHER SPECIFIED LEUKEMIA

207.01 - ACUTE ERYTHREMIA AND
ERYTHROLEUKEMIA IN REMISSION

207.02 - ACUTE ERYTHREMIA AND
ERYTHROLEUKEMIA IN RELAPSE

207.1 - CHRONIC ERYTHREMIA

207.10 - CHRONIC ERYTHREMIA WITHOUT
MENTION OF HAVING ACHIEVED REMISSION

207.12 - CHRONIC ERYTHREMIA IN RELAPSE

207.2 - MEGAKARYOCYTIC LEUKEMIA

207.20 - MEGAKARYOCYTIC LEUKEMIA
WITHOUT MENTION OF HAVING ACHIEVED
REMISSION

207.21 - MEGAKARYOCYTIC LEUKEMIA IN
REMISSION

C47.5 - Malignant neoplasm of peripheral nerves of pelvis

C47.6 - Malignant neoplasm of peripheral nerves of trunk,
unspecified

C48 - Malignant neoplasm of retroperitoneum and
peritoneum

C48.1 - Malignant neoplasm of specified parts of
peritoneum

C49.0 - Malignant neoplasm of connective and soft tissue
of head, face and neck

C49.1 - Malignant neoplasm of connective and soft tissue
of upper limb, including shoulder

C49.11 - Malignant neoplasm of connective and soft tissue
of right upper limb, including shoulder

C49.12 - Malignant neoplasm of connective and soft tissue
of left upper limb, including shoulder

C49.21 - Malignant neoplasm of connective and soft tissue
of right lower limb, including hip

C49.22 - Malignant neoplasm of connective and soft tissue
of left lower limb, including hip

C49.3 - Malignant neoplasm of connective and soft tissue
of thorax

C49.9 - Malignant neoplasm of connective and soft tissue,
unspecified

C49.A0 - Gastrointestinal stromal tumor, unspecified site

C49.A1 - Gastrointestinal stromal tumor of esophagus

C49.A4 - Gastrointestinal stromal tumor of large intestine

C50.0 - Malignant neoplasm of nipple and areola

Appendix A

207.22 - MEGAKARYOCYTIC LEUKEMIA IN RELAPSE	C50.01 - Malignant neoplasm of nipple and areola, female
207.8 - OTHER SPECIFIED LEUKEMIA	C50.011 - Malignant neoplasm of nipple and areola, right female breast
207.80 - OTHER SPECIFIED LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C50.019 - Malignant neoplasm of nipple and areola, unspecified female breast
207.82 - OTHER SPECIFIED LEUKEMIA IN RELAPSE	C50.022 - Malignant neoplasm of nipple and areola, left male breast
208.00 - ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C50.11 - Malignant neoplasm of central portion of breast, female
208.01 - ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE IN REMISSION	C50.111 - Malignant neoplasm of central portion of right female breast
208.02 - ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE IN RELAPSE	C50.112 - Malignant neoplasm of central portion of left female breast
208.11 - CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE IN REMISSION	C50.121 - Malignant neoplasm of central portion of right male breast
208.8 - OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE	C50.129 - Malignant neoplasm of central portion of unspecified male breast
208.80 - OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C50.2 - Malignant neoplasm of upper-inner quadrant of breast
208.81 - OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE IN REMISSION	C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast
208.9 - UNSPECIFIED LEUKEMIA	C50.219 - Malignant neoplasm of upper-inner quadrant of unspecified female breast
208.90 - UNSPECIFIED LEUKEMIA WITHOUT MENTION OF HAVING ACHIEVED REMISSION	C50.222 - Malignant neoplasm of upper-inner quadrant of left male breast
208.91 - UNSPECIFIED LEUKEMIA IN REMISSION	C50.229 - Malignant neoplasm of upper-inner quadrant of unspecified male breast
208.92 - UNSPECIFIED LEUKEMIA IN RELAPSE	C50.31 - Malignant neoplasm of lower-inner quadrant of breast, female
209.0 - MALIGNANT CARCINOID TUMORS OF THE SMALL INTESTINE	C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast

Appendix A

209.03 - MALIGNANT CARCINOID TUMOR OF THE ILEUM

209.1 - MALIGNANT CARCINOID TUMORS OF THE APPENDIX LARGE INTESTINE AND RECTUM

209.10 - MALIGNANT CARCINOID TUMOR OF THE LARGE INTESTINE UNSPECIFIED PORTION

209.13 - MALIGNANT CARCINOID TUMOR OF THE ASCENDING COLON

209.14 - MALIGNANT CARCINOID TUMOR OF THE TRANSVERSE COLON

209.15 - MALIGNANT CARCINOID TUMOR OF THE DESCENDING COLON

209.16 - MALIGNANT CARCINOID TUMOR OF THE SIGMOID COLON

209.2 - MALIGNANT CARCINOID TUMOR OF OTHER AND UNSPECIFIED SITES

209.20 - MALIGNANT CARCINOID TUMOR OF UNKNOWN PRIMARY SITE

209.21 - MALIGNANT CARCINOID TUMOR OF THE BRONCHUS AND LUNG

209.23 - MALIGNANT CARCINOID TUMOR OF THE STOMACH

209.24 - MALIGNANT CARCINOID TUMOR OF THE KIDNEY

209.26 - MALIGNANT CARCINOID TUMOR OF THE MIDGUT NOT OTHERWISE SPECIFIED

209.27 - MALIGNANT CARCINOID TUMOR OF THE HINDGUT NOT OTHERWISE SPECIFIED

209.35 - MERKEL CELL CARCINOMA OF THE TRUNK

209.36 - MERKEL CELL CARCINOMA OF OTHER SITES

C50.319 - Malignant neoplasm of lower-inner quadrant of unspecified female breast

C50.321 - Malignant neoplasm of lower-inner quadrant of right male breast

C50.41 - Malignant neoplasm of upper-outer quadrant of breast, female

C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast

C50.42 - Malignant neoplasm of upper-outer quadrant of breast, male

C50.421 - Malignant neoplasm of upper-outer quadrant of right male breast

C50.422 - Malignant neoplasm of upper-outer quadrant of left male breast

C50.429 - Malignant neoplasm of upper-outer quadrant of unspecified male breast

C50.5 - Malignant neoplasm of lower-outer quadrant of breast

C50.511 - Malignant neoplasm of lower-outer quadrant of right female breast

C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast

C50.519 - Malignant neoplasm of lower-outer quadrant of unspecified female breast

C50.52 - Malignant neoplasm of lower-outer quadrant of breast, male

C50.521 - Malignant neoplasm of lower-outer quadrant of right male breast

C50.529 - Malignant neoplasm of lower-outer quadrant of unspecified male breast

C50.611 - Malignant neoplasm of axillary tail of right female breast

Appendix A

209.7 - SECONDARY NEUROENDOCRINE
TUMORS

209.71 - SECONDARY NEUROENDOCRINE
TUMOR OF DISTANT LYMPH NODES

209.73 - SECONDARY NEUROENDOCRINE
TUMOR OF BONE

209.74 - SECONDARY NEUROENDOCRINE
TUMOR OF PERITONEUM

C50.62 - Malignant neoplasm of axillary tail of breast, male

C50.622 - Malignant neoplasm of axillary tail of left male
breast

C50.8 - Malignant neoplasm of overlapping sites of breast

C50.819 - Malignant neoplasm of overlapping sites of
unspecified female breast

C50.82 - Malignant neoplasm of overlapping sites of
breast, male

C50.821 - Malignant neoplasm of overlapping sites of right
male breast

C50.822 - Malignant neoplasm of overlapping sites of left
male breast

C50.9 - Malignant neoplasm of breast of unspecified site

C50.91 - Malignant neoplasm of breast of unspecified site,
female

C50.911 - Malignant neoplasm of unspecified site of right
female breast

C50.919 - Malignant neoplasm of unspecified site of
unspecified female breast

C52 - Malignant neoplasm of vagina

C53 - Malignant neoplasm of cervix uteri

C53.1 - Malignant neoplasm of exocervix

C53.8 - Malignant neoplasm of overlapping sites of cervix
uteri

C53.9 - Malignant neoplasm of cervix uteri, unspecified

C54 - Malignant neoplasm of corpus uteri

C54.0 - Malignant neoplasm of isthmus uteri

C54.8 - Malignant neoplasm of overlapping sites of corpus
uteri

C54.9 - Malignant neoplasm of corpus uteri, unspecified

Appendix A

C55 - Malignant neoplasm of uterus, part unspecified
C56.1 - Malignant neoplasm of right ovary
C56.2 - Malignant neoplasm of left ovary
C56.9 - Malignant neoplasm of unspecified ovary
C57 - Malignant neoplasm of other and unspecified female genital organs
C57.0 - Malignant neoplasm of fallopian tube
C57.01 - Malignant neoplasm of right fallopian tube
C57.10 - Malignant neoplasm of unspecified broad ligament
C57.2 - Malignant neoplasm of round ligament
C57.20 - Malignant neoplasm of unspecified round ligament
C57.21 - Malignant neoplasm of right round ligament
C57.22 - Malignant neoplasm of left round ligament
C57.3 - Malignant neoplasm of parametrium

C57.4 - Malignant neoplasm of uterine adnexa, unspecified
C57.7 - Malignant neoplasm of other specified female genital organs
C58 - Malignant neoplasm of placenta
C60 - Malignant neoplasm of penis
C60.2 - Malignant neoplasm of body of penis

C60.8 - Malignant neoplasm of overlapping sites of penis
C62 - Malignant neoplasm of testis
C62.0 - Malignant neoplasm of undescended testis
C62.1 - Malignant neoplasm of descended testis
C62.10 - Malignant neoplasm of unspecified descended testis

C62.11 - Malignant neoplasm of descended right testis
C62.91 - Malignant neoplasm of right testis, unspecified whether descended or undescended

Appendix A

C63 - Malignant neoplasm of other and unspecified male genital organs

C63.0 - Malignant neoplasm of epididymis

C63.00 - Malignant neoplasm of unspecified epididymis

C63.01 - Malignant neoplasm of right epididymis

C63.1 - Malignant neoplasm of spermatic cord

C63.10 - Malignant neoplasm of unspecified spermatic cord

C63.11 - Malignant neoplasm of right spermatic cord

C63.12 - Malignant neoplasm of left spermatic cord

C63.7 - Malignant neoplasm of other specified male genital organs

C63.9 - Malignant neoplasm of male genital organ, unspecified

C64.1 - Malignant neoplasm of right kidney, except renal pelvis

C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis

C65 - Malignant neoplasm of renal pelvis

C65.1 - Malignant neoplasm of right renal pelvis

C66.9 - Malignant neoplasm of unspecified ureter

C67.0 - Malignant neoplasm of trigone of bladder

C67.1 - Malignant neoplasm of dome of bladder

C67.4 - Malignant neoplasm of posterior wall of bladder

C67.5 - Malignant neoplasm of bladder neck

C67.7 - Malignant neoplasm of urachus

C67.8 - Malignant neoplasm of overlapping sites of bladder

C67.9 - Malignant neoplasm of bladder, unspecified

C68.0 - Malignant neoplasm of urethra

C68.1 - Malignant neoplasm of paraurethral glands

C68.8 - Malignant neoplasm of overlapping sites of urinary organs

Appendix A

C69 - Malignant neoplasm of eye and adnexa
C69.0 - Malignant neoplasm of conjunctiva

C69.00 - Malignant neoplasm of unspecified conjunctiva
C69.01 - Malignant neoplasm of right conjunctiva
C69.02 - Malignant neoplasm of left conjunctiva
C69.10 - Malignant neoplasm of unspecified cornea
C69.11 - Malignant neoplasm of right cornea
C69.2 - Malignant neoplasm of retina
C69.20 - Malignant neoplasm of unspecified retina
C69.22 - Malignant neoplasm of left retina
C69.31 - Malignant neoplasm of right choroid
C69.4 - Malignant neoplasm of ciliary body

C69.40 - Malignant neoplasm of unspecified ciliary body
C69.41 - Malignant neoplasm of right ciliary body
C69.42 - Malignant neoplasm of left ciliary body
C69.50 - Malignant neoplasm of unspecified lacrimal gland
and duct
C69.6 - Malignant neoplasm of orbit
C69.61 - Malignant neoplasm of right orbit
C69.62 - Malignant neoplasm of left orbit
C69.8 - Malignant neoplasm of overlapping sites of eye
and adnexa
C69.80 - Malignant neoplasm of overlapping sites of
unspecified eye and adnexa
C69.9 - Malignant neoplasm of unspecified site of eye
C69.90 - Malignant neoplasm of unspecified site of
unspecified eye
C71.0 - Malignant neoplasm of cerebrum, except lobes
and ventricles
C71.1 - Malignant neoplasm of frontal lobe
C72.1 - Malignant neoplasm of cauda equina
C72.2 - Malignant neoplasm of olfactory nerve

Appendix A

C72.20 - Malignant neoplasm of unspecified olfactory nerve

C72.21 - Malignant neoplasm of right olfactory nerve

C72.22 - Malignant neoplasm of left olfactory nerve

C72.31 - Malignant neoplasm of right optic nerve

C72.42 - Malignant neoplasm of left acoustic nerve

C72.5 - Malignant neoplasm of other and unspecified cranial nerves

C74.0 - Malignant neoplasm of cortex of adrenal gland

C74.02 - Malignant neoplasm of cortex of left adrenal gland

C74.1 - Malignant neoplasm of medulla of adrenal gland

C74.11 - Malignant neoplasm of medulla of right adrenal gland

C74.12 - Malignant neoplasm of medulla of left adrenal gland

C74.9 - Malignant neoplasm of unspecified part of adrenal gland

C74.90 - Malignant neoplasm of unspecified part of unspecified adrenal gland

C74.91 - Malignant neoplasm of unspecified part of right adrenal gland

C75.1 - Malignant neoplasm of pituitary gland

C75.2 - Malignant neoplasm of craniopharyngeal duct

C75.3 - Malignant neoplasm of pineal gland

C75.5 - Malignant neoplasm of aortic body and other paraganglia

C76 - Malignant neoplasm of other and ill-defined sites

C76.0 - Malignant neoplasm of head, face and neck

C76.1 - Malignant neoplasm of thorax

C76.2 - Malignant neoplasm of abdomen

C76.3 - Malignant neoplasm of pelvis

Appendix A

C76.4 - Malignant neoplasm of upper limb

C77 - Secondary and unspecified malignant neoplasm of lymph nodes

C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes

C77.4 - Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes

C77.5 - Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes

C77.8 - Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions

C78.0 - Secondary malignant neoplasm of lung

C78.01 - Secondary malignant neoplasm of right lung

C78.02 - Secondary malignant neoplasm of left lung

C78.3 - Secondary malignant neoplasm of other and unspecified respiratory organs

C78.4 - Secondary malignant neoplasm of small intestine

C78.8 - Secondary malignant neoplasm of other and unspecified digestive organs

C79 - Secondary malignant neoplasm of other and unspecified sites

C79.0 - Secondary malignant neoplasm of kidney and renal pelvis

C79.00 - Secondary malignant neoplasm of unspecified kidney and renal pelvis

C79.01 - Secondary malignant neoplasm of right kidney and renal pelvis

C79.1 - Secondary malignant neoplasm of bladder and other and unspecified urinary organs

C79.10 - Secondary malignant neoplasm of unspecified urinary organs

C79.19 - Secondary malignant neoplasm of other urinary organs

Appendix A

C79.32 - Secondary malignant neoplasm of cerebral meninges

C79.4 - Secondary malignant neoplasm of other and unspecified parts of nervous system

C79.40 - Secondary malignant neoplasm of unspecified part of nervous system

C79.49 - Secondary malignant neoplasm of other parts of nervous system

C79.51 - Secondary malignant neoplasm of bone

C79.52 - Secondary malignant neoplasm of bone marrow

C79.60 - Secondary malignant neoplasm of unspecified ovary

C79.61 - Secondary malignant neoplasm of right ovary

C79.71 - Secondary malignant neoplasm of right adrenal gland

C79.82 - Secondary malignant neoplasm of genital organs

C79.89 - Secondary malignant neoplasm of other specified sites

C80.0 - Disseminated malignant neoplasm, unspecified

C80.1 - Malignant (primary) neoplasm, unspecified

C80.2 - Malignant neoplasm associated with transplanted organ

C81.00 - Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site

C81.03 - Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes

C81.05 - Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.08 - Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites

Appendix A

- C81.10 - Nodular sclerosis Hodgkin lymphoma, unspecified site
- C81.11 - Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
- C81.13 - Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
- C81.21 - Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
- C81.23 - Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes
- C81.25 - Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
- C81.28 - Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites
- C81.29 - Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites
- C81.3 - Lymphocyte depleted Hodgkin lymphoma
- C81.32 - Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes
- C81.33 - Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes
- C81.35 - Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

- C81.37 - Lymphocyte depleted Hodgkin lymphoma, spleen
- C81.39 - Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites
- C81.40 - Lymphocyte-rich Hodgkin lymphoma, unspecified site
- C81.45 - Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
- C81.46 - Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes

- C81.47 - Lymphocyte-rich Hodgkin lymphoma, spleen

Appendix A

C81.48 - Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites

C81.49 - Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites

C81.74 - Other Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.76 - Other Hodgkin lymphoma, intrapelvic lymph nodes

C81.77 - Other Hodgkin lymphoma, spleen

C81.78 - Other Hodgkin lymphoma, lymph nodes of multiple sites

C81.9 - Hodgkin lymphoma, unspecified

C81.92 - Hodgkin lymphoma, unspecified, intrathoracic lymph nodes

C81.93 - Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes

C81.95 - Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb

C81.99 - Hodgkin lymphoma, unspecified, extranodal and solid organ sites

C82.0 - Follicular lymphoma grade I

C82.00 - Follicular lymphoma grade I, unspecified site

C82.01 - Follicular lymphoma grade I, lymph nodes of head, face, and neck

C82.02 - Follicular lymphoma grade I, intrathoracic lymph nodes

C82.03 - Follicular lymphoma grade I, intra-abdominal lymph nodes

C82.04 - Follicular lymphoma grade I, lymph nodes of axilla and upper limb

C82.10 - Follicular lymphoma grade II, unspecified site

C82.11 - Follicular lymphoma grade II, lymph nodes of head, face, and neck

Appendix A

C82.13 - Follicular lymphoma grade II, intra-abdominal lymph nodes

C82.16 - Follicular lymphoma grade II, intrapelvic lymph nodes

C82.17 - Follicular lymphoma grade II, spleen

C82.22 - Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes

C82.23 - Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes

C82.26 - Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes

C82.27 - Follicular lymphoma grade III, unspecified, spleen

C82.3 - Follicular lymphoma grade IIIa

C82.30 - Follicular lymphoma grade IIIa, unspecified site

C82.31 - Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck

C82.34 - Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb

C82.36 - Follicular lymphoma grade IIIa, intrapelvic lymph nodes

C82.37 - Follicular lymphoma grade IIIa, spleen

C82.38 - Follicular lymphoma grade IIIa, lymph nodes of multiple sites

C82.4 - Follicular lymphoma grade IIIb

C82.40 - Follicular lymphoma grade IIIb, unspecified site

C82.41 - Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck

C82.42 - Follicular lymphoma grade IIIb, intrathoracic lymph nodes

C82.43 - Follicular lymphoma grade IIIb, intra-abdominal lymph nodes

Appendix A

C82.45 - Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb

C82.48 - Follicular lymphoma grade IIIb, lymph nodes of multiple sites

C82.49 - Follicular lymphoma grade IIIb, extranodal and solid organ sites

C82.5 - Diffuse follicle center lymphoma

C82.50 - Diffuse follicle center lymphoma, unspecified site

C82.53 - Diffuse follicle center lymphoma, intra-abdominal lymph nodes

C82.54 - Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb

C82.57 - Diffuse follicle center lymphoma, spleen

C82.58 - Diffuse follicle center lymphoma, lymph nodes of multiple sites

C82.6 - Cutaneous follicle center lymphoma

C82.64 - Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb

C82.65 - Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb

C82.66 - Cutaneous follicle center lymphoma, intrapelvic lymph nodes

C82.67 - Cutaneous follicle center lymphoma, spleen

C82.81 - Other types of follicular lymphoma, lymph nodes of head, face, and neck

C82.82 - Other types of follicular lymphoma, intrathoracic lymph nodes

C82.83 - Other types of follicular lymphoma, intra-abdominal lymph nodes

C82.84 - Other types of follicular lymphoma, lymph nodes of axilla and upper limb

C82.85 - Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb

Appendix A

C82.88 - Other types of follicular lymphoma, lymph nodes of multiple sites

C82.9 - Follicular lymphoma, unspecified

C82.90 - Follicular lymphoma, unspecified, unspecified site

C82.91 - Follicular lymphoma, unspecified, lymph nodes of head, face, and neck

C82.93 - Follicular lymphoma, unspecified, intra-abdominal lymph nodes

C82.94 - Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb

C83 - Non-follicular lymphoma

C83.0 - Small cell B-cell lymphoma

C83.04 - Small cell B-cell lymphoma, lymph nodes of axilla and upper limb

C83.05 - Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb

C83.09 - Small cell B-cell lymphoma, extranodal and solid organ sites

C83.1 - Mantle cell lymphoma

C83.10 - Mantle cell lymphoma, unspecified site

C83.13 - Mantle cell lymphoma, intra-abdominal lymph nodes

C83.15 - Mantle cell lymphoma, lymph nodes of inguinal region and lower limb

C83.16 - Mantle cell lymphoma, intrapelvic lymph nodes

C83.3 - Diffuse large B-cell lymphoma

C83.32 - Diffuse large B-cell lymphoma, intrathoracic lymph nodes

C83.33 - Diffuse large B-cell lymphoma, intra-abdominal lymph nodes

C83.39 - Diffuse large B-cell lymphoma, extranodal and solid organ sites

Appendix A

C83.51 - Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck

C83.54 - Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb

C83.55 - Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb

C83.57 - Lymphoblastic (diffuse) lymphoma, spleen

C83.7 - Burkitt lymphoma

C83.70 - Burkitt lymphoma, unspecified site

C83.71 - Burkitt lymphoma, lymph nodes of head, face, and neck

C83.73 - Burkitt lymphoma, intra-abdominal lymph nodes

C83.74 - Burkitt lymphoma, lymph nodes of axilla and upper limb

C83.75 - Burkitt lymphoma, lymph nodes of inguinal region and lower limb

C83.78 - Burkitt lymphoma, lymph nodes of multiple sites

C83.81 - Other non-follicular lymphoma, lymph nodes of head, face, and neck

C83.82 - Other non-follicular lymphoma, intrathoracic lymph nodes

C83.85 - Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb

C83.86 - Other non-follicular lymphoma, intrapelvic lymph nodes

C83.87 - Other non-follicular lymphoma, spleen

C83.88 - Other non-follicular lymphoma, lymph nodes of multiple sites

C83.91 - Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck

C83.94 - Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb

Appendix A

C83.96 - Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes

C83.97 - Non-follicular (diffuse) lymphoma, unspecified, spleen

C83.98 - Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites

C83.99 - Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites

C84 - Mature T/NK-cell lymphomas

C84.0 - Mycosis fungoides

C84.00 - Mycosis fungoides, unspecified site

C84.01 - Mycosis fungoides, lymph nodes of head, face, and neck

C84.03 - Mycosis fungoides, intra-abdominal lymph nodes

C84.04 - Mycosis fungoides, lymph nodes of axilla and upper limb

C84.05 - Mycosis fungoides, lymph nodes of inguinal region and lower limb

C84.06 - Mycosis fungoides, intrapelvic lymph nodes

C84.08 - Mycosis fungoides, lymph nodes of multiple sites

C84.09 - Mycosis fungoides, extranodal and solid organ sites

C84.1 - Sezary disease

C84.10 - Sezary disease, unspecified site

C84.12 - Sezary disease, intrathoracic lymph nodes

C84.14 - Sezary disease, lymph nodes of axilla and upper limb

C84.16 - Sezary disease, intrapelvic lymph nodes

C84.19 - Sezary disease, extranodal and solid organ sites

C84.40 - Peripheral T-cell lymphoma, not classified, unspecified site

Appendix A

C84.46 - Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes

C84.47 - Peripheral T-cell lymphoma, not classified, spleen

C84.6 - Anaplastic large cell lymphoma, ALK-positive

C84.60 - Anaplastic large cell lymphoma, ALK-positive, unspecified site

C84.62 - Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes

C84.63 - Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes

C84.64 - Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb

C84.65 - Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb

C84.67 - Anaplastic large cell lymphoma, ALK-positive, spleen

C84.68 - Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites

C84.69 - Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites

C84.70 - Anaplastic large cell lymphoma, ALK-negative, unspecified site

C84.72 - Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes

C84.73 - Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes

C84.77 - Anaplastic large cell lymphoma, ALK-negative, spleen

C84.78 - Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites

C84.90 - Mature T/NK-cell lymphomas, unspecified, unspecified site

Appendix A

C84.91 - Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck

C84.92 - Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes

C84.A0 - Cutaneous T-cell lymphoma, unspecified, unspecified site

C84.A1 - Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck

C84.A2 - Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes

C84.A3 - Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes

C84.A5 - Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb

C84.A7 - Cutaneous T-cell lymphoma, unspecified, spleen

C84.Z - Other mature T/NK-cell lymphomas

C84.Z1 - Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck

C84.Z4 - Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb

C84.Z6 - Other mature T/NK-cell lymphomas, intrapelvic lymph nodes

C84.Z8 - Other mature T/NK-cell lymphomas, lymph nodes of multiple sites

C85.1 - Unspecified B-cell lymphoma

C85.12 - Unspecified B-cell lymphoma, intrathoracic lymph nodes

C85.13 - Unspecified B-cell lymphoma, intra-abdominal lymph nodes

C85.15 - Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb

C85.17 - Unspecified B-cell lymphoma, spleen

C85.18 - Unspecified B-cell lymphoma, lymph nodes of multiple sites

Appendix A

C85.19 - Unspecified B-cell lymphoma, extranodal and solid organ sites

C85.22 - Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes

C85.26 - Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes

C85.8 - Other specified types of non-Hodgkin lymphoma

C85.80 - Other specified types of non-Hodgkin lymphoma, unspecified site

C85.86 - Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes

C85.87 - Other specified types of non-Hodgkin lymphoma, spleen

C85.89 - Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites

C85.91 - Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck

C85.92 - Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes

C85.93 - Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes

C85.96 - Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes

C85.97 - Non-Hodgkin lymphoma, unspecified, spleen

C85.98 - Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites

C85.99 - Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites

C86 - Other specified types of T/NK-cell lymphoma

C86.0 - Extranodal NK/T-cell lymphoma, nasal type

C86.3 - Subcutaneous panniculitis-like T-cell lymphoma

C86.4 - Blastic NK-cell lymphoma

Appendix A

C86.5 - Angioimmunoblastic T-cell lymphoma

C86.6 - Primary cutaneous CD30-positive T-cell proliferations

C88.0 - Waldenstrom macroglobulinemia

C88.2 - Heavy chain disease

C88.4 - Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]

C88.8 - Other malignant immunoproliferative diseases

C90 - Multiple myeloma and malignant plasma cell neoplasms

C90.00 - Multiple myeloma not having achieved remission

C90.02 - Multiple myeloma in relapse

C90.1 - Plasma cell leukemia

C90.10 - Plasma cell leukemia not having achieved remission

C90.12 - Plasma cell leukemia in relapse

C90.21 - Extramedullary plasmacytoma in remission

C90.22 - Extramedullary plasmacytoma in relapse

C90.31 - Solitary plasmacytoma in remission

C90.32 - Solitary plasmacytoma in relapse

C91 - Lymphoid leukemia

C91.01 - Acute lymphoblastic leukemia, in remission

C91.02 - Acute lymphoblastic leukemia, in relapse

C91.1 - Chronic lymphocytic leukemia of B-cell type

C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission

C91.12 - Chronic lymphocytic leukemia of B-cell type in relapse

C91.30 - Prolymphocytic leukemia of B-cell type not having achieved remission

C91.32 - Prolymphocytic leukemia of B-cell type, in relapse

Appendix A

C91.42 - Hairy cell leukemia, in relapse

C91.51 - Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission

C91.52 - Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse

C91.62 - Prolymphocytic leukemia of T-cell type, in relapse

C91.9 - Lymphoid leukemia, unspecified

C91.90 - Lymphoid leukemia, unspecified not having achieved remission

C91.92 - Lymphoid leukemia, unspecified, in relapse

C91.A - Mature B-cell leukemia Burkitt-type

C91.A0 - Mature B-cell leukemia Burkitt-type not having achieved remission

C91.A2 - Mature B-cell leukemia Burkitt-type, in relapse

C91.Z0 - Other lymphoid leukemia not having achieved remission

C91.Z1 - Other lymphoid leukemia, in remission

C92 - Myeloid leukemia

C92.0 - Acute myeloblastic leukemia

C92.10 - Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission

C92.12 - Chronic myeloid leukemia, BCR/ABL-positive, in relapse

C92.2 - Atypical chronic myeloid leukemia, BCR/ABL-negative

C92.20 - Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission

C92.22 - Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse

C92.31 - Myeloid sarcoma, in remission

C92.32 - Myeloid sarcoma, in relapse

C92.40 - Acute promyelocytic leukemia, not having achieved remission

Appendix A

C92.5 - Acute myelomonocytic leukemia

C92.50 - Acute myelomonocytic leukemia, not having achieved remission

C92.51 - Acute myelomonocytic leukemia, in remission

C92.52 - Acute myelomonocytic leukemia, in relapse

C92.6 - Acute myeloid leukemia with 11q23-abnormality

C92.62 - Acute myeloid leukemia with 11q23-abnormality in relapse

C92.92 - Myeloid leukemia, unspecified in relapse

C92.A - Acute myeloid leukemia with multilineage dysplasia

C92.Z1 - Other myeloid leukemia, in remission

C92.Z2 - Other myeloid leukemia, in relapse

C93 - Monocytic leukemia

C93.00 - Acute monoblastic/monocytic leukemia, not having achieved remission

C93.02 - Acute monoblastic/monocytic leukemia, in relapse

C93.10 - Chronic myelomonocytic leukemia not having achieved remission

C93.11 - Chronic myelomonocytic leukemia, in remission

C93.9 - Monocytic leukemia, unspecified

C93.91 - Monocytic leukemia, unspecified in remission

C93.Z0 - Other monocytic leukemia, not having achieved remission

C93.Z2 - Other monocytic leukemia, in relapse

C94 - Other leukemias of specified cell type

C94.00 - Acute erythroid leukemia, not having achieved remission

C94.01 - Acute erythroid leukemia, in remission

C94.02 - Acute erythroid leukemia, in relapse

Appendix A

C94.2 - Acute megakaryoblastic leukemia

C94.30 - Mast cell leukemia not having achieved remission

C94.31 - Mast cell leukemia, in remission

C94.32 - Mast cell leukemia, in relapse

C94.41 - Acute panmyelosis with myelofibrosis, in remission

C94.8 - Other specified leukemias

C94.80 - Other specified leukemias not having achieved remission

C94.81 - Other specified leukemias, in remission

C94.82 - Other specified leukemias, in relapse

C95.00 - Acute leukemia of unspecified cell type not having achieved remission

C95.01 - Acute leukemia of unspecified cell type, in remission

C95.02 - Acute leukemia of unspecified cell type, in relapse

C95.10 - Chronic leukemia of unspecified cell type not having achieved remission

C95.11 - Chronic leukemia of unspecified cell type, in remission

C95.12 - Chronic leukemia of unspecified cell type, in relapse

C95.9 - Leukemia, unspecified

C95.91 - Leukemia, unspecified, in remission

C96.0 - Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis

C96.2 - Malignant mast cell neoplasm

C96.29 - Other malignant mast cell neoplasm

C96.4 - Sarcoma of dendritic cells (accessory cells)

C96.5 - Multifocal and unisystemic Langerhans-cell histiocytosis

C96.6 - Unifocal Langerhans-cell histiocytosis

Appendix A

C96.9 - Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified

C96.A - Histiocytic sarcoma

C96.Z - Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue

Appendix A

Dialysis Codes

Codes include:

- ICD9 prox codes:

39.95, Hemodialysis

54.98, Peritoneal dialysis

- ICD9 dx codes:

585.5x, Chronic kidney disease, Stage V (for ESRD with no mention of dialysis)

585.6x, End stage renal disease (for ESRD with dialysis)

V56.0x, encounter for dialysis NOS

V56.8x, encounter for peritoneal dialysis

V45.1x, renal dialysis status

- CPT4 codes:

90957, 90960, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 4 or more face-to-face physician visits per month

90958, 90961, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 2-3 face-to-face physician visits per

90959, 90962, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 1 face-to-face physician visit per month

90920, 90921, ESRD related services per full month; for patients 12-19 and twenty years of age and over

90924, 90925, ESRD related services (less than full month), per day; for patients 12-19 and twenty years of age and over

90935, Hemodialysis procedure with single physician evaluation

90937, Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription

90945, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single physician evaluation

90947, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated physician evaluations, with or without substantial revision of dialysis prescription

90965, 90966, ESRD related services for home dialysis per full month, for patients 12-19 and 20 years of age and older

90969, 90970, ESRD related services for dialysis less than a full month of service, per day; for patients 12-19 and 20 years of age and older

90989, Dialysis training, patient, including helper where applicable, any mode, completed course

90993, Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session

90999, Unlisted dialysis procedure, inpatient or outpatient

99512, Home visit for hemodialysis

- HCPCS codes:

G0257, Unscheduled or emergency dialysis treatment for ESRD patient in a hospital outpatient dept. that is not certified as an ESRD facility

Appendix A

G0314, G0317, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/4 or more physician visit per month

G0315, G0318, ESRD related services during the course of treatment, for patients 12-19 and 20yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/2 or 3 physician visit per month

G0316, G0319, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/1 physician visit per month

G0322, G0323, ESRD related services for home dialysis patients per full month: for patients 12-19 and 20 yrs of age and over to include monitoring for adequacy of nutrition and etc.

G0326, G0327, ESRD related services for home dialysis (less than full month), per day; for patients 12-19 and 20 yrs of age and over

S9335, Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately), per diem

S9339, Home therapy, peritoneal dialysis, administrative services, care coordination and all necessary supplies and equipment, per diem

OR

Kidney transplant, defined as either 1 inpatient or 1 outpatient code

Codes include:

-ICD9 dx codes:

V42.0x, Kidney transplant status

996.81 Complications of transplanted kidney

-ICD9 prox codes:

55.6x, Transplant of kidney (Exclude 55.61)

- CPT4 codes:

50360, Renal allotransplantation, implantation, graft, w/o donor & recipient nephrectomy

50365, Renal allotransplantation, implantation, graft, w/ donor & recipient nephrectomy

Appendix A

Liver Bypass ICD-10 Procedure Codes

06100Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Open Approach
0610496 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06104K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06104Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Percutaneous Endoscopic Approach
06104ZY - Bypass Inferior Vena Cava to Lower Vein, Percutaneous Endoscopic Approach
061107B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach
0611099 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach
06110AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06110J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Open Approach
0611479 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061147Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06114J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06120ZY - Bypass Gastric Vein to Lower Vein, Open Approach
06140AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
061507Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061509Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061549Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06154AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061647Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061709Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061807Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061809B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach
061809Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Open Approach
06180J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Open Approach
06180Z9 - Bypass Portal Vein to Right Renal Vein, Open Approach
0618479 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061849B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06184AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06184JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06184ZB - Bypass Portal Vein to Left Renal Vein, Percutaneous Endoscopic Approach
06190ZY - Bypass Right Renal Vein to Lower Vein, Open Approach
061947Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061949Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061B0ZY - Bypass Left Renal Vein to Lower Vein, Open Approach
061B4AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061B4KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
061J09Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061J0KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06L30ZZ - Occlusion of Esophageal Vein, Open Approach
061007Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Open Approach
06100A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Open Approach
06100J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Open Approach
06100K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach
06110JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Open Approach
06110KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach
06114JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
061207Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061407Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061409Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Open Approach

Appendix A

061449Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06144AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06150KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06154ZY - Bypass Superior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach
061607Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06160ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Open Approach
06164AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061749Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06174AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06174KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
0618099 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach
06180K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach
06184J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06184JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06184Z9 - Bypass Portal Vein to Right Renal Vein, Percutaneous Endoscopic Approach
061909Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061J4JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06L34CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Endoscopic Approach
0610075 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Open Approach
06100A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Open Approach
06100K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach
06100KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06100ZY - Bypass Inferior Vena Cava to Lower Vein, Open Approach
061049Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06104A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06104A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06104JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06104Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Percutaneous Endoscopic Approach
061107Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06110KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06110ZB - Bypass Splenic Vein to Left Renal Vein, Open Approach
061149Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06114A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06114AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06114AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06114ZB - Bypass Splenic Vein to Left Renal Vein, Percutaneous Endoscopic Approach
06140KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06140ZY - Bypass Hepatic Vein to Lower Vein, Open Approach
06144ZY - Bypass Hepatic Vein to Lower Vein, Percutaneous Endoscopic Approach
06150AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06150ZY - Bypass Superior Mesenteric Vein to Lower Vein, Open Approach
061609Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061649Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06164JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06164KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06164ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach
06170KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061807B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach
06180JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Open Approach
06180KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach

Appendix A

06180ZY - Bypass Portal Vein to Lower Vein, Open Approach
061847Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06184DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Endoscopic Approach
06184KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06190AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06194JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
061B07Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061B0AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
061B4ZY - Bypass Left Renal Vein to Lower Vein, Percutaneous Endoscopic Approach
061J07Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061J4ZY - Bypass Left Hypogastric Vein to Lower Vein, Percutaneous Endoscopic Approach
06L33DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Approach
06L34DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Endoscopic Approach
0610096 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Open Approach
061009Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Open Approach
06100Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Open Approach
0610476 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06104AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06104J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06104J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06104KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06110JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Open Approach
06110K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach
06110ZY - Bypass Splenic Vein to Lower Vein, Open Approach
0611499 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06114JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06114K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06114KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06114KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06114Z9 - Bypass Splenic Vein to Right Renal Vein, Percutaneous Endoscopic Approach
06114ZY - Bypass Splenic Vein to Lower Vein, Percutaneous Endoscopic Approach
06120KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061247Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061249Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06124AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06150JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach
06154JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06160KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061747Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06174ZY - Bypass Colic Vein to Lower Vein, Percutaneous Endoscopic Approach
0618079 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach
06180AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06180JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Open Approach
06180KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach
06180ZB - Bypass Portal Vein to Left Renal Vein, Open Approach
06183DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Approach
061847B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
0618499 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06184AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06184K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach

Appendix A

06184ZY - Bypass Portal Vein to Lower Vein, Percutaneous Endoscopic Approach
061907Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06194ZY - Bypass Right Renal Vein to Lower Vein, Percutaneous Endoscopic Approach
061B0JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Open Approach
061B0KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061B47Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061B4JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
061J0AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
061J0ZY - Bypass Left Hypogastric Vein to Lower Vein, Open Approach
061J47Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06L30CZ - Occlusion of Esophageal Vein with Extraluminal Device, Open Approach
06L30DZ - Occlusion of Esophageal Vein with Intraluminal Device, Open Approach
06L33CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Approach
06L33ZZ - Occlusion of Esophageal Vein, Percutaneous Approach
0610076 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Open Approach
0610095 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Open Approach
06100AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Open Approach
06100J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Open Approach
06100JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Open Approach
0610475 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061047Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
0610495 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06104K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
0611079 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach
061109B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach
061109Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Open Approach
06110A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach
06110AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach
06110Z9 - Bypass Splenic Vein to Right Renal Vein, Open Approach
061147B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061149B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061209Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
06120AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06120JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Open Approach
06124JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06124KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06124ZY - Bypass Gastric Vein to Lower Vein, Percutaneous Endoscopic Approach
06140JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Open Approach
061447Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06144JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06144KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
061547Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06154KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06160AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06160JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach
061707Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06170AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06170JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Open Approach
06170ZY - Bypass Colic Vein to Lower Vein, Open Approach
06174JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach

Appendix A

06180A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach
06180AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach
061849Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06184A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06184KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06190JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Open Approach
06190KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06194AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06194KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
061B09Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061B49Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061J0JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Open Approach
061J49Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061J4AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061J4KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06L34ZZ - Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach

Appendix A

Procedure Codes Description	
CPT-4 codes	
1960	Anesthesia for vaginal delivery only
1961	Anesthesia for cesarean delivery only
1962	Anesthesia for urgent hysterectomy following delivery
1963	Anesthesia for cesarean hysterectomy w/o any labor analgesia/anesthesia care
1967	Neuraxial labor analgesia/anesthesia, planned vaginal delivery
1968	Anesthesia for cesarean delivery following neuraxial labor analgesia/anesthesia
1969	Anes for cesarean hysterectomy following neuraxial labor analgesia/anesthesia
59050	Fetal monitoring in labor, physician w/written report; s & i
59051	Fetal monitoring in labor, physician w/written report; interpretation only
59400	ROUTINE TOTAL OBSTETRIC CARE including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care.
59409	Vaginal delivery only (w/wo episiotomy &/or forceps)
59410	Vaginal delivery only (w/wo episiotomy &/or forceps); w/postpartum care
59412	Ext cephalic version, w/wo tocolysis
59414	Delivery of placenta (separate proc)
59430	Postpartum care only
59510	Routine obstetric care w/antepartum care, cesarean delivery, & postpartum care
59514	Cesarean delivery only
59515	Cesarean delivery only; w/postpartum care
59525	Subtotal/total hysterectomy after cesarean delivery
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps)
59614	Vaginal delivery only, previous cesarean delivery w/postpartum care
59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery
59620	Cesarean delivery after failed vaginal delivery, previous cesarean delivery
59622	Cesarean delivery after failed vaginal delivery, previous cesarean delivery; w/postpartum care
99436	Attendance at delivery, at request of delivering physician, & stabilization of newborn
99440	Newborn resuscitation
ICD-9 procedure codes	
72.xx	Forceps, vacuum, & breech
73.xx	Other including manual delivery
74xx	Cesarean section
75.4x	Manual removal of placenta
ICD-10 procedure codes	
Normal Delivery	
10E0XZZ	Delivery of Products of Conception, External Approach
C-Section	
10D00Z0	Extraction of Products of Conception, High, Open Approach
10D00Z1	Extraction of Products of Conception, Low, Open Approach
10D00Z2	Extraction of Products of Conception, Extraperitoneal, Open Approach
Other assisted delivery (forceps, vacuum, internal version, other)	
10D07Z3	Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening
10D07Z4	Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening
10D07Z5	Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening
10D07Z6	Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening
10D07Z7	Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening
10D07Z8	Extraction of Products of Conception, Other, Via Natural or Artificial Opening
ICD-9 code	Definition Gestational Age

Appendix A

	Weeks	Days
765.21	Less than 24 c 24	168
765.22	24 completed weeks of gestation	
765.23	25-26 comple 26	182
765.24	27-28 comple 28	196
765.25	29-30 comple 30	210
765.26	31-32 comple 32	224
765.27	33-34 comple 34	238
765.28	35-36 comple 36	252

ICD-10 code	Definition	Gestational Age	
		Weeks	Days
P07.21	Extreme imm: 23	23	161
P07.22	Extreme imm: 23	23	161
P07.23	Extreme imm: 24	24	168
P07.24	Extreme imm: 25	25	175
P07.25	Extreme imm: 26	26	182
P07.26	Extreme imm: 27	27	189
P07.31	Preterm newt 28	28	196
P07.32	Preterm newt 29	29	203
P07.33	Preterm newt 30	30	210
P07.34	Preterm newt 31	31	217
P07.35	Preterm newt 32	32	224
P07.36	Preterm newt 33	33	231
P07.37	Preterm newt 34	34	238
P07.38	Preterm newt 35	35	245
P07.39	Preterm newt 36	36	252

Codes indicating extreme prematurity

ICD-9 code	Definition	Gestational Age	
		Weeks	Days
765.0	Disorders rela 28	28	196
765.00	Extreme immaturity, unspecified [weight]		
765.01	Extreme immaturity, less than 500 grams		
765.02	Extreme immaturity, 500-749 grams		
765.03	Extreme immaturity, 750-999 grams		
765.04	Extreme immaturity, 1,000-1,249 grams		
765.05	Extreme immaturity, 1,250-1,499 grams		
765.06	Extreme immaturity, 1,500-1,749 grams		
765.07	Extreme immaturity, 1,750-1,999 grams		
765.08	Extreme immaturity, 2,000-2,499 grams		

ICD-10 code	Definition	Gestational Age	
		Weeks	Days
P07.2	Extreme imm: 28	28	196
P07.20	Extreme immaturity of newborn, unspecified weeks of gestation		
O42.012	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, second trimester		

Other preterm codes

ICD-9 code	Definition	Gestational Age	
		Weeks	Days
765.1	Disorders rela 35	35	245
765.10	Other preterm infants, unspecified [weight]		
765.11	Other preterm infants, less than 500 grams		

Appendix A

765.12	Other preterm infants, 500-749 grams
765.13	Other preterm infants, 750-999 grams
765.14	Other preterm infants, 1,000-1,249 grams
765.15	Other preterm infants, 1,250-1,499 grams
765.16	Other preterm infants, 1,500-1,749 grams
765.17	Other preterm infants, 1,750-1,999 grams
765.18	Other preterm infants, 2,000-2,499 grams
644.21	Onset of delivery before 37 completed weeks of gestation

ICD-10 code	Definition	Gestational Age	
		Weeks	Days
P05.01	Disorders of n 35		245
P05.02	Disorders of newborn related to slow fetal growth and fetal malnutrition, 500-749 grams		
P05.03	Disorders of newborn related to slow fetal growth and fetal malnutrition, 750-999 grams		
P05.04	Disorders of newborn related to slow fetal growth and fetal malnutrition, 1000-1249 grams		
P05.05	Disorders of newborn related to slow fetal growth and fetal malnutrition, 1250-1499 grams		
P05.06	Disorders of newborn related to slow fetal growth and fetal malnutrition, 1500-1749 grams		
P05.07	Disorders of newborn related to slow fetal growth and fetal malnutrition, 1750-1999 grams		
P05.11	Newborn small for gestational age, less than 500 grams		
P05.12	Newborn small for gestational age, 500-749 grams		
P05.13	Newborn small for gestational age, 750-999 grams		
P05.14	Newborn small for gestational age, 1000-1249 grams		
P05.15	Newborn small for gestational age, 1250-1499 grams		
P05.16	Newborn small for gestational age, 1500-1749 grams		
P05.17	Newborn small for gestational age, 1750-1999 grams		
P07.0	Extremely low birth weight newborn		
P07.00	Extremely low birth weight newborn, unspecified weight		
P07.01	Extremely low birth weight newborn, less than 500 grams		
P07.02	Extremely low birth weight newborn, 500-749 grams		
P07.03	Extremely low birth weight newborn, 750-999 grams		
P07.1	Other low birth weight newborn		
P07.10	Other low birth weight newborn, unspecified weight		
P07.14	Other low birth weight newborn, 1000-1249 grams		
P07.15	Other low birth weight newborn, 1250-1499 grams		
P07.16	Other low birth weight newborn, 1500-1749 grams		
P07.17	Other low birth weight newborn, 1750-1999 grams		
P07.3	Preterm [premature] newborn [other]		
P07.30	Preterm newborn, unspecified weeks of gestation		
O60.1	Preterm labor with preterm delivery		
O42.01	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture		
O42.019	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, unspecified trimester		
O42.013	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester		
644.2	early onset of delivery		
644.20	Early onset of delivery, unspecified as to episode of care or not applicable		
644.21	Early onset of delivery, delivered, with or without mention of antepartum condition		
776.6	anemia of prematurity		
362.20	retinopathy of prematurity, unspecified		
362.22	retinopathy of prematurity, stage 0		
362.23	retinopathy of prematurity, stage 1		
362.24	retinopathy of prematurity, stage 2		
362.25	retinopathy of prematurity, stage 3		
362.26	retinopathy of prematurity, stage 4		
362.27	retinopathy of prematurity, stage 5		
CPT			

Appendix A

49491	repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception
49492	repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception
67229	treatment of extensive or progressive retinopathy, 1 or more sessions; preterm infant (less than 37 weeks gestation at birth), performed from
836	anesthesia for hernia repairs in the lower abdomen not otherwise specified, infants younger than 37 weeks gestational age at birth

ICD-10 code Definition

H35.1	Retinopathy of prematurity
P61.2	Anemia of prematurity
V27.2	Twins both liveborn
V27.3	Mother with twins one liveborn and one stillborn
V27.4	Mother with twins both stillborn
V27.5	Other multiple birth, all liveborn
V27.6	Other multiple birth, some liveborn
V31	Twin, mate liveborn
V32	Twin birth mate stillborn
V33	Twin, unspecified
V34	Other multiple, mates all liveborn
V35	Other multiple birth (three or more) mates all stillborn
V36	Other multiple, mates live- and stillborn
V37	Other multiple, unspecified
651	Multiple gestation
651.0x	Twin Pregnancy
651.1x	Triplet pregnancy
651.2x	Quadruplet pregnancy
651.3x	Twin pregnancy with fetal loss and retention of one fetus
651.4x	Triplet pregnancy with fetal loss and retention of one or more fetus(es)
651.5x	Quadruplet pregnancy with fetal loss and retention of one or more fetus(es)
651.6x	Other multiple pregnancy with fetal loss and retention of one or more fetus(es)
651.7x	Multiple gestation following (elective) fetal reduction
651.8x	Other specified multiple gestation
651.9x	Unspecified multiple gestation
652.6x	Multiple gestation with malpresentation of one fetus or more
660.5x	Locked Twins
662.3x	Delayed delivery of second twin, triplet, etc.
761.5x	Multiple pregnancy

ICD10 Code Description

O30xxxx	Multiple gestation
O31xxxx	Complications specific to multiple gestation
O43.02	Fetus-to-fetus placental transfusion syndrome
O63.2	Delayed delivery of second twin, triplet, etc.
Z37.2	Twins, both liveborn
Z37.3	Twins, one liveborn and one stillborn
Z37.5	Other multiple births, all liveborn
Z37.50	Multiple births, unspecified, all liveborn
Z37.51	Triplets, all liveborn
Z37.52	Quadruplets, all liveborn
Z37.53	Quintuplets, all liveborn
Z37.54	Sextuplets, all liveborn
Z37.59	Other multiple births, all liveborn
Z37.6	Other multiple births, some liveborn
Z37.60	Multiple births, unspecified, some liveborn
Z37.61	Triplets, some liveborn

Appendix A

Z37.62	Quadruplets, some liveborn
Z37.63	Quintuplets, some liveborn
Z37.64	Sextuplets, some liveborn
Z37.69	Other multiple births, some liveborn
Z38.3	Twin liveborn infant, born in hospital
Z38.30	Twin liveborn infant, delivered vaginally
Z38.31	Twin liveborn infant, delivered by cesarean
Z38.4	Twin liveborn infant, born outside hospital
Z38.5	Twin liveborn infant, unspecified as to place of birth
Z38.6	Other multiple liveborn infant, born in hospital
Z38.61	Triplet liveborn infant, delivered vaginally
Z38.62	Triplet liveborn infant, delivered by cesarean
Z38.63	Quadruplet liveborn infant, delivered vaginally
Z38.64	Quadruplet liveborn infant, delivered by cesarean
Z38.65	Quintuplet liveborn infant, delivered vaginally
Z38.66	Quintuplet liveborn infant, delivered by cesarean
Z38.68	Other multiple liveborn infant, delivered vaginally
Z38.69	Other multiple liveborn infant, delivered by cesarean
Z38.7	Other multiple liveborn infant, born outside hospital
Z38.8	Other multiple liveborn infant, unspecified as to place of birth
P01.5	Newborn affected by multiple pregnancy

645	Late Pregnancy
645.1	Post term pregnancy
645.10	Post term pregnancy, unspecified as to episode of care or not applicable
645.11	Post term pregnancy, delivered, with or without mention of antepartum condition
645.13	Post term pregnancy, antepartum condition or complication
645.2	Prolonged pregnancy
645.20	Prolonged pregnancy, unspecified as to episode of care or not applicable
645.21	Prolonged pregnancy, delivered, with or without mention of antepartum condition
645.23	Prolonged pregnancy, antepartum condition or complication
766.2	Late infant, not 'heavy-for-dates'
766.21	Post-term infant
766.22	Prolonged gestation of infant

O48	Late pregnancy
O48.0	Post-term pregnancy
O48.1	Prolonged pregnancy
P08.2	Late newborn, not heavy for gestational age
P08.21	Post-term newborn
P08.22	Prolonged gestation of newborn
Z3A.41	41 weeks gestation of pregnancy
Z3A.42	42 weeks gestation of pregnancy
Z3A.49	Greater than 42 weeks gestation of pregnancy

ICD-10 CODES

INDICATING

PREGNANCY

Dx codes:

- O09.XYZ Supervision of high risk pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
- O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
- O11 Pre-existing hypertension with pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
- O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
- O13 Gestational [pregnancy-induced] hypertension without significant proteinuria (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)

Appendix A

O14 Pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
O15 Eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
O16 Unspecified maternal hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
O20 Hemorrhage in early pregnancy
O21 Excessive vomiting in pregnancy (last digit refers to first/second/third/unspecified trimester)
O22 Venous complications and hemorrhoids in pregnancy
O23 Infections of genitourinary tract in pregnancy (last digit refers to first/second/third/unspecified trimester)
O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
O25 Malnutrition in pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
O26 Maternal care for other conditions predominantly related to pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)
O28 Abnormal findings on antenatal screening of mother
O29 Complications of anesthesia during pregnancy (last digit refers to first/second/third/unspecified trimester)
O30 Multiple gestation (last digit refers to first/second/third/unspecified trimester)
O31 Complications specific to multiple gestation (certain digit refers to first/second/third/unspecified trimester)
O32 Maternal care for malpresentation of fetus
O33 Maternal care for disproportion
O34 Maternal care for abnormality of pelvic organs (most codes indicate first/second/third/unspecified trimester)
O35 Maternal care for known or suspected fetal abnormality and damage
O36 Maternal care for other fetal problems (codes indicate first/second/third/unspecified trimester)
O40 Polyhydramnios (codes indicate first/second/third/unspecified trimester)
O41 Other disorders of amniotic fluid and membranes (codes indicate first/second/third/unspecified trimester)
O42.1 Premature rupture of membranes, onset of labor more than 24 hours following rupture
O42.9 Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor
O43 Placental disorders (last digit refers to first/second/third/unspecified trimester)
O44 Placenta previa (last digit refers to first/second/third/unspecified trimester)
O45 Premature separation of placenta (last digit refers to first/second/third/unspecified trimester)
O46 Antepartum hemorrhage, not elsewhere classified (last digit refers to first/second/third/unspecified trimester)
O47 False labor
O60.0 Preterm labor without delivery
O61 Failed induction of labor
O71.0 Rupture of uterus (spontaneous) before onset of labor
O72 Postpartum hemorrhage
O72.2 Delayed and secondary postpartum hemorrhage
O72.3 Postpartum coagulation defects
O73 Retained placenta and membranes, without hemorrhage
O75 Other complications of labor and delivery, not elsewhere classified
O94 Sequelae of complication of pregnancy, childbirth, and the puerperium
O98 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing)
O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing)
O9A Maternal malignant neoplasms, traumatic injuries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing)
Z32.01 Encounter for pregnancy test - result positive
Z33 Pregnant state
Z34 Encounter for supervision of normal pregnancy
Z36 Encounter for antenatal screening of mother
Z39 Encounter for maternal postpartum care and examination
Z39.1 Encounter for care and examination of lactating mother
Z39.2 Encounter for routine postpartum follow-up
Z3A Weeks of gestation

Proc codes:

102 Change
109 Drainage
10H Insertion
10J Inspection
10P Removal
10Q Repair

Appendix A

10S Reposition

10Y Transplantation

ICD-10 CODES INDICATING DELIVERY (diagnostic codes that were not considered in the algorithm to identify deliveries)

Dx codes:

Use the following codes only if the last digit indicates childbirth or puerperium or labor

O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium

O11 Pre-existing hypertension with pre-eclampsia

O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension

O13 Gestational [pregnancy-induced] hypertension without significant proteinuria

O14 Pre-eclampsia

O15 Eclampsia

O16 Unspecified maternal hypertension

O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium

O25 Malnutrition in pregnancy, childbirth and the puerperium

O26 Maternal care for other conditions predominantly related to pregnancy

O42.0 Premature rupture of membranes, onset of labor within 24 hours of rupture, except O42.011 (first trimester)

O48 Late pregnancy

O60.1 Preterm labor with preterm delivery

O60.2 Term delivery with preterm labor

O62 Abnormalities of forces of labor

O63 Long labor

O64 Obstructed labor due to malposition and malpresentation of fetus

O65 Obstructed labor due to maternal pelvic abnormality

O66 Other obstructed labor

O67 Labor and delivery complicated by intrapartum hemorrhage, not elsewhere classified

O68 Labor and delivery complicated by abnormality of fetal acid-base balance

O69 Labor and delivery complicated by umbilical cord complications

O70 Perineal laceration during delivery

O71.1 Rupture of uterus during labor

O71.2 Postpartum inversion of uterus

O71.3 Obstetric laceration of cervix

O71.4 Obstetric high vaginal laceration alone

O72.0 Third-stage hemorrhage

O72.1 Other immediate postpartum hemorrhage

O74 Complications of anesthesia during labor and delivery

O76 Abnormality in fetal heart rate and rhythm complicating labor and delivery

O77 Other fetal stress complicating labor and delivery

O80 Encounter for full-term uncomplicated delivery

O82 Encounter for cesarean delivery without indication

O98 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium)

O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium)

O9A Maternal malignant neoplasms, traumatic injuries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium)

Z37 Outcome of delivery (For livebirth cohort, exclude Z37.1, Z37.4, Z37.7 - all stillbirth codes)

Z38 Liveborn infants according to place of birth and type of delivery

Z39.0 Encounter for care and examination of mother immediately after delivery

ICD-10 CODES INDICATING PREGNANCY WITH ABORTIVE/NON-LIVE BIRTH OUTCOMES

Dx codes:

O00-O08 Pregnancy with abortive outcome

Proc codes:

10A Abortion

10D17Z9 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening

10D17ZZ Extraction of Products of Conception, Retained, Via Natural or Artificial Opening

10D18Z9 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic

10D18ZZ Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic

ICD-10 CODES INDICATING ECTOPIC PREGNANCY

Appendix A

10D27ZZ Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening
10D28ZZ Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening Endoscopic
10S2 Reposition Products of Conception, Ectopic
10T Resection (Ectopic)

Appendix B

Unmatched												
Variable	Optum			MarketScan			Medicare			Pooled		
	Rivaroxaban	Apixaban	St. Diff	Rivaroxaban	Apixaban	St. Diff	Rivaroxaban	Apixaban	St. Diff	Rivaroxaban	Apixaban	St. Diff
Number of patients	4,499			6,339			12,786			23,624		
Age												
...mean [sd]	61.83 (16.97)	69.01 (15.57)	-0.44	53.93 (15.65)	57.11 (15.97)	-0.20	70.91 (13.02)	74.18 (12.37)	-0.26	64.62 (14.57)	68.25 (14.31)	-0.25
...median [IQR]	64.00 [51.00, 75.00]	61.00 [48.00, 81.00]	-0.49	55.00 [44.00, 63.00]	57.00 [47.00, 66.00]	-0.13	72.00 [66.00, 80.00]	75.00 [68.00, 83.00]	-0.24	65.91 (14.57)	69.43 (14.31)	-0.24
Age categories												
...18 - 54; n (%)	1,386 (30.8%)	883 (17.4%)	0.32	3,104 (49.0%)	1,981 (41.4%)	0.15	1,412 (11.0%)	592 (7.1%)	0.14	5,902 (25.0%)	3,456 (19.0%)	0.15
...55 - 64; n (%)	865 (19.2%)	676 (13.3%)	0.16	1,888 (29.8%)	1,536 (32.1%)	-0.05	1,202 (9.4%)	619 (7.4%)	0.07	3,955 (16.7%)	2,831 (15.6%)	0.03
...65 - 74; n (%)	1,095 (24.3%)	1,341 (26.4%)	-0.05	723 (11.4%)	552 (11.5%)	0.00	4,839 (37.8%)	2,798 (33.6%)	0.09	6,657 (28.2%)	4,691 (25.8%)	0.05
...≥ 75; n (%)	1,153 (25.6%)	2,187 (43.0%)	-0.37	624 (9.8%)	712 (14.9%)	-0.16	5,333 (41.7%)	4,320 (51.9%)	-0.21	7,110 (30.1%)	7,219 (39.7%)	-0.20
Calendar Year (2014-2020)												
...2014; n (%)	295 (6.6%)	23 (0.5%)	0.33	837 (13.2%)	69 (1.4%)	0.47	1,392 (10.9%)	175 (2.1%)	0.36	2,524 (10.7%)	267 (1.5%)	0.39
...2015; n (%)	761 (16.9%)	193 (3.8%)	0.44	1,592 (25.1%)	465 (9.7%)	0.41	3,619 (28.3%)	1,581 (19.0%)	0.22	5,972 (25.3%)	2,239 (12.3%)	0.34
...2016; n (%)	834 (18.5%)	513 (10.1%)	0.24	1,424 (22.5%)	893 (18.7%)	0.09	3,778 (29.5%)	3,246 (39.0%)	-0.20	6,036 (25.6%)	4,652 (25.6%)	0.00
...2017; n (%)	793 (17.6%)	774 (15.2%)	0.06	1,032 (16.3%)	1,069 (22.4%)	-0.15	3,997 (31.3%)	3,327 (39.9%)	-0.18	5,822 (24.6%)	5,170 (28.4%)	-0.09
...2018; n (%)	869 (19.3%)	1,276 (25.1%)	-0.14	823 (13.0%)	1,079 (22.6%)	-0.25	0 (0.0%)	0 (0.0%)	0.00	1,692 (7.2%)	2,355 (12.9%)	-0.19
...2019; n (%)	727 (16.2%)	1,514 (29.8%)	-0.33	631 (10.0%)	1,206 (25.2%)	-0.41	0 (0.0%)	0 (0.0%)	0.00	1,358 (5.7%)	2,720 (14.9%)	-0.31
...2020; n (%)	220 (4.9%)	794 (15.6%)	-0.36	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	220 (0.9%)	794 (4.4%)	-0.22
Race												
...White; n (%)	3,257 (72.4%)	3,455 (67.9%)	0.10	0 (0.0%)	0 (0.0%)	0.00	10,471 (81.9%)	6,881 (82.6%)	-0.02	13,728 (58.1%)	10,336 (56.8%)	0.03
...Asian; n (%)	79 (1.8%)	73 (1.4%)	0.03	0 (0.0%)	0 (0.0%)	0.00	100 (0.8%)	76 (0.9%)	-0.01	179 (0.8%)	149 (0.8%)	0.00
...Black; n (%)	635 (14.1%)	822 (16.2%)	-0.06	0 (0.0%)	0 (0.0%)	0.00	1,661 (13.0%)	1,086 (13.0%)	0.00	2,296 (9.7%)	1,908 (10.5%)	-0.03
...Hispanic; n (%)	336 (7.5%)	453 (8.9%)	-0.05	0 (0.0%)	0 (0.0%)	0.00	234 (1.8%)	123 (1.5%)	0.02	570 (2.4%)	576 (3.2%)	-0.05
...North American Native; n (%)	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	68 (0.5%)	22 (0.3%)	0.03	68 (0.3%)	22 (0.1%)	0.04
...Other; n (%)	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	101 (0.8%)	63 (0.8%)	0.00	101 (0.4%)	63 (0.3%)	0.02
...Unknown/Missing; n (%)	192 (4.3%)	284 (5.6%)	-0.06	0 (0.0%)	0 (0.0%)	0.00	151 (1.2%)	78 (0.9%)	0.03	343 (1.5%)	362 (2.0%)	-0.04
Gender												
...Males; n (%)	2,247 (49.9%)	2,172 (42.7%)	0.14	3,418 (53.9%)	2,483 (51.9%)	0.04	5,549 (43.4%)	3,205 (38.5%)	0.10	11,214 (47.5%)	7,861 (43.2%)	0.09
...Females; n (%)	2,252 (50.1%)	2,915 (57.3%)	-0.14	2,921 (46.1%)	2,298 (48.1%)	-0.04	7,237 (56.6%)	5,123 (61.5%)	-0.10	12,410 (52.5%)	10,336 (56.8%)	-0.09
Region												
...Northeast; n (%)	528 (11.7%)	544 (10.7%)	0.03	1,311 (20.7%)	962 (20.1%)	0.01	2,384 (18.6%)	1,613 (19.4%)	-0.02	4,223 (17.9%)	3,119 (17.1%)	0.02
...South; n (%)	1,870 (41.6%)	2,524 (49.6%)	-0.16	1,599 (40.2%)	2,236 (46.8%)	-0.13	5,001 (39.1%)	3,826 (45.9%)	-0.14	9,420 (39.9%)	8,586 (47.2%)	-0.15
...Midwest; n (%)	1,082 (24.0%)	996 (19.6%)	0.11	1,625 (25.6%)	1,028 (21.5%)	0.10	3,191 (25.0%)	1,720 (20.7%)	0.10	5,898 (25.0%)	3,744 (20.6%)	0.11
...West; n (%)	1,004 (22.3%)	1,016 (20.0%)	0.06	823 (13.0%)	544 (11.4%)	0.05	2,200 (17.2%)	1,162 (14.0%)	0.09	4,029 (17.1%)	2,722 (15.0%)	0.06
...Unknown+missing; n (%)	15 (0.3%)	7 (0.1%)	0.04	29 (0.5%)	11 (0.2%)	0.05	--	--	--	--	--	--
Combined comorbidity score, 180 days Cop												
...mean [sd]	2.62 (2.34)	3.65 (2.64)	-0.41	1.61 (1.72)	2.19 (1.89)	-0.32	2.17 (2.08)	2.74 (2.27)	-0.26	2.11 (2.04)	2.85 (2.29)	-0.34
...median [IQR]	2.00 [1.00, 4.00]	3.00 [2.00, 5.00]	-0.40	1.00 [0.00, 3.00]	2.00 [1.00, 3.00]	-0.32	2.00 [1.00, 3.00]	2.00 [1.00, 4.00]	-0.20	1.73 (2.04)	2.28 (2.29)	-0.25
Lifestyle Factors												
Lifestyle - Smoking; n (%)	1,587 (35.3%)	1,929 (37.9%)	-0.05	1,226 (19.3%)	925 (19.3%)	0.00	5,433 (42.5%)	3,322 (39.9%)	0.05	8,246 (34.9%)	6,176 (33.9%)	0.02
Lifestyle - Drug abuse or dependence; n (%)	220 (4.9%)	274 (5.4%)	-0.02	180 (2.8%)	135 (2.8%)	0.00	605 (4.7%)	300 (3.6%)	0.06	1,005 (4.3%)	709 (3.9%)	0.02
Lifestyle - Alcohol abuse or dependence; n (%)	190 (4.2%)	193 (3.8%)	0.02	166 (2.6%)	127 (2.7%)	-0.01	465 (3.6%)	241 (2.9%)	0.04	821 (3.5%)	561 (3.1%)	0.02
Comorbidities												
DM - Diabetic Retinopathy; n (%)	42 (0.9%)	83 (1.6%)	-0.06	33 (0.5%)	32 (0.7%)	-0.03	112 (0.9%)	89 (1.1%)	-0.02	187 (0.8%)	204 (1.1%)	-0.03
DM - Diabetic Neuropathy; n (%)	211 (4.7%)	361 (7.1%)	-0.10	156 (2.5%)	163 (3.4%)	-0.05	589 (4.6%)	440 (5.3%)	-0.03	956 (4.0%)	964 (5.3%)	-0.06
DM - Diabetic Nephropathy; n (%)	144 (3.2%)	381 (7.5%)	-0.19	80 (1.3%)	105 (2.2%)	-0.07	299 (2.3%)	364 (4.4%)	-0.12	523 (2.2%)	850 (4.7%)	-0.14
DM - Diabetes with peripheral circulatory disorders; n (%)	9 (0.2%)	11 (0.2%)	0.00	20 (0.3%)	7 (0.1%)	0.04	64 (0.5%)	27 (0.3%)	0.03	93 (0.4%)	45 (0.2%)	0.04
DM - Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%)	46 (1.0%)	61 (1.2%)	-0.02	34 (0.5%)	20 (0.4%)	0.01	199 (1.6%)	107 (1.3%)	0.03	279 (1.2%)	188 (1.0%)	0.02
DM - Diabetes with unspecified complications; n (%)	58 (1.3%)	146 (2.9%)	-0.11	879 (13.9%)	768 (16.1%)	-0.06	174 (1.4%)	124 (1.5%)	-0.01	1,111 (4.7%)	1,038 (5.7%)	-0.05
DM - Diabetes mellitus without mention of complications; n (%)	780 (17.3%)	1,249 (24.6%)	-0.18	68 (1.1%)	75 (1.6%)	-0.04	2,920 (22.8%)	1,979 (23.8%)	-0.02	3,768 (15.9%)	3,303 (18.2%)	-0.06
CV - Hypertension; n (%)	2,622 (58.3%)	3,588 (70.5%)	-0.26	2,922 (46.1%)	2,632 (55.1%)	-0.18	9,714 (76.0%)	6,715 (80.6%)	-0.11	15,258 (64.6%)	12,935 (71.1%)	-0.14
CV - Hyperlipidemia; n (%)	1,932 (42.9%)	2,645 (52.0%)	-0.18	2,051 (32.4%)	1,737 (36.3%)	-0.08	6,823 (53.4%)	4,603 (55.3%)	-0.04	10,806 (45.7%)	8,985 (49.4%)	-0.07
CV - Acute MI; n (%)	207 (4.6%)	313 (6.2%)	-0.07	226 (3.6%)	215 (4.5%)	-0.05	507 (4.0%)	466 (5.6%)	-0.07	940 (4.0%)	994 (5.5%)	-0.07
CV - ACS/unstable angina; n (%)	130 (2.9%)	232 (4.6%)	-0.09	147 (2.3%)	151 (3.2%)	-0.06	442 (3.5%)	308 (3.7%)	-0.01	719 (3.0%)	691 (3.8%)	-0.04
CV - Old MI; n (%)	158 (3.5%)	258 (5.1%)	-0.08	104 (1.6%)	92 (1.9%)	-0.02	602 (4.7%)	454 (5.5%)	-0.04	864 (3.7%)	804 (4.4%)	-0.04
CV - Stable angina; n (%)	96 (2.1%)	165 (3.2%)	-0.07	107 (1.7%)	109 (2.3%)	-0.02	277 (2.2%)	240 (2.9%)	-0.04	480 (2.0%)	514 (2.8%)	-0.05
CV - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	603 (13.4%)	976 (19.2%)	-0.16	539 (8.5%)	482 (10.1%)	-0.06	2,387 (18.7%)	1,832 (22.0%)	-0.08	3,529 (14.9%)	3,290 (18.1%)	-0.09
CV - Other atherosclerosis; n (%)	41 (0.9%)	58 (1.1%)	-0.02	26 (0.4%)	21 (0.4%)	0.00	128 (1.0%)	74 (0.9%)	0.01	195 (0.8%)	153 (0.8%)	0.00
CV - Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%)	184 (4.1%)	304 (6.0%)	-0.09	99 (1.6%)	64 (1.3%)	0.03	888 (6.9%)	663 (8.0%)	-0.04	1,171 (5.0%)	1,031 (5.7%)	-0.03
CV - Ischemic stroke; n (%)	239 (5.3%)	446 (8.8%)	-0.14	230 (3.6%)	227 (4.7%)	-0.06	830 (6.5%)	685 (8.2%)	-0.07	1,299 (5.5%)	1,358 (7.5%)	-0.08
CV - Hemorrhagic stroke; n (%)	8 (0.2%)	20 (0.4%)	-0.04	5 (0.1%)	2 (0.0%)	0.04	21 (0.2%)	16 (0.2%)	0.00	34 (0.1%)	38 (0.2%)	-0.03
CV - TIA; n (%)	72 (1.6%)	118 (2.3%)	-0.05	69 (1.1%)	77 (1.6%)	-0.04	216 (1.7%)	176 (2.1%)	-0.03	357 (1.5%)	371 (2.0%)	-0.04
CV - Other cerebrovascular disease; n (%)	122 (2.7%)	246 (4.8%)	-0.11	93 (1.5%)	124 (2.6%)	-0.08	365 (2.9%)	302 (3.6%)	-0.04	580 (2.5%)	672 (3.7%)	-0.07
CV - Late effects of cerebrovascular disease; n (%)	94 (2.1%)	203 (4.0%)	-0.11	67 (1.1%)	59 (1.2%)	-0.01	375 (2.9%)	273 (3.3%)	-0.02	536 (2.3%)	535 (2.9%)	-0.04
CV - Heart failure (CHF); n (%)	538 (12.0%)	974 (19.1%)	0.00	462 (7.3%)	511 (10.7%)	-0.12	1,842 (14.4%)	1,573 (18.9%)	-0.12	2,842 (12.0%)	3,058 (16.8%)	-0.14
CV - Peripheral Vascular Disease (PVD) or PVD Surgery; n (%)	371 (8.2%)	525 (10.3%)	-0.07	301 (4.7%)	247 (5.2%)	-0.02	1,056 (8.3%)	803 (9.6%)	-0.05	1,728 (7.3%)	1,575 (8.7%)	-0.05
CV - Other cardiac dysrhythmia; n (%)	651 (14.5%)	904 (17.8%)	-0.09	773 (12.2%)	653 (13.7%)	-0.04	1,963 (15.4%)	1,347 (16.2%)	-0.02	3,387 (14.3%)	2,904 (16.0%)	-0.05
CV - Cardiac conduction disorders; n (%)	330 (7.3%)	538 (10.6%)	-0.12	311 (4.9%)	266 (5.6%)	-0.03	1,008 (7.9%)	777 (9.9%)	-0.05	1,649 (7.0%)	1,581 (8.7%)	-0.06
CV - Other CVD; n (%)	1,268 (28.2%)	1,764 (34.7%)	-0.14	1,420 (22.4%)	1,311 (27.4%)	-0.12	3,183 (24.9%)	2,346 (28.2%)	-0.07	5,871 (24.9%)	5,421 (28.8%)	-0.11
CV Medications - ACE inhibitors; n (%)	199 (20.4%)	1,236 (24.3%)	-0.09	1,077 (17.0%)	937 (19.6%)	-0.07	3,436 (26.9%)	2,317 (27.8%)	-0.02	5,432 (23.0%)	4,490 (24.7%)	-0.04
CV Medications - ARBs; n (%)	601 (13.4%)	882 (17.3%)	-0.11	720 (11.4%)	659 (13.8%)	-0.07	2,108 (16.5%)	1,547 (18.6%)	-0.06	3,429 (14.5%)	3,088 (17.0%)	-0.07
CV Medications - Alpha blockers; n (%)	319 (7.1%)	480 (9.4%)	-0.08	333 (5.3%)	299 (6.3%)	-0.04	1,308 (10.2%)	845 (10.1%)	0.00	1,960 (8.3%)	1,624 (8.9%)	-0.02
CV Medications - Beta blockers; n (%)	945 (21.0%)	1,496 (29.4%)	-0.19	1,112 (17.5%)	1,052 (22.0%)	-0.11	3,972 (31.1%)	3,007 (36.1%)	-0.11	6,029 (25.5%)	5,555 (30.5%)	-0.11
CV Medications - Loop Diuretics; n (%)	442 (9.8%)	750 (14.7%)	-0.15	373 (5.9%)	435 (9.1%)	-0.12	1,913 (15.0%)	1,613 (19.4%)	-0.12	2,728 (11.5%)	2,798 (15.4%)	-0.11
CV Medications - Other diuretics; n (%)	99 (2.2%)	159 (3.1%)	-0.06	125								

Appendix B

CV Medications - calcium channel blockers; n (%)	765 (17.0%)	1,232 (24.2%)	-0.18	835 (13.2%)	821 (17.2%)	-0.11	2,960 (23.2%)	2,243 (26.9%)	-0.09	4,560 (19.3%)	4,296 (23.6%)	-0.10
CV Medications - Use of Low Weight Molecular Heparins; n (%)	90 (2.0%)	102 (2.0%)	0.00	162 (2.6%)	97 (2.0%)	0.04	217 (1.7%)	158 (1.9%)	-0.02	469 (2.0%)	357 (2.0%)	0.00
Other Comorbidity - Osteoporosis; n (%)	345 (7.7%)	603 (11.9%)	-0.14	184 (2.9%)	156 (3.3%)	-0.02	1,464 (11.5%)	1,109 (13.3%)	-0.05	1,993 (8.4%)	1,868 (10.3%)	-0.07
Other Comorbidity - Dementia; n (%)	494 (11.0%)	958 (18.8%)	-0.22	223 (3.5%)	255 (5.3%)	-0.09	1,816 (14.2%)	1,646 (19.8%)	-0.15	2,533 (10.7%)	2,859 (15.7%)	-0.15
Other Comorbidity - Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland; n (%)	853 (19.0%)	1,184 (23.3%)	-0.11	863 (13.6%)	770 (16.1%)	-0.07	1,487 (11.6%)	743 (8.9%)	0.09	3,203 (13.6%)	2,697 (14.8%)	-0.03
Other Comorbidity - Edema; n (%)	941 (20.9%)	1,268 (24.9%)	-0.10	986 (15.6%)	810 (16.9%)	-0.04	2,150 (16.8%)	1,563 (18.8%)	-0.05	4,077 (17.3%)	3,641 (20.0%)	-0.07
Other Comorbidity - Depression; n (%)	836 (18.6%)	1,020 (20.1%)	-0.04	816 (12.9%)	635 (13.3%)	-0.01	2,678 (20.9%)	1,758 (21.1%)	0.00	4,330 (18.3%)	3,413 (18.8%)	-0.01
Other Comorbidity - Anxiety; n (%)	908 (20.2%)	1,163 (22.9%)	-0.07	921 (14.5%)	827 (17.3%)	-0.08	2,675 (20.9%)	1,732 (20.8%)	0.00	4,504 (19.1%)	3,722 (20.5%)	-0.04
Other Comorbidity - Pneumonia; n (%)	719 (16.0%)	1,105 (21.7%)	-0.15	833 (13.1%)	729 (15.2%)	-0.06	2,169 (17.0%)	1,538 (18.2%)	-0.03	3,721 (15.8%)	3,352 (18.4%)	-0.07
Other Comorbidity - COPD; n (%)	772 (17.2%)	1,163 (22.9%)	-0.14	585 (9.2%)	496 (10.4%)	-0.04	2,910 (22.8%)	2,061 (24.7%)	-0.04	4,267 (18.1%)	3,720 (20.4%)	-0.06
Other Comorbidity - Asthma; n (%)	479 (10.6%)	557 (10.9%)	-0.01	639 (10.1%)	489 (10.2%)	0.00	1,573 (12.3%)	980 (11.8%)	0.02	2,691 (11.4%)	2,026 (11.1%)	0.01
Other Comorbidity - Acute renal disease; n (%)	493 (11.0%)	960 (18.9%)	-0.22	456 (7.2%)	478 (10.0%)	-0.10	1,430 (11.2%)	1,371 (16.5%)	-0.15	2,379 (10.1%)	2,809 (15.4%)	-0.16
Other Comorbidity CKD Stage 1; n (%)	14 (0.3%)	15 (0.3%)	0.00	11 (0.2%)	4 (0.1%)	0.03	33 (0.3%)	28 (0.3%)	0.00	58 (0.2%)	47 (0.3%)	-0.02
Other Comorbidity - CKD Stage 2; n (%)	88 (2.0%)	142 (2.8%)	-0.05	40 (0.6%)	46 (1.0%)	-0.04	177 (1.4%)	168 (2.0%)	-0.05	305 (1.3%)	356 (2.0%)	-0.05
Other Comorbidity - CKD Stage 3; n (%)	295 (6.6%)	712 (14.0%)	-0.25	147 (2.3%)	203 (4.2%)	-0.11	796 (6.2%)	980 (11.8%)	-0.20	1,238 (5.2%)	1,895 (10.4%)	-0.19
Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD; n (%)	245 (5.4%)	473 (9.3%)	-0.15	127 (2.0%)	185 (3.9%)	-0.11	679 (5.3%)	726 (8.7%)	-0.13	1,051 (4.4%)	1,384 (7.6%)	-0.14
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%)	385 (8.6%)	553 (10.9%)	-0.08	324 (5.1%)	301 (6.3%)	-0.05	905 (7.1%)	764 (9.2%)	-0.08	1,614 (6.8%)	1,618 (8.9%)	-0.08
Other Comorbidity - Hypertensive nephropathy; n (%)	333 (7.4%)	739 (14.5%)	-0.23	162 (2.6%)	257 (5.4%)	-0.14	1,056 (8.3%)	1,275 (15.3%)	-0.22	1,551 (6.6%)	2,271 (12.5%)	-0.20
Other Comorbidity - Obstructive sleep apnea; n (%)	387 (8.6%)	442 (8.7%)	0.00	626 (9.9%)	533 (11.1%)	-0.04	897 (7.0%)	602 (7.2%)	-0.01	1,390 (8.1%)	1,577 (8.7%)	-0.02
Other Comorbidity - Osteoarthritis; n (%)	1,152 (25.6%)	1,658 (32.6%)	-0.15	1,178 (18.6%)	964 (20.2%)	-0.04	4,067 (31.8%)	2,876 (34.5%)	-0.06	6,397 (27.1%)	5,498 (30.2%)	-0.07
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%)	3,025 (67.2%)	3,460 (68.0%)	-0.02	4,026 (63.5%)	2,894 (60.5%)	0.06	8,043 (62.9%)	5,180 (62.2%)	0.01	15,094 (63.9%)	11,594 (63.4%)	0.01
Other Comorbidity - Dorsopathies; n (%)	1,513 (33.6%)	1,835 (36.1%)	-0.05	1,815 (28.6%)	1,452 (30.4%)	-0.04	4,377 (34.2%)	2,780 (33.4%)	0.02	7,705 (32.6%)	6,067 (33.3%)	-0.01
Other Comorbidity - Fractures; n (%)	472 (10.5%)	647 (12.7%)	-0.07	487 (7.7%)	391 (8.2%)	-0.02	1,209 (9.5%)	845 (10.1%)	-0.02	2,168 (9.2%)	1,883 (10.3%)	-0.04
Other Comorbidity - Falls; n (%)	502 (11.2%)	897 (17.6%)	-0.18	263 (4.1%)	243 (5.1%)	-0.05	602 (4.7%)	453 (5.4%)	-0.03	1,367 (5.8%)	1,599 (8.8%)	-0.12
Other Comorbidity - Sleep Disorder; n (%)	217 (4.8%)	171 (3.4%)	0.07	379 (6.0%)	159 (3.3%)	0.13	670 (5.2%)	291 (3.5%)	0.08	1,266 (5.4%)	621 (3.4%)	0.10
Other Comorbidity - Delirium; n (%)	257 (5.7%)	466 (9.2%)	-0.13	142 (2.2%)	144 (3.0%)	-0.05	754 (5.9%)	646 (7.8%)	-0.08	1,153 (4.9%)	1,256 (6.9%)	-0.08
Other Comorbidity - Psychosis; n (%)	149 (3.3%)	191 (3.8%)	-0.03	80 (1.3%)	60 (1.3%)	0.00	775 (6.1%)	401 (4.8%)	0.06	1,004 (4.2%)	652 (3.6%)	0.03
Procedures												
Procedure - Hip Surgery; n (%)	38 (0.8%)	74 (1.5%)	-0.07	55 (0.9%)	36 (0.8%)	-0.01	139 (1.1%)	87 (1.0%)	0.01	232 (1.0%)	197 (1.1%)	-0.01
Medications												
DM Medications - Meglitinides; n (%)	5 (0.1%)	6 (0.1%)	0.00	4 (0.1%)	7 (0.1%)	0.00	35 (0.3%)	20 (0.2%)	0.02	44 (0.2%)	33 (0.2%)	0.00
DM Medications - AGIs; n (%)	3 (0.1%)	0 (0.0%)	0.04	1 (0.0%)	2 (0.0%)	0.00	--	--	--	--	--	--
DM Medications - Insulin; n (%)	176 (3.9%)	299 (5.9%)	-0.09	32 (0.5%)	26 (0.5%)	0.00	505 (3.9%)	362 (4.3%)	-0.02	713 (3.0%)	687 (3.8%)	-0.04
DM Medications - Glitazones; n (%)	20 (0.4%)	34 (0.7%)	-0.04	210 (3.3%)	221 (4.6%)	-0.07	93 (0.7%)	49 (0.6%)	0.01	323 (1.4%)	304 (1.7%)	-0.02
DM Medications - 1st and 2nd Generation SUs; n (%)	176 (3.9%)	292 (5.7%)	-0.08	201 (3.2%)	194 (4.1%)	-0.05	640 (5.0%)	466 (5.6%)	-0.03	1,017 (4.3%)	952 (5.2%)	-0.04
DM Medications - DPP-4 Inhibitors; n (%)	63 (1.4%)	116 (2.3%)	-0.07	97 (1.5%)	115 (2.4%)	-0.07	279 (2.2%)	219 (2.6%)	-0.03	439 (1.9%)	450 (2.5%)	-0.04
DM Medications - GLP-1 RA; n (%)	27 (0.6%)	56 (1.1%)	-0.05	53 (0.8%)	54 (1.1%)	-0.03	58 (0.5%)	47 (0.6%)	-0.01	138 (0.6%)	157 (0.9%)	-0.03
DM Medications - SGLT-2 Inhibitors; n (%)	37 (0.8%)	68 (1.1%)	-0.01	68 (1.1%)	57 (1.2%)	-0.01	40 (0.5%)	40 (0.5%)	0.00	164 (0.7%)	145 (0.8%)	-0.01
DM Medications - Metformin; n (%)	362 (8.0%)	615 (12.1%)	-0.14	509 (8.0%)	438 (9.2%)	-0.04	1,357 (10.6%)	841 (10.1%)	0.02	2,228 (9.4%)	1,894 (10.4%)	-0.03
DM Medications - All antidiabetic medications except Insulin; n (%)	465 (10.3%)	808 (15.9%)	-0.17	645 (10.2%)	576 (12.0%)	-0.06	1,775 (13.9%)	1,188 (14.3%)	-0.01	2,885 (12.2%)	2,572 (14.1%)	-0.06
Other Medications - Use of NSAIDs; n (%)	887 (19.7%)	936 (18.4%)	0.03	1,479 (23.3%)	1,054 (22.0%)	0.03	2,647 (20.7%)	1,646 (19.8%)	0.02	5,013 (21.2%)	3,636 (20.0%)	0.03
Other Medications - Use of other hypertension drugs; n (%)	174 (3.9%)	296 (5.8%)	-0.09	161 (3.4%)	177 (3.4%)	-0.03	747 (5.8%)	554 (6.7%)	-0.04	1,099 (4.7%)	1,011 (5.6%)	-0.04
Other Medications - Digoxin; n (%)	17 (0.4%)	18 (0.4%)	0.00	12 (0.2%)	19 (0.4%)	-0.04	83 (0.6%)	56 (0.7%)	-0.01	112 (0.5%)	93 (0.5%)	0.00
Other Medications - Use of Anti-arrhythmics; n (%)	17 (0.4%)	27 (0.5%)	-0.01	19 (0.3%)	30 (0.6%)	-0.04	57 (0.4%)	53 (0.6%)	-0.03	93 (0.4%)	110 (0.6%)	-0.03
Other Medications - Use of antipsychotics; n (%)	263 (5.8%)	357 (7.0%)	-0.05	230 (3.6%)	214 (4.5%)	-0.05	1,436 (11.2%)	864 (10.4%)	0.03	1,929 (8.2%)	1,435 (7.9%)	0.01
Other Medications - Use of dementia meds; n (%)	210 (4.7%)	386 (7.6%)	-0.12	105 (2.2%)	936 (7.3%)	-0.05	936 (7.3%)	900 (9.6%)	-0.08	1,240 (5.2%)	1,291 (7.1%)	-0.08
Other Medications - Use of antiparkinsonian meds; n (%)	148 (3.3%)	193 (3.8%)	-0.03	139 (2.2%)	118 (2.5%)	-0.02	722 (5.6%)	493 (5.9%)	-0.01	1,009 (4.3%)	804 (4.4%)	0.00
Other Medications - Use of anxiolytics/hypnotics; n (%)	291 (6.5%)	330 (6.5%)	0.00	443 (7.0%)	362 (7.6%)	-0.02	1,091 (8.5%)	679 (8.2%)	0.01	1,825 (7.7%)	1,371 (7.5%)	0.01
Other Medications - Use of anticoagulants; n (%)	738 (16.4%)	1,036 (20.4%)	-0.10	844 (13.3%)	718 (15.0%)	-0.05	2,968 (23.2%)	1,871 (22.5%)	0.02	4,550 (19.3%)	3,625 (19.9%)	-0.02
Other Medications - Use of antidepressants; n (%)	1,187 (26.4%)	1,520 (29.9%)	-0.08	1,443 (22.8%)	1,205 (25.2%)	-0.06	4,303 (33.7%)	2,949 (35.4%)	-0.04	6,933 (29.3%)	5,674 (31.7%)	-0.04
Other Medications - Use of lithium; n (%)	13 (0.3%)	14 (0.3%)	0.00	21 (0.3%)	15 (0.3%)	0.00	79 (0.6%)	40 (0.5%)	0.01	113 (0.5%)	69 (0.4%)	0.01
Other Medications - Use of Benzos; n (%)	686 (15.2%)	792 (15.6%)	-0.01	929 (14.7%)	734 (15.4%)	-0.02	2,714 (21.2%)	1,762 (21.2%)	0.00	4,329 (18.3%)	3,288 (18.1%)	0.01
Other Medication - Use of CNS stimulants; n (%)	39 (0.9%)	47 (0.9%)	0.00	100 (1.6%)	75 (1.6%)	0.00	94 (0.7%)	49 (0.6%)	0.01	233 (1.0%)	171 (0.9%)	0.01
Other Medications - Use of opioids; n (%)	1,901 (42.3%)	1,922 (37.8%)	0.09	3,029 (47.8%)	2,095 (43.8%)	0.08	5,620 (44.0%)	3,499 (42.0%)	0.04	10,550 (44.7%)	7,516 (41.3%)	0.07
Other Medications - Use of COPD/asthma meds; n (%)	728 (16.2%)	1,062 (20.9%)	-0.12	1,010 (15.9%)	803 (16.8%)	-0.02	2,991 (23.4%)	1,969 (23.6%)	0.00	4,729 (20.0%)	3,834 (21.1%)	-0.03
Other Medications - Use of oral corticosteroids; n (%)	1,204 (26.8%)	1,433 (28.2%)	-0.03	1,628 (25.7%)	1,307 (27.3%)	-0.04	3,906 (30.5%)	2,715 (32.6%)	-0.05	6,738 (28.5%)	5,455 (30.0%)	-0.03
Other Medications - Use of Sympathomimetic agents; n (%)	68 (1.5%)	58 (1.1%)	0.04	156 (2.5%)	135 (2.8%)	-0.02	143 (1.1%)	73 (0.9%)	0.02	367 (1.6%)	266 (1.5%)	0.01
Other Medications - Use of bisphosphonates; n (%)	121 (2.7%)	188 (3.7%)	-0.06	67 (1.1%)	49 (1.0%)	0.01	502 (3.9%)	337 (4.0%)	-0.01	690 (2.9%)	574 (3.2%)	-0.02
Other Medications - Use of thiazide; n (%)	329 (7.3%)	448 (8.8%)	-0.06	363 (5.7%)	362 (7.6%)	-0.08	1,249 (9.8%)	831 (10.0%)	-0.01	1,941 (8.2%)	1,641 (9.0%)	-0.03
Other Medications - Use of estrogens, progestins, androgens; n (%)	388 (8.6%)	281 (5.5%)	0.12	872 (13.8%)	617 (12.9%)	0.03	578 (4.5%)	371 (4.5%)	0.00	1,838 (7.8%)	1,269 (7.0%)	0.03
Healthcare Utilization												
HU - Bone mineral density; n (%)	120 (2.7%)	164 (3.2%)	-0.03	86 (1.4%)	73 (1.5%)	-0.01	490 (3.8%)	331 (4.0%)	-0.01	696 (2.9%)	568 (3.1%)	-0.01
HU - Occurrence of creatinine tests ordered; n (%)	250 (5.6%)	330 (6.5%)	-0.04	264 (4.2%)	203 (4.2%)	0.00	878 (6.9%)	586 (7.0%)	0.00	1,392 (5.9%)	1,119 (6.1%)	-0.01
HU - Number of D-dimer tests												
...mean (sd)	0.11 (0.35)	0.11 (0.35)	0.00	0.13 (0.38)	0.12 (0.38)	0.03	0.11 (0.35)	0.10 (0.33)	0.03	0.12 (0.36)	0.11 (0.35)	0.03
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.36)	0.00 (0.35)	0.00
HU - Number of CRP, high-sensitivity CRP tests												
...mean (sd)	0.12 (0.55)	0.12 (0.52)	0.00	0.10 (0.47)	0.11 (0.58)	-0.02	0.15 (0.59)	0.16 (0.64)	-0.02	0.13 (0.55)	0.14 (0.59)	-0.02
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.55)	0.00 (0.59)	0.00
HU - Colonoscopy; n (%)	157 (3.5%)	172 (3.4%)	0.01	223 (3.5%)	200 (4.2%)	-0.0						

Appendix B

...mean (sd)	1.18 (0.55)	1.25 (0.66)	-0.12	1.13 (0.41)	1.15 (0.46)	-0.05	1.30 (0.73)	1.31 (0.67)	-0.01	1.23 (0.63)	1.25 (0.62)	-0.03
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.00	1.00 (0.63)	1.00 (0.62)	0.00
HU - Number of hospital days												
...mean (sd)	5.54 (7.53)	7.01 (9.17)	-0.18	4.83 (6.87)	5.47 (8.41)	-0.08	6.63 (8.92)	6.78 (7.60)	-0.02	5.94 (8.16)	6.50 (8.28)	-0.07
...median [IQR]	4.00 [3.00, 6.00]	4.00 [3.00, 7.00]	0.00	3.00 [2.00, 5.00]	4.00 [3.00, 5.00]	-0.13	4.00 [3.00, 7.00]	4.00 [3.00, 7.00]	0.00	3.73 (8.16)	4.00 (8.28)	-0.03
HU - Number of Emergency Department (ED) visits												
...mean (sd)	1.66 (2.41)	1.83 (2.28)	-0.07	3.07 (4.52)	3.35 (5.71)	-0.05	2.26 (8.21)	2.12 (3.30)	0.02	2.36 (6.56)	2.36 (3.87)	0.00
...median [IQR]	1.00 [1.00, 2.00]	1.00 [1.00, 2.00]	0.00	2.00 [0.00, 4.00]	2.00 [0.00, 4.00]	0.00	1.00 [1.00, 3.00]	1.00 [1.00, 3.00]	0.00	1.27 (6.56)	1.26 (3.87)	0.00
HU - Number of internal medicine/family medicine visits												
...mean (sd)	9.55 (14.11)	12.64 (16.03)	-0.20	5.11 (7.96)	5.61 (9.10)	-0.06	10.96 (11.24)	11.46 (10.71)	-0.05	9.12 (11.10)	10.25 (12.09)	-0.10
...median [IQR]	5.00 [3.00, 12.00]	8.00 [3.00, 16.00]	-0.20	3.00 [1.00, 6.00]	3.00 [1.00, 7.00]	0.00	8.00 [4.00, 14.00]	9.00 [5.00, 15.00]	-0.09	6.09 (11.10)	7.14 (12.09)	-0.09
HU - Number of different/distinct medication prescriptions												
...mean (sd)	7.95 (5.27)	9.08 (5.48)	-0.21	7.55 (5.18)	8.25 (5.32)	-0.13	9.54 (5.35)	10.02 (5.31)	-0.09	8.70 (5.29)	9.29 (5.36)	-0.11
...median [IQR]	7.00 [4.00, 11.00]	8.00 [5.00, 12.00]	-0.19	6.00 [4.00, 10.00]	7.00 [4.00, 11.00]	-0.19	9.00 [6.00, 12.00]	9.00 [6.00, 13.00]	0.00	7.81 (5.29)	8.19 (5.36)	-0.07
HU Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level												
...mean (sd)	12.59 (13.28)	18.31 (15.13)	-0.40	8.39 (9.96)	11.92 (11.17)	-0.33	14.89 (13.11)	17.85 (13.14)	-0.23	12.71 (12.38)	16.42 (13.26)	-0.29
...median [IQR]	9.00 [1.00, 19.00]	15.00 [7.00, 26.00]	-0.42	5.00 [0.00, 14.00]	11.00 [2.00, 18.00]	-0.57	13.00 [4.00, 22.00]	16.00 [8.00, 25.00]	-0.23	10.09 (12.38)	14.41 (13.26)	-0.34
HU - Number of Office visits												
...mean (sd)	4.38 (4.11)	4.56 (4.04)	-0.04	4.32 (4.06)	4.47 (4.13)	-0.04	11.38 (13.70)	11.16 (11.88)	0.02	8.15 (10.45)	7.56 (8.58)	0.06
...median [IQR]	3.00 [1.00, 6.00]	4.00 [2.00, 6.00]	-0.25	3.00 [1.00, 6.00]	4.00 [2.00, 6.00]	-0.24	8.00 [3.00, 15.00]	8.00 [3.00, 15.00]	0.00	5.71 (10.45)	5.83 (8.58)	-0.01
HU - Number of Cardiologist visits												
...mean (sd)	2.32 (3.74)	2.91 (4.20)	-0.15	0.61 (1.84)	0.74 (2.03)	-0.07	2.52 (3.93)	2.83 (4.43)	-0.07	1.97 (3.45)	2.30 (3.87)	-0.09
...median [IQR]	1.00 [0.00, 3.00]	1.00 [0.00, 4.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.00	1.00 [0.00, 3.00]	1.00 [0.00, 4.00]	0.00	0.73 (3.45)	0.74 (3.87)	0.00
HU - Number electrocardiograms												
...mean (sd)	1.79 (1.98)	2.06 (2.21)	-0.13	0.75 (1.19)	0.80 (1.23)	-0.04	1.93 (2.08)	1.99 (1.96)	-0.03	1.59 (1.86)	1.70 (1.88)	-0.06
...median [IQR]	1.00 [1.00, 2.00]	2.00 [1.00, 3.00]	-0.48	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	1.00 [1.00, 3.00]	2.00 [1.00, 3.00]	-0.49	0.73 (1.86)	1.47 (1.88)	-0.40
HU - Number of echocardiograms												
...mean (sd)	1.07 (3.06)	1.16 (3.08)	-0.03	0.61 (0.71)	0.70 (0.77)	-0.12	0.73 (0.93)	0.80 (0.97)	-0.07	0.76 (1.54)	0.87 (1.80)	-0.07
...median [IQR]	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	1.00 (1.54)	1.00 (1.80)	0.00
HU - Number of neurologist visits												
...mean (sd)	0.53 (2.11)	0.71 (2.70)	-0.07	0.30 (1.41)	0.43 (2.85)	-0.06	0.51 (2.05)	0.59 (2.52)	-0.03	0.46 (1.91)	0.58 (2.66)	-0.05
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.91)	0.00 (2.66)	0.00
HU - Fecal occult blood (FOB) test; n (%)	122 (2.7%)	114 (2.2%)	0.03	176 (2.8%)	124 (2.6%)	0.01	308 (2.4%)	221 (2.7%)	-0.02	606 (2.6%)	459 (2.5%)	0.00
HU - Number of PT or aPTT tests												
...mean (sd)	0.44 (1.15)	0.51 (1.26)	-0.06	0.43 (1.04)	0.45 (1.18)	-0.02	0.26 (0.65)	0.25 (0.65)	0.02	0.34 (0.88)	0.38 (1.00)	-0.04
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.88)	0.00 (1.00)	0.00
N of days in database anytime prior												
...mean (sd)	1,791.06 (1,353.03)	1,916.04 (1,463.00)	-0.09	2,164.61 (1,520.58)	2,298.62 (1,602.77)	-0.09	715.30 (383.18)	742.93 (368.81)	-0.07	1,309.06 (1,023.95)	1,479.61 (1,155.63)	-0.16
...median [IQR]	1,406.00 [684.00, 2,631.47]	1,475.00 [741.00, 2,799.00]	-0.05	1,847.00 [812.00, 3,202.00]	1,872.50 [872.50, 3,420.00]	-0.11	644.00 [486.00, 830.00]	675.00 [518.00, 891.00]	-0.08	1,111.92 (1,023.95)	1,252.55 (1,155.63)	-0.13
Socioeconomic Status Proxy Variables												
SES - Mean Copay for per prescription cost (charges in U.S. \$)												
...mean (sd)	18.46 (26.31)	18.38 (27.06)	0.00	12.27 (21.28)	11.83 (19.16)	0.02	18.70 (36.80)	19.70 (48.22)	-0.02	16.93 (31.41)	17.26 (36.95)	-0.01
...median [IQR]	12.11 [4.29, 24.08]	10.72 [4.02, 23.29]	17.55	7.50 [0.96, 15.55]	7.30 [1.00, 15.00]	0.01	9.07 [2.67, 22.95]	9.93 [2.88, 24.06]	-0.02	9.23 (31.41)	9.46 (36.95)	-0.01
...Missing; n (%)	479 (10.6%)	370 (7.3%)	0.12	1,021 (16.1%)	1,094 (22.9%)	-0.17	1,930 (15.1%)	453 (5.4%)	0.32	3,430 (14.5%)	1,917 (10.5%)	0.12
SES - Copay: pharmacy cost												
...mean (sd)	161.56 (270.51)	184.68 (336.22)	-0.08	99.03 (224.48)	91.21 (179.55)	0.04	181.04 (376.97)	226.18 (755.70)	-0.08	155.32 (323.07)	179.12 (549.07)	-0.05
...median [IQR]	65.00 [8.28, 207.12]	72.61 [14.35, 228.00]	-0.02	24.78 [0.00, 117.74]	16.90 [0.00, 107.17]	0.04	55.69 [2.93, 202.24]	79.75 [17.63, 254.70]	-0.04	49.17 (323.07)	61.24 (549.07)	-0.03
SES - Business type: Commercial vs Medicare												
...Commercial; n (%)	2,178 (48.4%)	1,399 (27.5%)	0.44	4,978 (78.5%)	3,523 (73.7%)	0.11	0 (0.0%)	0 (0.0%)	0.00	7,156 (30.3%)	4,922 (27.0%)	0.07
...Medicare; n (%)	2,321 (51.6%)	3,688 (72.5%)	-0.44	1,361 (21.5%)	1,258 (26.3%)	-0.11	0 (0.0%)	0 (0.0%)	0.00	3,682 (15.6%)	4,946 (27.2%)	-0.29
SES - Low income indicator; n (%)	615 (13.7%)	931 (18.3%)	-0.13	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	615 (2.6%)	931 (5.1%)	-0.13
SES - Urban vs Rural (MSA variable)												
...Urban; n (%)	0 (0.0%)	0 (0.0%)	0.00	4,492 (70.9%)	3,008 (62.9%)	0.17	0 (0.0%)	0 (0.0%)	0.00	4,492 (19.0%)	3,008 (16.5%)	0.07
...Rural; n (%)	0 (0.0%)	0 (0.0%)	0.00	407 (6.4%)	557 (11.7%)	-0.19	0 (0.0%)	0 (0.0%)	0.00	4,492 (19.0%)	557 (3.1%)	0.52
...Unknown/Missing; n (%)	0 (0.0%)	0 (0.0%)	0.00	1,440 (22.7%)	1,216 (25.4%)	-0.06	0 (0.0%)	0 (0.0%)	0.00	1,440 (6.1%)	1,216 (6.7%)	-0.02
SES - Dual Status; n (%)	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	4,066 (31.8%)	2,524 (30.3%)	0.03	4,066 (17.2%)	2,524 (13.9%)	0.09
SES - Generic name prescription - unique value												
...mean (sd)	7.95 (5.27)	9.08 (5.48)	-0.21	7.55 (5.18)	8.25 (5.32)	-0.13	9.54 (5.35)	10.02 (5.31)	-0.09	8.70 (5.29)	9.29 (5.36)	-0.11
...median [IQR]	7.00 [4.00, 11.00]	8.00 [5.00, 12.00]	-0.19	6.00 [4.00, 10.00]	7.00 [4.00, 11.00]	-0.19	9.00 [6.00, 12.00]	9.00 [6.00, 13.00]	0.00	7.81 (5.29)	8.19 (5.36)	-0.07
SES - Brand name prescription - unique value												
...mean (sd)	8.04 (5.38)	9.17 (5.59)	-0.21	7.64 (5.28)	8.34 (5.42)	-0.13	9.65 (5.46)	10.13 (5.41)	-0.09	8.80 (5.40)	9.39 (5.46)	-0.11
...median [IQR]	7.00 [4.00, 11.00]	8.00 [5.00, 12.00]	-0.18	6.00 [4.00, 10.00]	7.00 [4.00, 11.00]	-0.19	9.00 [6.00, 13.00]	9.00 [6.00, 13.00]	0.00	7.81 (5.40)	8.19 (5.46)	-0.07

Appendix B

Variable	Matched											
	Optum			MarketScan			Medicare			Pooled		
	Rivaroxaban 3,032	Apixaban 3,032	St. Diff	Rivaroxaban 3,694	Apixaban 3,694	St. Diff	Rivaroxaban 7,476	Apixaban 7,476	St. Diff	Rivaroxaban 14,202	Apixaban 14,202	St. Diff
Age												
...mean (sd)	65.10 (16.13)	65.21 (16.49)	-0.006743918	55.41 (15.52)	55.52 (15.87)	-0.007008166	73.18 (12.05)	73.20 (12.34)	-0.0016399	66.83 (13.95)	66.90 (14.27)	-0.004960702
...median [IQR]	68.00 [56.00, 77.00]	68.00 [55.00, 78.00]	0	56.00 [46.00, 64.00]	56.00 [45.00, 64.00]	0	74.00 [68.00, 81.00]	74.00 [68.00, 82.00]	0	66.84 (13.95)	68.04 (14.27)	0
Age categories												
...18 - 54; n (%)	704 (23.2%)	740 (24.4%)	-0.028181129	1,653 (44.7%)	1,662 (45.0%)	-0.00603211	601 (8.0%)	586 (7.8%)	0.007414632	2,958 (20.8%)	2,988 (21.0%)	-0.004918922
...55 - 64; n (%)	521 (17.2%)	498 (16.4%)	0.021399249	1,191 (32.2%)	1,170 (31.7%)	0.010723258	576 (7.7%)	604 (8.1%)	-0.01482957	2,288 (16.1%)	2,272 (16.0%)	0.002724285
...65 - 74; n (%)	834 (27.5%)	874 (28.5%)	-0.036172905	407 (11.0%)	408 (11.0%)	0	2,648 (35.4%)	2,668 (35.7%)	-0.006267468	3,889 (27.4%)	3,860 (27.2%)	0.004489341
...≥ 75; n (%)	973 (32.1%)	1,010 (33.3%)	-0.025582051	443 (12.0%)	454 (12.3%)	-0.009182624	3,651 (48.8%)	3,618 (48.4%)	0.008003202	5,067 (35.7%)	5,082 (35.8%)	-0.002086535
Calendar Year (2014-2020)												
...2014; n (%)	26 (0.9%)	23 (0.8%)	0.010893078	63 (1.7%)	69 (1.9%)	-0.015048348	183 (2.4%)	175 (2.3%)	0.006601343	272 (1.9%)	267 (1.9%)	0
...2015; n (%)	187 (6.2%)	193 (6.4%)	-0.008231777	450 (12.2%)	461 (12.6%)	-0.012136925	1,518 (20.3%)	1,559 (20.8%)	-0.012374437	2,155 (15.2%)	2,215 (15.6%)	-0.011082076
...2016; n (%)	477 (15.7%)	472 (15.6%)	0.007523331	891 (24.1%)	851 (23.3%)	0.018813637	2,825 (37.8%)	2,838 (38.0%)	-0.004122546	4,171 (29.5%)	4,171 (29.4%)	0.000193861
...2017; n (%)	621 (20.5%)	630 (20.8%)	-0.007411238	897 (24.3%)	881 (23.8%)	0.011699196	2,950 (39.5%)	2,905 (38.9%)	0.01290361	4,468 (31.5%)	4,416 (31.1%)	0.00862608
...2018; n (%)	797 (26.3%)	777 (25.6%)	0.015969108	772 (20.9%)	788 (21.3%)	-0.009803598	0 (0.0%)	0 (0.0%)	0	1,569 (11.0%)	1,565 (11.0%)	0
...2019; n (%)	704 (23.2%)	725 (23.9%)	-0.016497898	621 (16.8%)	631 (17.1%)	-0.00799595	0 (0.0%)	0 (0.0%)	0	1,325 (9.3%)	1,356 (9.5%)	-0.006853375
...2020; n (%)	220 (7.3%)	212 (7.0%)	0.011643529	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	220 (1.5%)	0	0
Race												
...White; n (%)	2,141 (70.6%)	2,149 (70.9%)	-0.006594737	0 (0.0%)	0 (0.0%)	0	6,174 (82.6%)	6,188 (82.8%)	-0.005287565	8,315 (58.5%)	8,337 (58.7%)	-0.004060522
...Asian; n (%)	50 (1.6%)	44 (1.5%)	0.008095242	0 (0.0%)	0 (0.0%)	0	72 (1.0%)	66 (0.9%)	0.010390904	110 (0.8%)	110 (0.8%)	0
...Black; n (%)	445 (14.7%)	457 (15.1%)	-0.011233341	0 (0.0%)	0 (0.0%)	0	938 (12.5%)	951 (12.7%)	-0.006026858	1,383 (9.7%)	1,408 (9.9%)	-0.006726918
...Hispanic; n (%)	245 (8.1%)	235 (7.8%)	0.011090024	0 (0.0%)	0 (0.0%)	0	118 (1.6%)	117 (1.6%)	0	363 (2.6%)	352 (2.5%)	0.006243679
...North American Native; n (%)	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	25 (0.3%)	22 (0.3%)	0	25 (0.2%)	22 (0.2%)	0
...Other; n (%)	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	66 (0.9%)	57 (0.8%)	0.010893078	66 (0.5%)	57 (0.4%)	0.014941191
...Unknown/Missing; n (%)	151 (5.0%)	147 (4.8%)	0.00926502	0 (0.0%)	0 (0.0%)	0	83 (1.1%)	75 (1.0%)	0.009810761	234 (1.6%)	222 (1.6%)	0
Gender												
...Males; n (%)	1,404 (46.3%)	1,427 (47.1%)	-0.016035478	1,969 (53.3%)	1,953 (52.9%)	0.008015485	4,900 (40.0%)	2,968 (39.7%)	0.006127613	6,363 (44.8%)	6,348 (44.7%)	0.002011118
...Females; n (%)	1,628 (53.7%)	1,605 (52.9%)	0.016035478	1,725 (46.7%)	1,741 (47.1%)	-0.008015485	4,486 (60.0%)	4,508 (60.3%)	-0.006127613	7,839 (55.2%)	7,854 (55.3%)	-0.002011118
Region												
...Northeast; n (%)	353 (11.6%)	341 (11.2%)	0.012586336	737 (20.0%)	751 (20.3%)	-0.007479099	1,451 (19.4%)	1,445 (19.3%)	0.002531382	2,541 (17.9%)	2,537 (17.9%)	0
...South; n (%)	1,330 (43.9%)	1,347 (44.4%)	-0.010609283	1,643 (44.5%)	1,637 (44.3%)	0.004052335	3,275 (43.8%)	3,282 (43.9%)	-0.002015304	6,248 (44.1%)	6,266 (44.1%)	-0.002014314
...Midwest; n (%)	676 (22.3%)	678 (22.4%)	-0.002400044	848 (23.0%)	849 (23.0%)	0	1,624 (21.7%)	1,629 (21.8%)	-0.002043977	3,148 (22.2%)	3,156 (22.2%)	0
...West; n (%)	667 (22.0%)	667 (21.8%)	0.004835971	459 (12.4%)	447 (12.1%)	0.009150276	1,119 (15.0%)	1,112 (14.9%)	0.002804118	2,241 (15.8%)	2,221 (15.8%)	0.005497535
...Unknown-missing; n (%)	6 (0.2%)	4 (0.1%)	0.025841432	7 (0.2%)	10 (0.3%)	-0.020026051	7 (0.1%)	8 (0.1%)	0	20 (0.1%)	22 (0.2%)	-0.025841432
Combined comorbidity score, 180 days												
...mean (sd)	3.08 (2.42)	3.13 (2.42)	-0.020661157	1.98 (1.78)	1.98 (1.76)	-0.005649627	2.51 (2.14)	2.52 (2.16)	-0.004651112	2.49 (2.12)	2.51 (2.12)	-0.009433962
...median [IQR]	3.00 (1.00, 4.00)	3.00 (1.00, 5.00)	0	2.00 (1.00, 3.00)	2.00 (1.00, 3.00)	0	2.00 (1.00, 4.00)	2.00 (1.00, 4.00)	0	2.21 (2.12)	2.21 (2.12)	0
Lifestyle Factors												
Lifestyle - Smoking; n (%)	1,128 (37.2%)	1,123 (37.0%)	0.004140175	752 (20.4%)	742 (20.1%)	0.007465285	3,003 (40.2%)	3,057 (40.9%)	-0.014257314	4,883 (34.4%)	4,922 (34.7%)	-0.006308768
Lifestyle - Drug abuse or dependence; n (%)	143 (4.7%)	152 (5.0%)	-0.013965503	109 (3.0%)	101 (2.7%)	0.018029973	275 (3.7%)	287 (3.8%)	-0.005263632	540 (3.8%)	540 (3.8%)	-0.005263632
Lifestyle - Alcohol abuse or dependence; n (%)	128 (4.2%)	117 (3.9%)	0.01521892	97 (2.6%)	96 (2.6%)	0	232 (3.1%)	233 (3.1%)	0	457 (3.2%)	446 (3.1%)	0.005725279
Comorbidities												
DM - Diabetic Retinopathy; n (%)	36 (1.2%)	32 (1.1%)	0.009379237	20 (0.5%)	23 (0.6%)	-0.013521541	71 (0.9%)	78 (1.0%)	-0.010309004	127 (0.9%)	133 (0.9%)	0
DM - Diabetic Neuropathy; n (%)	163 (5.4%)	172 (5.7%)	-0.013103373	108 (2.9%)	107 (2.9%)	0	361 (4.8%)	376 (5.0%)	-0.00926520	632 (4.5%)	655 (4.6%)	-0.004798523
DM - Diabetic Nephropathy; n (%)	136 (4.5%)	140 (4.6%)	-0.004798523	61 (1.7%)	68 (1.8%)	-0.00762637	249 (3.3%)	245 (3.3%)	0	446 (3.2%)	453 (3.2%)	-0.005725279
DM - Diabetes with peripheral circulatory disorders; n (%)	6 (0.2%)	0	0	7 (0.2%)	7 (0.2%)	0	23 (0.3%)	24 (0.3%)	0	036 (0.3%)	37 (0.3%)	0
DM - Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%)	35 (1.2%)	34 (1.1%)	0.009379237	16 (0.4%)	14 (0.4%)	0	91 (1.2%)	95 (1.3%)	-0.009000794	142 (1.0%)	143 (1.0%)	0
DM - Diabetes with unspecified complications; n (%)	52 (1.7%)	52 (1.7%)	0	555 (15.0%)	573 (15.5%)	-0.013908354	102 (1.4%)	106 (1.4%)	0	709 (5.0%)	731 (5.1%)	-0.004566758
DM - Diabetes mellitus without mention of complications; n (%)	600 (19.8%)	602 (19.8%)	-0.002507081	602 (16.4%)	602 (16.4%)	0	1,709 (22.9%)	1,730 (23.2%)	-0.007123349	2,359 (16.8%)	2,389 (16.8%)	-0.005362296
CV - Hypertension; n (%)	1,947 (64.2%)	1,945 (64.1%)	0.002085246	1,885 (51.0%)	1,859 (50.3%)	0.014001526	5,908 (79.0%)	5,907 (79.0%)	0	9,710 (68.4%)	9,710 (68.4%)	0.004305568
CV - Hyperlipidemia; n (%)	1,426 (47.0%)	1,422 (46.9%)	0.002003732	1,264 (34.2%)	1,249 (33.8%)	0.008440082	4,068 (54.4%)	4,081 (54.6%)	-0.004016307	6,758 (47.6%)	6,752 (47.6%)	0.002002406
CV - Acute MI; n (%)	164 (5.4%)	153 (5.0%)	0.018016556	140 (3.8%)	148 (4.0%)	-0.010330986	359 (4.8%)	360 (4.8%)	0	663 (4.7%)	661 (4.7%)	0
CV - ACS/unstable angina; n (%)	103 (3.4%)	103 (3.4%)	0	94 (2.5%)	95 (2.6%)	-0.006343679	273 (3.7%)	268 (3.6%)	0.00533248	470 (3.3%)	466 (3.3%)	0
CV - Old MI; n (%)	129 (4.3%)	137 (4.5%)	-0.00975169	60 (1.6%)	66 (1.8%)	-0.015471833	380 (5.1%)	376 (5.0%)	0.004566758	579 (4.1%)	579 (4.1%)	-0.005072843
CV - Stable angina; n (%)	77 (2.5%)	82 (2.7%)	-0.012568181	72 (1.9%)	69 (1.9%)	0	194 (2.6%)	189 (2.5%)	0.005343679	343 (2.4%)	340 (2.4%)	0
CV - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	475 (15.5%)	471 (15.5%)	0.005511859	333 (9.0%)	343 (9.3%)	-0.010405288	1,549 (20.7%)	1,561 (20.9%)	-0.0049927618	2,357 (16.8%)	2,374 (16.7%)	0.002684356
CV - Other atherosclerosis; n (%)	30 (1.0%)	34 (1.1%)	-0.009810761	15 (0.4%)	14 (0.4%)	0	57 (0.8%)	66 (0.9%)	-0.010893078	102 (0.7%)	114 (0.8%)	-0.011590746
CV - Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%)	150 (4.9%)	140 (4.6%)	0.01410434	48 (1.3%)	50 (1.4%)	-0.008665401	566 (7.6%)	564 (7.5%)	0.003785069	764 (5.4%)	754 (5.3%)	0.004443896
CV - Ischemic stroke; n (%)	192 (6.3%)	179 (5.9%)	0.016713886	149 (4.0%)	149 (4.0%)	0.019942251	540 (7.2%)	565 (7.6%)	-0.015280984	894 (6.3%)	893 (6.3%)	0
CV - Hemorrhagic stroke; n (%)	7 (0.2%)	7 (0.2%)	0	2 (0.1%)	2 (0.1%)	0	11 (0.1%)	14 (0.2%)	-0.025841432	020 (0.1%)	23 (0.2%)	-0.025841432
CV - TIA; n (%)	53 (1.7%)	49 (1.6%)	0.007850082	52 (1.4%)	50 (1.4%)	0	159 (2.1%)	148 (2.0%)	0.007057056	264 (1.9%)	247 (1.7%)	0.015043548
CV - Other cerebrovascular disease; n (%)	99 (3.3%)	97 (3.2%)	0.005639422	74 (2.0%)	73 (2.0%)	0	246 (3.3%)	254 (3.4%)	-0.005557486	419 (3.0%)	424 (3.0%)	0
CV - Late effects of cerebrovascular disease; n (%)	78 (2.6%)	73 (2.4%)	0.012810515	43 (1.2%)	36 (1.0%)	0.019175887	228 (3.0%)	230 (3.1%)	-0.005815379	349 (2.5%)	339 (2.4%)	0.00646853
CV - Heart failure (CHF); n (%)	433 (14.3%)	439 (14.5%)	-0.00569572	308 (8.3%)	326 (8.8%)	-0.007188185	1,235 (16.8%)	1,266 (16.9%)	-0.002671587	1,994 (14.0%)	2,021 (14.3%)	-0.008607498
CV - Peripheral Vascular Disease (PVD) or PVD Surgery; n (%)	269 (8.9%)	270 (8.9%)	0	165 (4.5%)	173 (4.7%)	-0.009547328	664 (8.9%)	681 (9.1%)	-0.006898608	1,098 (7.7%)	1,124 (7.9%)	-0.007457963
CV - Other cardiac dysrhythmia; n (%)	469 (15.5%)	470 (15.5%)	0	482 (13.0%)	471 (12.8%)	0.005966615	1,151 (15.4%)	1,177 (15.7%)	-0.008278658	2,102 (14.8%)	2,118 (14.9%)	-0.002812191
CV - Cardiac conduction disorders; n (%)	271 (8.9%)	280 (9.2%)	-0.010456866	199 (5.4%)	195 (5.3%)	0.004443896	680 (9.1%)	657 (8.8%)	0.010509348	1,150 (8.1%)	1,132 (8.0%)	0.003675589
CV - Other CVI; n (%)	954 (31.5%)	952 (31.4%)	0.002153705	934 (25.3%)	917 (24.8%)	0.011539515	1,999 (26.7%)	2,016 (27.0%)	-0.00676931	3,887 (27.4%)	3,885 (27.4%)	0
CV Medications - ACE inhibitors; n (%)	678 (22.2%)	675 (22.3%)	-0.00240428	678 (18.4%)	689 (18.7%)	-0.00718039	2,019 (27.0%)	2,047 (27.4%)	-0.008989059	3,371 (23.7%)	3,411 (24.0%)	-0.007039548
CV Medications - ARBs; n (%)	449 (14.8%)	454 (14.9%)	-0.002812191	449 (12.2%)	449 (12.2%)	0	1,341 (17.9%)	1,351 (18.1%)	-0.005205891	2,239 (15.8%)	2,251 (15.8%)	0
CV Medications - Alpha blockers; n (%)	261 (8.3%)	265 (8.3%)	-0.014343665	216 (5.9%)	222 (6.0							


Appendix B

Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%)	200 (6.6%)	194 (6.4%)	0.008112806	90 (2.4%)	100 (2.7%)	-0.019031802	518 (6.9%)	516 (6.9%)	0	808 (5.7%)	810 (5.7%)	0
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%)	297 (9.8%)	293 (9.7%)	0.003371124	210 (5.7%)	220 (6.0%)	-0.012783272	607 (8.1%)	607 (8.1%)	0	1,114 (7.8%)	1,124 (7.8%)	-0.003718076
Other Comorbidity - Hypertensive nephropathy; n (%)	289 (9.5%)	295 (9.7%)	-0.006789107	133 (3.6%)	138 (3.7%)	-0.005332448	852 (11.4%)	851 (11.4%)	0	1,274 (9.0%)	1,284 (9.0%)	0
Other Comorbidity - Obstructive sleep apnea; n (%)	260 (8.6%)	273 (9.0%)	-0.014119914	399 (10.8%)	389 (10.5%)	0.009235329	552 (7.4%)	550 (7.4%)	0	550 (7.4%)	550 (7.4%)	0
Other Comorbidity - Osteoarthritis; n (%)	870 (28.7%)	898 (29.6%)	-0.019804989	177 (19.4%)	739 (20.0%)	-0.015085952	2,533 (33.9%)	2,528 (33.8%)	0.002113275	4,119 (29.0%)	4,165 (29.3%)	-0.006013375
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%)	2,025 (66.8%)	2,049 (67.6%)	-0.017040573	2,284 (61.8%)	2,264 (61.3%)	0.010278117	4,654 (62.3%)	4,631 (61.9%)	0.008245145	8,963 (63.1%)	8,944 (63.0%)	0.000271813
Other Comorbidity - Dorsopathies; n (%)	1,039 (34.3%)	1,052 (34.7%)	-0.008414603	1,079 (29.2%)	1,089 (29.5%)	-0.00658815	2,509 (33.6%)	2,516 (33.7%)	-0.002116349	4,627 (32.6%)	4,657 (32.8%)	-0.004263336
Other Comorbidity - Fractures; n (%)	331 (10.9%)	342 (11.3%)	-0.012733753	298 (8.1%)	296 (8.0%)	0.003675589	746 (10.0%)	746 (10.0%)	0	1,379 (9.7%)	1,384 (9.7%)	0
Other Comorbidity - Falls; n (%)	403 (13.3%)	408 (13.5%)	-0.005871114	174 (4.7%)	184 (5.0%)	-0.013965503	395 (5.3%)	378 (5.1%)	0.009008004	972 (8.5%)	970 (8.6%)	0
Other Comorbidity - Sleep Disorder; n (%)	92 (3.0%)	97 (3.2%)	-0.011539699	137 (3.7%)	137 (3.7%)	0	267 (3.6%)	275 (3.7%)	-0.005332448	496 (3.5%)	509 (3.6%)	-0.005404261
Other Comorbidity - Delirium; n (%)	211 (7.0%)	203 (6.7%)	0.011876602	105 (2.8%)	94 (2.5%)	0.018678813	520 (7.0%)	519 (6.9%)	0.003932333	836 (5.9%)	816 (5.7%)	0.008556468
Other Comorbidity - Psychosis; n (%)	107 (3.5%)	117 (3.7%)	-0.021191923	47 (1.3%)	43 (1.2%)	0.009007094	386 (5.2%)	370 (4.9%)	0.013700558	540 (3.9%)	550 (3.7%)	0.005263632
Procedures												
Procedure - Hip Surgery; n (%)	33 (1.1%)	33 (1.1%)	0	27 (0.7%)	28 (0.8%)	-0.011590746	86 (1.2%)	79 (1.1%)	0.009379237	146 (1.0%)	140 (1.0%)	0
Medications												
DM Medications - Meglitinides; n (%)	3 (0.1%)	3 (0.1%)	0	2 (0.1%)	4 (0.1%)	0	18 (0.2%)	17 (0.2%)	0	23 (0.2%)	24 (0.2%)	0
DM Medications - AGIs; n (%)	0 (0.0%)	0 (0.0%)	0	1 (0.0%)	1 (0.0%)	0	--	--	--	--	--	0
DM Medications - Insulin; n (%)	137 (4.5%)	129 (4.3%)	0.00975169	20 (0.5%)	21 (0.6%)	-0.013521541	299 (4.0%)	308 (4.1%)	-0.005072843	581 (4.1%)	458 (3.2%)	0.04800597
DM Medications - Glitazones; n (%)	15 (0.5%)	11 (0.4%)	0.014941191	145 (3.9%)	145 (3.9%)	0	43 (0.7%)	43 (0.6%)	0.012444223	209 (1.5%)	199 (1.4%)	0.008365492
DM Medications - 1st and 2nd Generation SUs; n (%)	140 (4.6%)	142 (4.7%)	-0.004749134	137 (3.7%)	144 (3.9%)	-0.0104606	398 (5.3%)	399 (5.3%)	0	675 (4.8%)	685 (4.8%)	0
DM Medications - DPP-4 Inhibitors; n (%)	49 (1.6%)	42 (1.4%)	0.016454358	75 (2.0%)	75 (2.0%)	0	175 (2.3%)	188 (2.5%)	-0.013067988	299 (2.1%)	305 (2.1%)	0
DM Medications - GLP-1 RA; n (%)	25 (0.8%)	20 (0.7%)	0.011590746	38 (1.0%)	38 (1.0%)	0	38 (0.5%)	40 (0.5%)	0	101 (0.7%)	98 (0.7%)	0
DM Medications - SGLT-2 Inhibitors; n (%)	27 (0.9%)	21 (0.7%)	0.022452077	42 (1.1%)	44 (1.2%)	-0.009379237	33 (0.4%)	37 (0.5%)	-0.014941191	102 (0.7%)	102 (0.7%)	0
DM Medications - Metformin; n (%)	285 (9.4%)	284 (9.0%)	0	328 (8.9%)	335 (9.1%)	-0.006988608	757 (10.1%)	770 (10.3%)	-0.006608366	1,379 (9.6%)	1,389 (9.6%)	-0.00675776
Other Medications - Use of NSAIDs; n (%)	555 (18.3%)	597 (19.7%)	-0.035692574	822 (22.3%)	851 (23.0%)	-0.016724339	1,508 (20.2%)	1,511 (20.3%)	-0.002488413	2,885 (20.3%)	2,965 (20.9%)	-0.014836086
Other Medications - Use of other hypertension drugs; n (%)	10 (0.3%)	13 (0.4%)	-0.009356117	40 (1.1%)	43 (1.2%)	-0.003245027	458 (6.1%)	476 (6.4%)	-0.012393785	79 (0.5%)	80 (0.5%)	-0.009091097
Other Medications - Digoxin; n (%)	10 (0.3%)	9 (0.3%)	0	8 (0.2%)	10 (0.3%)	-0.020026051	51 (0.7%)	49 (0.7%)	0	69 (0.5%)	68 (0.5%)	0
Other Medications - Use of Anti-arrhythmics; n (%)	12 (0.4%)	15 (0.5%)	-0.014941191	13 (0.4%)	16 (0.4%)	0	38 (0.5%)	36 (0.5%)	0	61 (0.4%)	67 (0.5%)	-0.014941191
Other Medications - Use of antipsychotics; n (%)	195 (6.4%)	198 (6.4%)	-0.004070982	154 (4.2%)	144 (3.9%)	0.01521892	775 (10.4%)	774 (10.4%)	0	1,124 (7.9%)	1,116 (7.9%)	0
Other Medications - Use of dementia meds; n (%)	174 (5.7%)	161 (5.3%)	0.017546054	66 (1.8%)	66 (1.8%)	0	667 (9.0%)	648 (8.7%)	0.007059825	907 (6.4%)	875 (6.2%)	0.008231777
Other Medications - Use of antiparkinsonian meds; n (%)	106 (3.5%)	100 (3.3%)	0.011035921	78 (2.1%)	88 (2.4%)	-0.020229904	442 (5.9%)	442 (5.9%)	-0.008556468	630 (4.4%)	610 (4.4%)	-0.004024641
Other Medications - Use of anxiolytics/hypnotics; n (%)	196 (6.5%)	182 (6.0%)	0.020657013	269 (7.3%)	260 (7.0%)	0.011643529	613 (8.2%)	618 (8.3%)	-0.003634718	1,078 (7.6%)	1,060 (7.5%)	0.003785069
Other Medications - Use of anticonvulsants; n (%)	553 (18.2%)	590 (19.5%)	-0.033243244	525 (14.2%)	504 (13.6%)	0.017346473	1,679 (22.5%)	1,679 (22.5%)	0	2,757 (19.4%)	2,733 (19.5%)	-0.002526433
Other Medications - Use of antidepressants; n (%)	849 (28.0%)	865 (28.5%)	-0.011105971	90 (2.4%)	88 (2.4%)	0	2,600 (38.4%)	2,591 (38.4%)	0.002100064	4,350 (30.6%)	4,306 (30.6%)	0.02170594
Other Medications - Use of lithium; n (%)	9 (0.3%)	10 (0.3%)	0	15 (0.4%)	12 (0.3%)	0.01693335	41 (0.5%)	39 (0.5%)	0	065 (0.5%)	61 (0.4%)	0.014941191
Other Medications - Use of Benzos; n (%)	467 (15.4%)	472 (15.6%)	-0.005526338	560 (15.2%)	560 (15.2%)	0	1,562 (20.9%)	1,565 (20.9%)	0	2,592 (18.3%)	2,597 (18.3%)	0
Other Medication - Use of CNS stimulants; n (%)	25 (0.8%)	25 (0.8%)	0	54 (1.5%)	62 (1.7%)	-0.015399924	37 (0.5%)	47 (0.6%)	-0.013521541	116 (0.8%)	134 (0.9%)	-0.010893078
Other Medications - Use of opioids; n (%)	1,208 (39.8%)	1,228 (40.5%)	-0.014280199	1,666 (45.1%)	1,658 (44.9%)	0.010201519	3,150 (42.1%)	3,162 (42.3%)	-0.004049587	6,024 (42.4%)	6,048 (42.6%)	-0.004045782
Other Medications - Use of COPD/asthma meds; n (%)	550 (18.1%)	560 (18.5%)	-0.01034497	582 (15.8%)	598 (16.2%)	-0.010911057	1,735 (23.2%)	1,757 (23.5%)	-0.007091477	2,807 (20.2%)	2,915 (20.5%)	-0.007451594
Other Medications - Use of oral corticosteroids; n (%)	837 (27.6%)	877 (28.9%)	-0.028878088	953 (25.8%)	975 (26.4%)	-0.013662146	2,413 (32.3%)	2,401 (32.1%)	0.004280438	4,263 (29.6%)	4,253 (29.9%)	-0.006562313
Other Medications - Use of sympathomimetic agents; n (%)	44 (1.5%)	39 (1.3%)	0.017023238	99 (2.7%)	109 (2.9%)	-0.018029973	73 (1.0%)	69 (0.9%)	0.010309004	216 (1.5%)	217 (1.5%)	0
Other Medications - Use of bisphosphonates; n (%)	98 (3.2%)	92 (3.0%)	0.011539699	40 (1.1%)	38 (1.0%)	0.009810761	316 (4.2%)	308 (4.1%)	0.005013965	454 (3.2%)	438 (3.1%)	0.005725279
Other Medications - Use of thiazide; n (%)	246 (8.1%)	253 (8.3%)	-0.007289615	233 (6.3%)	245 (6.6%)	-0.01213147	716 (9.6%)	739 (9.9%)	-0.010113486	1,195 (8.4%)	1,237 (8.7%)	-0.007288836
Other Medications - Use of estrogens, progestins, androgens; n (%)	215 (7.1%)	204 (6.7%)	0.015782439	513 (13.9%)	504 (13.6%)	0.008711531	342 (4.6%)	333 (4.5%)	0.004798523	1,070 (7.5%)	1,041 (7.3%)	0.007640325
Healthcare Utilization												
HU - Bone mineral density; n (%)	90 (3.0%)	93 (3.1%)	-0.005815379	50 (1.4%)	53 (1.4%)	0	294 (3.9%)	307 (4.1%)	-0.01020634	434 (3.1%)	453 (3.2%)	-0.005251286
HU - Occurrence of creatinine tests ordered ; n (%)	167 (5.6%)	183 (6.0%)	-0.021479316	160 (4.3%)	164 (4.5%)	-0.00975169	536 (7.0%)	533 (7.1%)	0.003906444	858 (6.0%)	658 (4.6%)	0.062521869
HU - Number of D-dimer tests												
...mean (sd)	0.12 (0.36)	0.12 (0.36)	0	0.13 (0.39)	0.13 (0.39)	0	0.11 (0.34)	0.10 (0.34)	0.029411765	0.12 (0.36)	0.11 (0.36)	0.027777778
...median [IQR]	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0
HU - Number of CRP, high-sensitivity CRP tests												
...mean (sd)	0.12 (0.52)	0.12 (0.54)	0	0.11 (0.53)	0.11 (0.63)	0	0.15 (0.61)	0.16 (0.65)	-0.015865023	0.13 (0.83)	0.14 (0.62)	-0.013650685
...median [IQR]	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0	0.00 (0.83)	0.00 (0.62)	0
HU - Colonoscopy; n (%)	102 (3.4%)	126 (4.2%)	-0.041850988	142 (3.8%)	130 (3.5%)	0.015997896	263 (3.5%)	264 (3.5%)	0	507 (3.6%)	520 (3.7%)	-0.005332448
HU - Flu vaccine; n (%)	446 (14.7%)	428 (14.0%)	0.019967792	352 (9.6%)	354 (9.6%)	-0.003402473	2,224 (29.7%)	2,204 (29.5%)	0.004381258	3,022 (21.3%)	2,981 (21.0%)	0.017346473
HU - Mammogram; n (%)	249 (8.2%)	245 (8.2%)	0.011026916	241 (6.5%)	247 (6.6%)	-0.001802188	684 (9.1%)	684 (9.1%)	-0.006988608	1,205 (8.5%)	1,206 (8.5%)	0
HU - PSA test or Prostate exam for DRE; n (%)	253 (8.3%)	253 (8.4%)	-0.003614858	350 (9.5%)	310 (8.4%)	0.038540897	679 (9.1%)	668 (9.3%)	0.006988608	1,282 (9.0%)	1,234 (8.7%)	0.005627584
HU - Pap smear; n (%)	106 (3.5%)	105 (3.5%)	0	225 (6.1%)	225 (6.1%)	0	187 (2.5%)	173 (2.3%)	0.013067988	518 (3.6%)	503 (3.5%)	0.005404261
HU - Pneumonia vaccine; n (%)	685 (22.6%)	668 (22.0%)	0.0144145	465 (12.6%)	472 (12.8%)	-0.006006521	2,451 (32.8%)	2,413 (32.3%)	0.010671113	3,601 (25.4%)	3,553 (25.0%)	0.009213266
F frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2												
...mean (sd)	0.20 (0.07)	0.20 (0.07)	0	0.16 (0.05)	0.16 (0.05)	0	0.21 (0.07)	0.21 (0.07)	0	0.19 (0.07)	0.19 (0.07)	0
...median [IQR]	0.18 (0.14, 0.23)	0.18 (0.14, 0.23)	0	0.15 (0.12, 0.18)	0.15 (0.13, 0.19)	0	0.20 (0.16, 0.25)	0.20 (0.16, 0.25)	0	0.18 (0.07)	0.18 (0.07)	0
HU - Number of Hospitalizations												
...mean (sd)	0.90 (1.07)	0.90 (1.08)	-0.009302225	0.58 (0.92)	0.59 (0.94)	-0.010752067	0.79 (0.92)	0.79 (0.93)	0	0.76 (0.95)	0.76 (0.97)	0
...median [IQR]	1.00 (0.00, 1.00)	1.00 (0.00, 1.00)	0	0.00 (0.00, 1.00)	0.00 (0.00, 1.00)	0	1.00 (0.00, 1.00)	1.00 (0.00, 1.00)	0	0.74 (0.95)	0.74 (0.97)	0
HU - Number of hospital days												
...mean (sd)	1.20 (0.57)	1.21 (0.61)	-0.016939423	1.14 (0.43)	1.14 (0.43)	0	1.30 (0.71)	1.30 (0.65)	0	1.24 (0.62)	1.24 (0.59)	0
...median [IQR]	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)	0	1.00 (1.00, 1.00)	1.00 (1.00,							


Appendix B

...mean (sd)	0.48 (1.19)	0.48 (1.21)	0	0.46 (1.11)	0.46 (1.19)	0	0.26 (0.63)	0.25 (0.66)	0.015499685	0.36 (1.33)	0.35 (0.95)	0.008652578
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [1.33]	0.00 [0.95]	0
Socioeconomic Status Proxy Variables												
SES - Mean Copay for per prescription cost (charges in U.S. \$)												
...mean (sd)	18.05 (23.07)	18.18 (27.14)	-0.005161322	11.59 (18.47)	11.98 (20.33)	-0.020080033	19.52 (36.04)	19.14 (33.98)	0.010849347	17.14 (43.26)	17.07 (29.54)	0.001889809
...median [IQR]	11.75 [4.01, 23.76]	10.66 [3.95, 22.77]	0.043275704	7.21 [1.00, 14.46]	7.19 [0.77, 15.00]	0.001029745	10.06 [2.95, 24.13]	9.71 [2.88, 23.73]	0.00999282	9.68 [43.26]	9.26 [29.54]	0.011338853
...Missing; n (%)	272 (9.0%)	266 (8.8%)	0.007023903	719 (19.5%)	703 (19.0%)	0.012682127	452 (6.0%)	446 (6.0%)	0	1,443 (10.2%)	1,415 (10.0%)	0
SES - Copay; pharmacy cost												
...mean (sd)	170.24 (267.22)	171.77 (323.09)	-0.005160655	92.46 (181.81)	96.72 (189.23)	-0.022957894	9.92 (5.45)	9.90 (5.33)	0.003710345	65.62 (224.46)	67.04 (177.80)	-0.007013088
...median [IQR]	70.00 [10.00, 221.90]	65.46 [10.00, 211.95]	0.015313315	20.79 [0.00, 110.18]	20.00 [0.00, 112.32]	0.00425745	9.00 [6.00, 13.00]	9.00 [6.00, 13.00]	0	25.09 (224.46)	23.91 (177.80)	0.005827778
SES - Business type: Commercial vs Medicare												
...Commercial; n (%)	1,171 (38.6%)	1,154 (38.1%)	0.010283158	2,840 (76.9%)	2,829 (76.6%)	0.00710188	0 (0.0%)	0 (0.0%)	0	4,011 (28.2%)	3,983 (28.0%)	0.004449523
...Medicare; n (%)	1,861 (61.4%)	1,878 (61.9%)	-0.010283158	854 (23.1%)	865 (23.4%)	-0.00710188	0 (0.0%)	0 (0.0%)	0	2,715 (19.1%)	2,743 (19.3%)	-0.005077794
SES - Low income indicator; n (%)	461 (15.2%)	467 (15.4%)	-0.00555577	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	461 (3.2%)	467 (3.3%)	-0.005639422
SES - Urban vs Rural (MSA variable)												
...Urban; n (%)	0 (0.0%)	0 (0.0%)	0	2,479 (67.1%)	2,458 (66.5%)	0.012740979	0 (0.0%)	0 (0.0%)	0	2,479 (17.5%)	2,458 (17.3%)	0.005275539
...Rural; n (%)	0 (0.0%)	0 (0.0%)	0	365 (9.9%)	369 (10.0%)	-0.003340775	0 (0.0%)	0 (0.0%)	0	365 (2.6%)	369 (2.6%)	0
...Unknown/Missing; n (%)	0 (0.0%)	0 (0.0%)	0	850 (23.0%)	867 (23.5%)	-0.011836599	0 (0.0%)	0 (0.0%)	0	850 (6.0%)	867 (6.1%)	-0.004194449
SES - Dual Status; n (%)	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	2,256 (30.2%)	2,260 (30.2%)	0	2,256 (15.9%)	2,260 (15.9%)	0
SES - Generic name prescription - unique value												
...mean (sd)	8.43 (5.39)	8.51 (5.40)	-0.014828539	7.87 (5.42)	7.90 (5.21)	-0.005643302	9.82 (5.36)	9.80 (5.24)	0.003773343	9.02 (7.82)	9.03 (5.27)	-0.001499693
...median [IQR]	7.00 [4.00, 11.00]	8.00 [4.00, 12.00]	-0.185356732	7.00 [4.00, 11.00]	7.00 [4.00, 11.00]	0	9.00 [6.00, 13.00]	9.00 [6.00, 13.00]	0	8.05 (7.82)	8.27 (5.27)	-0.032993243
SES - Brand name prescription - unique value												
...mean (sd)	8.52 (5.50)	8.60 (5.51)	-0.014532237	7.96 (5.53)	8.00 (5.32)	-0.007371891	9.92 (5.45)	9.90 (5.33)	0.003710345	9.11 (7.97)	9.13 (5.37)	-0.002943122
...median [IQR]	8.00 [4.00, 12.00]	8.00 [4.00, 12.00]	0	7.00 [4.00, 11.00]	7.00 [4.00, 11.00]	0	9.00 [6.00, 13.00]	9.00 [6.00, 13.00]	0	8.27 (7.97)	8.27 (5.37)	0


Appendix B



The c-statistics for the propensity score model, pre-matching was 0.746. The post-matching c-statistic was 0.541



The c-statistics for the propensity score model, pre-matching was 0.732. The post-matching c-statistic was 0.538



The c-statistics for the propensity score model, pre-matching was 0.674. The post-matching c-statistic was 0.538